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Summary 
 
 
The hematopoietic system is a highly versatile regenerative tissue, in which hematopoietic 
stem cells drive the life-long production of multiple mature blood cell types. During 
hematopoietic differentiation, the regulation of genome-wide epigenetic patterns of 
histone modification or DNA methylation marks is an essential process orchestrating cell 
identities, lineage decisions and developmental cell fates. In acute myeloid leukemia, 
mutations frequently affect direct and indirect epigenetic regulators and modifiers such 
as isocitrate dehydrogenase 1 (IDH1) or DNA methyltransferase 3 alpha (DNMT3A), and 
result in disturbed epigenetic landscapes and differentiation patterns. Here, IDH1 
mutations promote oncogenic transformation through the de novo production of the 
metabolite D2-hydroxyglutarate, which induces a genome and epigenome instability by 
inhibiting multiple histone and DNA demethylases. Yet, molecular details of how IDH1 
mutations alter characteristics of individual hematopoietic cell types remain poorly 
understood.  
 In the course of this thesis, combinatorial mouse models carrying specific Idh1-
R132H and DNMT3A-R882H mutations, which frequently co-occur in acute myeloid 
leukemia patients, were extensively characterized. By integrating phenotypic readouts in 
combination with latest advances in high-throughput single-cell RNA-sequencing 
approaches, cooperativity and impact of these mutations on individual cell types of the 
hematopoietic system were delineated and gene regulatory networks which are altered 
upon the expression of an Idh1-R132H or a DNMT3A-R882H mutation were identified. At 
a phenotypic level, neither an Idh1-R132H mutation alone nor in combination with a 
DNMT3A-R882H mutation resulted in the development of myeloid malignancies, 
suggesting a restricted oncogenic potential of these mutations and additional intrinsic or 
extrinsic factors to be required for further malignant transformation. However, Idh1-
R132H mutated hematopoietic stem cells displayed increased engraftment and 
reconstitution potential during serial transplantations and featured aberrant expression 
of genes associated with DNA damage and DNA repair. Furthermore, both Idh1-R132H 
single-mutant and Idh1-R132H DNMT3A-R882H double-mutant mice displayed aberrant 
differentiation patterns predominantly affecting the myelo-monocytic lineage, 
culminating in a favored monocytic cell fate and increased monocyte and monocyte 
progenitor counts in the bone marrow.  
 By employing a multi-layered single-cell transcriptome analysis of nearly all cell types 
within the hematopoietic compartment, differentiation trajectories from hematopoietic 
stem cells towards mature differentiated cells were reconstructed and underlying 
molecular defects characterized. Pseudotime-inferred myeloid lineage trajectories 
revealed an aberrant lineage specification in particular for Idh1-R132H DNMT3A-R882H 
double-mutated myeloid progenitor cells, resembling a differentiation arrest at the stage 
of common myeloid progenitors and an ineffective hematopoietic differentiation as seen 
in myelodysplastic syndromes. At the molecular level, this aberrant population was 
characterized by an altered metabolic signature and elevated Myc signaling, which is 
involved in the regulation of terminal myeloid differentiation. Importantly, we could 
correlate this transcriptome-defined population to a surface marker-defined population, 
allowing the prospective isolation of these cells for further investigation.  
 Independent of a DNMT3A-R882H mutation, the expression of an Idh1-R132H 
mutation resulted in the deregulation of several key regulatory factors which either 
orchestrate monocyte and macrophage development or their activation upon 
inflammatory stimuli. In line with this, monocyte progenitor cells displayed elevated 
 x 
interferon signaling levels, suggesting that a proinflammatory environment is a common 
characteristic of an Idh1-R132H mutated hematopoietic compartment and could 
contribute to leukemic transformation upon additional events. 
 In summary, the experimental framework presented in this thesis enhanced our 
understanding of how IDH1-R132H mutations alone or in combination with a DNMT3A-
R882H mutation in patients synergistically drive leukemia initiation and progression. The 
identified molecular characteristics will be of benefit in designing treatment strategies for 
patients carrying IDH1-R132H and DNMT3A-R882H mutations and can be used as a 
resource when studying these mutations in the context of altered physiological conditions 
and upon additional extrinsic stimuli. 
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Zusammenfassung 
 
 
Das hämatopoetische System ist ein äußerst dynamisches regeneratives Gewebe, in dem 
hämatopoetische Stammzellen für die lebenslange Produktion von verschiedenen reifen 
Blutzelltypen verantwortlich sind. Die Regulation genomweiter epigenetischer Muster der 
DNA Methylierung und Histonmodifikation ist ein wichtiger Mechanismus zur Kontrolle 
von Zellidentitäten und der Spezifikation von Differenzierungsprozessen. Bei der akuten 
myeloischen Leukämie beeinflussen Mutationen häufig direkte und indirekte 
epigenetische Regulatoren wie z.B. Isocitrat-Dehydrogenase 1 (IDH1) oder DNA-
Methyltransferase 3 alpha (DNMT3A) und führen zu veränderten epigenetischen 
Strukturen und Differenzierungsmustern. Hier unterstützen IDH1 Mutationen die 
onkogene Transformation durch die de novo Produktion des Metaboliten D2-
Hydroxyglutarat, welcher durch die Inhibierung verschiedener Histon- und DNA-
Demethylasen eine Instabilsierung des Genoms und des Epigenoms hervorruft. Allerdings 
sind molekulare Grundlagen wie sich die Expression von IDH1 Mutationen auf 
verschiedene hämatopoetische Zelltypen auswirkt, nur unzureichend verstanden.  
 Im Rahmen dieser Doktorarbeit wurde eine umfassende Charakterisierung von 
kombinatorischen Mausmodellen mit spezifischen, in Patienten mit akuter myeloischer 
Leukämie auftretenden, Idh1-R132H und DNMT3A-R882H Mutationen durchgeführt. 
Durch die Integration von phänotypischen Analysen in Kombination mit Hochdurchsatz-
Einzelzell-RNA-Sequenzierungsmethoden konnte ein Zusammenspiel beider Mutationen 
und deren Einfluss auf einzelne Zelltypen des hämatopoetischen System detailliert 
untersucht werden. Des Weiteren wurden Genregulationsnetzwerke identifiziert, die 
durch die Expression einer Idh1-R132H oder einer DNMT3A-R882H Mutation 
beeinträchtigt werden.  
 Auf phänotypische Ebene führte weder eine Idh1-R132H Mutation alleine noch in 
Kombination mit einer DNMT3A-R882H Mutation zur Entwicklung myeloider Neoplasien, 
was auf ein beschränktes onkogenes Potenzial dieser Mutationen schließen lässt. Vielmehr 
deutet dies darauf hin, dass zusätzliche intrinsische oder extrinsische Faktoren auftreten 
müssen, damit es zu einer malignen Transformation im Blutsystem kommt. Idh1-R132H 
mutierte hämatopoetische Stammzellen wiesen jedoch ein erhöhtes Engraftment- und 
Rekonstitutionspotenzial in seriellen Transplantationsexperimenten auf, sowie eine 
Deregulation von Genen, die mit der Reparatur von DNA-Schäden in Verbindung gebracht 
werden. Darüber hinaus zeigten sowohl Idh1-R132H einzel-mutierte als auch Idh1-R132H 
DNMT3A-R882H doppel-mutierte Mäuse aberrante Differenzierungsmuster, die 
vorwiegend die myelo-monozytäre Linie beeinflussten und zu einer erhöhten Anzahl an 
monozytären Vorläuferzellen und reifen Monozyten im Knochenmark der Mäuse führten.  
 Durch die Anwendung von Einzelzell-Transkriptomanalysen von nahezu allen 
hämatopoetischen Zelltypen konnten Differenzierungsmuster von hämatopoetischen 
Stammzellen zu terminal differenzierten Zellen rekonstruiert und die zu Grunde 
liegenden molekularen Defekte analysiert werden. Insbesondere Idh1-R132H DNMT3A-
R882H doppel-mutierte Zellen zeigten stark abweichende myeloide 
Differenzierungsmuster, die einem Differenzierungsarrest auf dem Stadium der 
gemeinsamen myeloiden Vorläuferzellen und einer ineffektiven hämatopoetischen 
Differenzierung, wie sie charakteristisch für myelodysplastische Syndrome ist, ähneln. 
Auf molekularer Ebene wies diese aberrante Population eine veränderte metabolische 
Signatur sowie eine erhöhte Myc-Aktivität, welche die terminale Differenzierung 
myeloider Zellen reguliert, auf. Des Weiteren konnte diese Transkriptom-definierte 
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Population mit einer Oberflächenmarker-definierten Population korreliert werden, sodass 
die prospektive Isolation dieser Zellen für weitere Analysen ermöglicht wurde.   
 Unabhängig von einer DNMT3A-R882H Mutation führte die Expression einer Idh1-
R132H Mutation zur Deregulierung von mehreren zentralen Faktoren, die entweder die 
Entwicklung von Monozyten und Makrophagen, oder deren Aktivierung durch 
inflammatorische Stimuli, steuern. In Übereinstimmung damit zeigten monozytäre 
Vorläuferzellen eine erhöhte Aktitivität des Interferon Signalweges, was darauf hindeutet, 
dass ein entzündungsförderndes Millieu ein Merkmal eines Idh1-R132H mutierten 
hämatopoetischen Kompartiments ist und zu einer leukämischen Transformation 
beitragen könnte.  
 Zusammenfassend liefert der hier beschriebene experimentelle Datensatz neue 
Erkenntnisse, wie IDH1-R132H Mutationen alleine oder zusammen mit DNMT3A-R882H 
Mutationen in Patienten die Initiierung oder das Fortschreiten einer leukämischen 
Erkrankung beeinflussen. Die identifizierten molekularen Grundlagen sind entscheidend 
für die Entwicklung von neuen Therapieansätzen für Pateinten mit einer IDH1-R132H und 
/ oder einer DNMT3A-R882H Mutation und dienen zudem als Ressource für 
Untersuchungen dieser Mutationen im Kontext veränderter physiologischer Bedingungen 
oder zusätzlich angewandter externer Stimuli.   
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1  
 
 
Introduction 
 
 
1.1 The Hematopoietic System  
  
The mammalian blood system represents a highly dynamic regenerative tissue aimed at 
the life-long production and regeneration of mature blood cell types. The renewal of 
hematopoietic cells is essential for the perpetuation of physiological functions and takes 
place in the adult bone marrow with around 1012 cells being produced every day [Doulatov 
et al., 2012]. The hematopoietic system encompasses a variety of mature cell types, 
including erythrocytes, platelets, B-cells, T-cells, natural killer cells, monocytes, 
macrophages, dendritic cells, granulocytes and mast cells [Seita and Weissman, 2010]. The 
functions of these cell types are very diverse; erythrocytes for instance are required for 
the supply of oxygen, platelets drive the coagulation of blood upon injuries, whereas other 
cell types are involved in adaptive and naïve immunity in response to pathogen infections. 
The short life-span of these cells, however, requires a continuous replenishment of 
mature cells, which, despite their diversity, all share one common progenitor cell.  
 
1.1.1 Concepts of Hematopoietic Stem Cells 
 
The existence of stem cells in the hematopoietic system was first proposed in the 1960s 
by Till and McCulloch in seminal studies investigating the regenerative potential of bone 
marrow cells [Till and McCulloch, 1961, Till et al., 1964, Becker et al., 1963]. Yet, only 
upon the advent of new technologies, such as fluorescence activated cell sorting (FACS) 
or monoclonal antibodies, these cells could prospectively be purified [Spangrude et al., 
1988]. Combining cell surface markers with functional readouts and in vivo reconstitution 
experiments over the years has led to a detailed characterization of individual cell types 
and their functional properties within the hematopoietic system. Based on this 
understanding, cell types were consolidated into a cellular hierarchy that reflects 
developmental stages of hematopoietic differentiation with hematopoietic stem cells 
(HSCs) residing at the apex of the hierarchy [Laurenti and Gottgens, 2018, Haas et al., 
2018].  
 Akin to other tissue-specific stem cells in the intestine or the skin, HSCs are defined 
by two essential properties. While they have the potential to produce all differentiated 
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cell types within the hematopoietic system, they at the same time have the ability to self-
renew and perpetuate themselves by dividing and giving rise to a new stem cell [Seita and 
Weissman, 2010, Laurenti and Gottgens, 2018]. Maintenance of the stem cell pool through 
self-renewal is a crucial measure to ensure the sustained production of cells throughout 
the life time of an individual. In contrast, downstream cells lack any extended self-renewal 
potential or are confined in their capacity to regenerate only a certain subset of mature 
cell types [Morrison and Weissman, 1994, Christensen and Weissman, 2001, Doulatov et 
al., 2010]. 
 The number of stem cells that are actively contributing to blood production at any 
given time is estimated to range between 50,000 and 200,000 in humans [Lee-Six et al., 
2018]. Yet, under homeostatic conditions cellular output is mainly sustained by short-
lived and restricted multipotent progenitors (MPPs) with only limited contribution from 
actual HSCs [Busch et al., 2015, Sun et al., 2014b, Sawai et al., 2016]. To prevent early stem 
cell exhaustion and an acquisition of genetic aberrations, HSCs reside in a quiescent state 
with only infrequent cell divisions, but are efficiently activated upon injury, blood loss, 
infection, or inflammation [Wilson et al., 2008, Essers et al., 2009, Baldridge et al., 2010, 
Cheshier et al., 2007, Takizawa et al., 2011]. Unfavorably, an exit from quiescence is 
associated with a drastic impairment of stem cell function due to the accumulation of 
DNA damage [Walter et al., 2015, Flach et al., 2014, Rossi et al., 2007], highlighting the 
importance of regulatory mechanisms that balance quiescence, activation, self-renewal 
and differentiation in order to assert homeostatic blood production.  
 
1.1.2 Classical Models of Hematopoietic 
Differentiation 
 
The classical hierarchical model depicts hematopoietic differentiation as a stepwise 
process which is defined by discrete cell stages and a gradual loss of both self-renewal 
potential and multipotency paralleling hematopoietic commitment to certain lineages 
[Seita and Weissman, 2010]. Binary branching points successively segregate lineages and 
cell fates, leading to a progression from multipotent via oligo- and bipotent to unipotent 
progenitor states [Seita and Weissman, 2010]. Within the stem cell population, several 
distinct subsets are distinguished based on the increasing restriction in self-renewal 
capacity. Whereas long-term HSCs (LT-HSCs) are characterized by the ability to 
reconstitute the hematopoietic system throughout the whole lifespan, descendant short-
term HSCs (ST-HSCs) sustain blood production only for a limited time (usually several 
weeks) [Morrison and Weissman, 1994, Christensen and Weissman, 2001, Yang et al., 
2005b, Kiel et al., 2005]. ST-HSCs give rise to further restricted MPPs, which still possess 
full lineage differentiation potential, but already lack any repopulation capacity [Morrison 
and Weissman, 1994, Christensen and Weissman, 2001, Morrison et al., 1997, Kiel et al., 
2005].  
 The first branching point separates lymphoid potential from myeloid, erythroid and 
megakaryocytic potential and results in the formation of either common lymphoid 
progenitors (CLP) or common myeloid progenitors (CMPs) (Figure 1-1A) [Kondo et al., 
1997, Akashi et al., 2000]. Further restricted bipotent progenitors arise from CMPs, 
segregated into a megakaryocytic-erythroid fate (megakaryocyte erythroid progenitor 
(MEP)) or a granulocytic-monocytic fate (granulocyte monocyte / macrophage progenitor 
(GMP)) [Pronk et al., 2007, Na Nakorn et al., 2002]. Eventually, the next branching points 
culminate in the emergence of unipotent progenitors which will continue to differentiate 
into mature megakaryocytes, erythrocytes, monocytes or granulocytes which carry out 
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characteristic and specialized functions within the hematopoietic compartment [Laurenti 
and Gottgens, 2018].  
 
1.1.3 Revised Models of the Hematopoietic Hierarchy 
 
Over the years, the discovery of additional surface markers combined with single-cell 
assays to readout characteristic lineage potentials has led to the introduction of various 
modifications to the initial hierarchical model. The identification of progenitor subsets 
that share myeloid and lymphoid potential (lymphoid-primed multipotent progenitor 
(LMPP)), but no megakaryocytic and erythroid potential, has indicated that myeloid and 
lymphoid fates are not segregated by the first branching point but only in later bifurcation 
steps (Figure 1-1B) [Adolfsson et al., 2005]. Additional bi- or unipotent subsets have since 
been identified in the myeloid-megakaryocytic-erythroid branch based on extended 
combinations of surface markers [Pronk et al., 2007, Guo et al., 2013]. Similarly, the origin 
of monocytes, macrophages and dendritic cells has been revised through the 
identification of monocyte / dendritic cell progenitors (MDPs) and downstream unipotent 
common monocyte progenitor (cMoPs) as well as common dendritic cell progenitor (CDPs) 
populations [Geissmann et al., 2010, Fogg et al., 2006, Hettinger et al., 2013, Onai et al., 
2007].   
 
 
 
 
Figure 1-1: Hierarchical Models of Hematopoietic Differentiation. 
(A) The earliest hierarchical model of the hematopoietic system depicted differentiation as a stepwise process in which 
HSCs reside at the apex of the hierarchy. The first binary branching point segregates myeloid and lymphoid potential. 
(B) Over time, additional cell populations have been identified that have led to modifications of the classical hierarchy. 
The hematopoietic stem and progenitor cell pool consist of heterogeneous subsets that differ in self-renewal and 
differentiation potential, myeloid and lymphoid potential remains associated during the first branching points and 
additional bi-or unipotent progenitor populations drive the production of mature cell types. The horizontal axis within 
the HSC / MPP pool illustrates biased differentiation potential of MPP subsets (MPP2 = megakaryocytic / erythroid, MPP3 
= myeloid, MPP4 = Lymphoid) (Figure adapted from [Laurenti and Gottgens, 2018]).  
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Other studies revealed that the MPP compartment can be subdivided in further subsets 
(MPP2, MPP3, MPP4, MPP5) that are already primed to differentiate into certain lineages 
[Pietras et al., 2015, Wilson et al., 2008]. Here, MPP2 cells were predominantly associated 
with a megakaryocytic and erythroid cell fate, whereas MPP3 and MPP4 populations 
featured a biased differentiation into myeloid or lymphoid cell fates, respectively [Pietras 
et al., 2015]. Molecular priming even has been detected at the HSC level, with certain 
megakaryocytic restricted HSCs directly giving rise to megakaryocytes in emergency 
situations without progressing though any progenitor stages [Haas et al., 2015, Sanjuan-
Pla et al., 2013, Yamamoto et al., 2013, Rodriguez-Fraticelli et al., 2018]. Likewise, HSCs 
which are dissimilar in their myeloid or lymphoid potential have been identified 
[Yamamoto et al., 2013, Muller-Sieburg et al., 2004, Dykstra et al., 2007, Rodriguez-
Fraticelli et al., 2018], illustrating a high degree of heterogeneity already within the HSC 
pool. 
 
The Continuous Model of Hematopoietic Differentiation  
However, the classical model of hematopoiesis was most fundamentally challenged with 
the advent of single-cell transcriptomic analysis methods. Profiling gene expression at the 
single-cell level provides a transcriptomic snapshot as cells transition through 
hematopoietic differentiation landscapes and thereby allows to deconvolute cellular 
heterogeneity within specific populations irrespective of any surface marker 
combinations [Nestorowa et al., 2016, Macaulay et al., 2016, Giladi et al., 2018, Paul et al., 
2015]. Integrating single-cell transcriptomic data specifically across the hematopoietic 
stem and progenitor cell (HSPC) compartment has led to the proposal of a continuous 
model of the hematopoietic hierarchy, according to which lineage specification is already 
determined at the level of HSPCs and acquired in a continuous process (Figure 1-2) [Velten 
et al., 2017, Nestorowa et al., 2016, Macaulay et al., 2016, Giladi et al., 2018]. Without 
transitioning any multipotent or oligopotent progenitor cell states, unilineage restricted 
cells originate directly from a continuum of unprimed HSCs and follow their specified 
differentiation trajectory (Figure 1-2A) [Velten et al., 2017, Nestorowa et al., 2016, 
Macaulay et al., 2016, Giladi et al., 2018]. Underpinning these findings, multipotent 
progenitor cells likewise were associated with a restricted unilineage output during native 
and unperturbed hematopoiesis [Rodriguez-Fraticelli et al., 2018]. Similarly, single-cell 
analysis of myeloid progenitor populations such as CMPs, GMPs, and MEPs, revealed that 
these seemingly homogenous populations in truth are composed of distinct and 
functionally heterogeneous subsets that are primed towards one particular differentiation 
fate and are rather defined by a unilineage potential (Figure 1-2B) [Paul et al., 2015]. 
Importantly, understanding the molecular characteristics that drive cellular heterogeneity 
and cell fate choices is in direct relevance not only to the functionality of the 
hematopoietic system, but also to the development of hematological malignancies [Haas 
et al., 2018].  
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Figure 1-2: Continuous Models of Hematopoietic Differentiation. 
(A) Within the HSPC compartment, unilineage restricted HSCs emerge from a continuum of unprimed cells and acquire 
lineage biases into designated directions in a continuous manner. Accordingly, lineage commitment decisions are 
already made within the HSC compartment and cells traverse differentiation trajectories without passing discrete and 
hierarchically organized progenitor stages (Figure adapted from [Velten et al., 2017]). (B) As individual and distinctly 
primed cells traverse denoted trajectories, they pass progenitor compartments, which are defined by certain 
combinations of surface markers (indicated as ellipses). Although cells share the expression of common surface 
markers at this stage, their predetermined transcriptional and epigenetic profile defines their developmental path 
(Figure adapted from [Laurenti and Gottgens, 2018]. 
 
1.1.4 Monocyte Development and Function 
 
Monocytes belong to the ‘mononuclear phagocyte system’ (MPS), a part of the immune 
system consisting of phagocytic cells and which, beside monocytes, also encompasses 
conventional dendritic cells (cDCs) and macrophages [Guilliams et al., 2014]. Monocytes 
develop in the adult bone marrow from myeloid progenitor cells and following their 
generation are released into blood circulation, where they constitute around 4 % of all 
leukocytes [Guilliams et al., 2018]. Upon inflammation, monocytes are mobilized in large 
numbers and recruited to inflamed sites to function as proinflammatory mediators or aid 
in resolving inflammation by giving rise to several functionally distinct monocyte-derived 
cells [Shi and Pamer, 2011].  
 
Monocytes are Generated through Mobilization of Distinct Progenitor Subsets 
Within the bone marrow, classical monocytes were thought to arise from MDPs, which 
possess monocytic- and dendritic cell- (DC), but no neutrophil potential [Fogg et al., 2006, 
Auffray et al., 2009, Geissmann et al., 2010]. MDPs, in a binary cell fate decision, then give 
rise either to unipotent cMoPs, producing mature monocytes, or CDPs which are ancestral 
to both cDCs and plasmacytoid dendritic cells (pDCs) [Hettinger et al., 2013, Onai et al., 
2007, Naik et al., 2007]. While it was initially believed that MDPs originate from the GMP 
population, recent evidence suggests that MDPs can directly emerge from the CMP 
population to give rise to monocytes without any GMP intermediate [Yanez et al., 2017]. 
Yet, a monocyte specific transcriptional program was identified both in CMP and GMP 
populations [Paul et al., 2015, Olsson et al., 2016], indicating that functionally distinct 
monocyte subtypes can originate from two independent pathways, either from GMPs 
(carrying monocyte and neutrophil potential) or from CMP-derived MDPs (carrying 
monocyte and DC potential) [Yanez et al., 2017]. The mobilization of different progenitor 
populations here was shown to depend on the microbial stimulus applied, suggesting that 
functionally distinct monocyte subtypes are produced only upon demand under certain 
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conditions and the balance between GMP and MDP differentiation defines the monocyte 
cell repertoire [Yanez et al., 2017]. On the transcriptional level, commitment towards a 
monocytic cell fate is associated with the expression of a distinct set of hematopoietic 
transcription factors, including PU.1, GATA2, IRF8 and KLF4, since disruption of this 
signaling axis severely disturbs monocyte precursor and peripheral monocyte numbers 
[Guilliams et al., 2018, Kurotaki et al., 2013]. On a cytokine level, the development and 
survival of monocytes is contingent on the growth factor colony-stimulating factor 1 / 
macrophage colony-stimulating factor (CSF1 / M-CSF) and downstream CSF1-receptor 
(CSF1R / CD115) signaling as deficiency in either CSF1 or CSF1R is associated with a severe 
monocytopenia [Cecchini et al., 1994, Wiktor-Jedrzejczak and Gordon, 1996, Dai et al., 
2002].  
 
Functional Heterogeneity of Monocyte Subsets 
Heterogeneity within mature monocytes in humans was first described in 1989 based on 
their morphology and diverging expression levels of the cell surface markers CD14 and 
CD16 [Passlick et al., 1989]. In mice, two different monocyte subsets can be distinguished 
based on the expression of the surface markers Ly6C, CX
3
CR1, CCR2, CD62L, and CD43. 
Ly6CHigh monocytes (termed classical inflammatory monocytes, corresponding to CD14+ 
CD16— human monocytes) are defined as Ly6CHigh CX3CR1Int CCR2+ CD62L+ CD43Low, 
whereas Ly6CLow monocytes (termed non-classical patrolling monocytes, corresponding to 
CD14Low CD16+ human monocytes) are defined as Ly6CLow CX3CR1High CCR2Low CD62L— CD43+ 
[Jung et al., 2000, Geissmann et al., 2003, Palframan et al., 2001, Jakubzick et al., 2013]. 
Following their generation in the bone marrow, Ly6CHigh monocytes are released into 
circulation, equipped with a transcriptional program enabling their migration into tissues 
[Jakubzick et al., 2017]. Under homeostatic conditions, Ly6CHigh monocytes remain in 
circulation for roughly a day and then extravasate into various tissues, such as the 
intestine, dermis or lung to repopulate tissue-resident macrophages, or alternatively, 
while remaining in circulation, convert into Ly6CLow monocytes [Bain et al., 2014, 
Tamoutounour et al., 2013, Jakubzick et al., 2013, Yona et al., 2013, Patel et al., 2017]. 
Ly6CLow monocytes are characterized by a longer life-span (between two and seven days) 
and by an extensive retention in circulation where they monitor the vasculature through 
‘crawling’ mechanisms and surveil endothelial cell integrity [Auffray et al., 2007, Carlin et 
al., 2013].  
 
Monocyte Functions During Inflammation 
Upon inflammation, Ly6CHigh monocytes are avidly recruited to the injured tissues and 
extravasate from circulation in order to fulfill several critical effector functions such as 
antigen presentation, tissue remodeling, or the modulation of pro- and anti-inflammatory 
activities [Jakubzick et al., 2017, Guilliams et al., 2018]. Some of the effector functions 
can be accomplished by monocytes directly due to their potent capacity for phagocytosis 
and the release of inflammatory mediators upon bacterial- (e.g. reactive oxygen species, 
tumor necrosis factor alpha (TNFa), nitric oxide, interleukin 1 beta (IL-1b)) and viral 
infections (e.g. type I interferons alpha and beta (IFNa / b) [Serbina et al., 2008, Barbalat et 
al., 2009, Yang et al., 2014]. In many instances, however, efficiently resolving an infection 
or an inflammatory state further requires the differentiation of monocytes to monocyte-
derived DCs (moDCs) or macrophages. Whereas moDCs play an essential role during 
antigen presentation and priming of T-cells [Cheong et al., 2010, Nierkens et al., 2013, 
Briseno et al., 2016], macrophages are critical for restoring tissue homeostasis by 
eliminating pathogenic insults and repairing damaged tissue [Wynn et al., 2013, Ginhoux 
and Guilliams, 2016]. Depending on the microenvironment, macrophages can acquire 
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heterogeneous activation states with customized functions, termed classically activated 
(M1-) macrophages, and alternatively activated (M2-) macrophages [Mosser and Edwards, 
2008, Lawrence and Natoli, 2011, Murray, 2017]. Bacterial lipopolysaccharide (LPS) or 
interferon gamma (IFNg) promotes the generation of M1 macrophages, which are 
characterized by an antimicrobial activity and the secretion of proinflammatory factors, 
such as IFNb, IL-6, IL-12 or TNFa [Mosser and Edwards, 2008, Lawrence and Natoli, 2011, 
Murray, 2017]. On the other hand, IL-4 or IL-13 favors the generation of M2 macrophages, 
which are implicated in tissue remodeling, wound healing and the secretion of anti-
inflammatory factors [Mosser and Edwards, 2008, Lawrence and Natoli, 2011, Murray, 
2017].  
 Importantly, not only the conversion between monocyte subsets but also the 
transition from monocytes to macrophages as well as the induction of macrophage 
polarization programs involves substantial epigenetic remodeling, illustrating that a 
deregulation of the epigenetic landscape could provoke alterations in monocyte- or 
macrophage-specific cell fates and respective cell activation states [Mildner et al., 2017, 
Rico et al., 2017, Saeed et al., 2014, Chen et al., 2019].  
 
 
1.2 Molecular Determinants of Cell Fate 
Choices 
 
1.2.1 Lineage-Specific Transcription Factors 
 
In contrast to external or environmental stimuli that include interactions with the stem 
cell niche or exposure to certain cytokines, lineage-specific transcription factors (TFs) act 
as the intrinsic determinants, that impact cellular identities and cell fate decisions. TFs 
belong to various classes of DNA binding proteins and induce the activation of 
transcriptional programs that lead to the successive specification of progenitor cells 
[Orkin, 2000]. Studies using gene knockouts in mice were of great importance to provide 
insights into the functionality of TFs and highlighted that disturbances in TF levels are 
tightly linked to the development of hematological malignancies [Orkin and Zon, 2008].  
 In general, factors that are essential for HSC formation or function and factors that 
specify differentiation into certain lineages can be distinguished. For instance, the activity 
of Scl, Lmo2, Runx1 or Mll is required for the production of stem cells during 
embryogenesis or their survival and self-renewal in the adult hematopoietic system [Orkin 
and Zon, 2008]. The expression of other factors such as Gata1, PU.1, Gata2, Cebpa, Gfi1, 
Fli1 or Klf1 on the other hand is essential for the production of myeloid, erythroid or 
megakaryocytic cells [Orkin and Zon, 2008]. The interactions of these TFs are highly 
complex and often cross-antagonistic, suggesting that the random dominance of one TF 
within a cell defines the eventual lineage fate [Graf and Enver, 2009, Iwasaki and Akashi, 
2007, Arinobu et al., 2007]. Yet, novel reporter mouse lines coupled with single-cell based 
long-term quantifications of TF levels revealed that a stochastic variation in expression 
levels is not decisive to initiate lineage choice [Hoppe et al., 2016]. More likely, TFs 
irreversibly execute and reinforce lineage choices, but other upstream mechanism specify 
cell fates in the first place [Hoppe et al., 2016]. These could be extracellular signals and 
interactions with the hematopoietic niche [Pinho and Frenette, 2019], as illustrated by the 
direct instruction of the myeloid master regulator PU.1 by niche-derived TNF signals 
Molecular Determinants of Cell Fate Choices 
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[Etzrodt et al., 2019]. Alternatively, cell fates seem to be predetermined by the cell type-
specific epigenetic configuration which furthermore restricts their plasticity in response 
to certain cues [Yu et al., 2016, Haas et al., 2018]. 
 
1.2.2 The Multi-Layered Epigenome 
 
Conceived by Conrad Waddington in the year of 1942, the term ‘epigenetics’ describes 
how phenotypic traits and effects or nowadays heritable changes in gene expression and 
function are impacted by non-genetic factors that are not encoded in the genomic DNA 
sequence [Waddington, 1942]. Technological advances enabled a profiling of epigenetic 
patterns both on a genome-wide and on a single-cell level, with epigenetic configurations 
reflecting cell identities and activation states during differentiation, development, ageing 
and disease contexts [Stricker et al., 2017, Smith and Meissner, 2013, Feinberg et al., 2016].  
 
DNA Methylation Serves as a Stable Mark for Epigenetic Memory  
Within a cell, multiple layers of epigenetic regulatory mechanisms can be distinguished, 
which jointly determine the epigenetic configuration (Figure 1-3). On the nucleotide level, 
carbon-5 or nitrogen-3 positions on cytosines as well as nitrogen-6 positions on adenines 
can be modified, with the cytosine carbon-5 methylation being the most common and best 
characterized modification [Stricker et al., 2017]. Methylation usually occurs in the 
context of cytosine-phosphate-guanine (CpG) dinucelotides with around 60-80 % of CpGs 
(3-8 % of all cytosines) being methylated in mammalian cells, and is established by DNA 
methyltransferases (DNMTs) which catalyze the transfer of methyl groups (Figure 1-3). 
[Lister et al., 2009, Okano et al., 1998]. DNMT3 alpha (DNMT3A) and DNMT3 beta 
(DNMT3B) establish methylation marks de novo, whereas DNMT1 maintains methylation 
marks at newly synthesized DNA strands using a methylated strand as a template [Okano 
et al., 1998, Okano et al., 1999, Smith and Meissner, 2013]. Being a reversible modification, 
ten-eleven translocation (TET) methylcytosine dioxygenases catalyze the active 
demethylation of DNA by oxidizing methylated cytosines via several intermediates to 
unmethylated cytosines (Figure 1-3) [Tahiliani et al., 2009, Ito et al., 2010, Wu and Zhang, 
2017, He et al., 2011].  
 DNA methylation analysis initially focused on CpG islands, regions enriched for CpG- 
dinucleotides, which overlap with promoter sequences or transcriptional start sites and 
where methylation levels highly correlate with transcriptional activity (high methylation 
levels associated with gene silencing, low methylation levels associated with open 
chromatin, accessibility and active transcription) [Smith and Meissner, 2013, Saxonov et 
al., 2006, Luo et al., 2018]. Yet, high-resolution genome-wide methylation maps indicated 
that, while the number of dynamically regulated CpGs is limited (~20 %), they are often 
located in CpG-poor regions which frequently overlap with regulatory elements (e.g. 
enhancers or TF binding sites) [Ziller et al., 2013]. Coupling differentially methylated 
regions (DMRs) with binding of lineage-specific transcription factors thereby provides a 
framework that determines developmental cell fates and specifies lineage trajectories.  
 Due to the stability of DNA methylation as an epigenetic modification which is passed 
on to daughter cells, large-scale genomic patterns function as a molecular fingerprint 
which enables to define cell states, reconstruct cellular hierarchies or infer lineage 
specifications [Hodges et al., 2011, Bock et al., 2012, Farlik et al., 2016]. Serving as a mark 
which stabilizes specific cell states, many cancer entities are characterized by severely 
disturbed DNA methylation profiles. Yet, these profiles can be harnessed to deconvolute 
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intratumor heterogeneity or identify the cell of origin for a particular type of neoplasm 
[Brocks et al., 2014, Lutsik et al., 2017, Oakes et al., 2016, Kulis et al., 2015].  
 
Histone Modifications Define Functional Elements  
The compact organization of DNA into nucleosomes which consist of individual histone 
subunits, allows further epigenetic modifications without a direct modification of DNA 
nucleotides. Covalent post-translational histone modifications frequently encompass 
acetylation, methylation and phosphorylation at a large number of specific histone tail 
sites and by being coupled with the deposition of various histone variants amount to a 
complex regulatory network [Stricker et al., 2017]. Multiple evolutionary conserved 
enzymes classified as ‘writers’, ‘erasers’ or ‘readers’ establish or remove histone 
modifications at certain sites or recognize and bind to specific modifications, respectively 
(Figure 1-3) [Atlasi and Stunnenberg, 2017]. Charting histone marks across functional 
elements has led to the association of individual marks with certain activation states, e.g. 
tri-methylation of histone H3 at the lysine residue 27 (H3K27me3) and H3K9me2 with 
repression of gene expression, H3K27 acetylation (H3K27ac) with activation of gene 
expression, or H3K4me1 with priming of enhancers [Zhao et al., 2007, Leeb et al., 2010, 
Wen et al., 2009, Lienert et al., 2011, Creyghton et al., 2010, Kundu et al., 2000, Heinz et 
al., 2015].  
 
  
 
 
Figure 1-3: Epigenetic Layers and Modifications. 
Several layers of epigenetic marks and features make up the epigenomic profile of a cell. Epigenome dynamics are a 
characteristic feature during cell state transitions, differentiation and development. Specific enzymes, termed ‘writers’ 
and ‘erasers’, establish or remove particular modifications and therefore are critical regulators of cellular plasticity 
(Figure adapted from [Stricker et al., 2017] and [Atlasi and Stunnenberg, 2017]). 
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The Three-Dimensional Architecture of Chromatin 
Histone marks furthermore influence the nucleosome occupancy of DNA and specific 
chromatin interactions. Opening up of compact chromatin and removal of nucleosome 
occupancy is mediated by pioneering factors dependent on existing histone marks and is 
critical to increase DNA accessibility for the recruitment of additional factors to activate 
regulatory regions as enhancers or promoters [Atlasi and Stunnenberg, 2017]. 
Furthermore, long-range spatial chromatin interactions between promoter and enhancer 
elements as well as the compartmentalization of the genome into larger topologically 
associating domains (TADs), which facilitate interactions, provide the dynamic three-
dimensional structural basis for the regulation of gene expression [Zheng and Xie, 2019, 
Atlasi and Stunnenberg, 2017].  
 Eventually, it is important to note that DNA methylation, histone marks, and higher-
order structures do not govern gene expression on a solitary basis, but rather a complex 
interplay and crosstalk of the individual epigenetic layers is required to enforce correct 
transcriptomic profiles. 
 
Epigenome Dynamics During Hematopoietic Differentiation  
Early array-based technologies employed to investigate methylation changes in the 
hematopoietic system revealed that lineage-specific differentiation involves a modulation 
of DNA methylation marks [Ji et al., 2010, Hodges et al., 2011]. DMRs furthermore were 
enriched for lineage-specific TF binding sites, thereby correlating DNA methylation to 
gene expression levels and leading to the identification of regulatory programs implicated 
in the coordination of self-renewal and differentiation cell fates [Ji et al., 2010, Hodges et 
al., 2011]. First DNA methylation maps covering the whole hematopoietic hierarchy not 
only illustrated the inference of cellular lineage hierarchies based on methylation profiles, 
but also that cell type-specific methylation patterns are conserved throughout 
trajectories, starting from HSCs and ending in mature differentiated cells [Bock et al., 
2012]. Characteristic methylation signatures were proposed to act as gatekeepers that, by 
obstructing aberrant TF binding, instruct and reinforce specified lineage fates throughout 
developmental trajectories [Bock et al., 2012]. Genome-wide single-base resolution 
methylation maps of the HSPC compartment further corroborated the directive role of 
DNA methylation at the earliest stages of hematopoietic commitment [Cabezas-
Wallscheid et al., 2014, Lipka et al., 2014]. Unidirectional and progressive changes in DNA 
methylation were already detected during the transition from LT-HSCs to ST-HSCs and 
individual MPP subsets in particular at cis-acting regulatory regions [Cabezas-Wallscheid 
et al., 2014, Lipka et al., 2014].  These were enriched in TF binding sites that instruct 
lineage- and differentiation stage-specific transcriptional programs (e.g. Gata1, Gata2, 
Lmo2, Runx1 or Pbx1) [Cabezas-Wallscheid et al., 2014, Lipka et al., 2014], indicating that 
DNA methylation drives or at least mirrors the decisive activity of regulatory elements 
during hematopoietic commitment.  
 Assisting DNA methylation maps, genome-wide maps of histone modifications and 
chromatin accessibility were constructed to chart the regulatory landscape during 
hematopoietic differentiation [Lara-Astiaso et al., 2014, Buenrostro et al., 2018, Corces et 
al., 2016]. The establishment of lineage-specific enhancer repertoires precedes both 
lineage commitment and the activation of transcriptional programs characteristic for 
certain differentiated cell types [Lara-Astiaso et al., 2014]. Likewise, chromatin 
accessibility maps allowed the reconstruction of lineage-specific differentiation 
trajectories with dynamic TF activity paralleling the accessibility of chromatin around the 
TF binding motif [Buenrostro et al., 2018]. Eventually, analysis of the three-dimensional 
structure of the genome revealed long-range interactions between active promoters and 
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epigenetically marked active enhancers to be cell type-specific and to reflect lineage 
relationships between hematopoietic cell types [Javierre et al., 2016].  
 Unanimously, the epigenetic fingerprint of hematopoietic cells is a pivotal regulatory 
mechanism that shapes fundamental cellular characteristics by determining 
developmental fates, lineage decisions, self-renewal, quiescence or functional behavior in 
response to environmental stimuli. Since the integrity of the epigenome ensures the 
functionality of the hematopoietic system, aberrant epigenetic profiles are linked to the 
age-dependent decline in HSC functionality [Beerman et al., 2013, Sun et al., 2014a], as 
well as the development of hematological malignancies [Genovese et al., 2014, Jaiswal et 
al., 2014, Steensma et al., 2015, Papaemmanuil et al., 2016].  
 
 
1.3 Mutational Landscapes in Preleukemia 
and Hematological Malignancies 
 
1.3.1 Clonality of the Hematopoietic System  
 
In the hematopoietic system, blood production is sustained by the activity of thousands 
of HSCs, which are heterogeneous and display a stereotypic clonal behavior based on their 
epigenetic configuration [Yu et al., 2016]. During the lifespan of an individual, the 
expansion of several clones will result in a clonal mosaicism where particular clones 
continuously contribute more to blood production than others. Clonal expansions were 
initially identified by investigating cytogenetic patterns in patients with chronic myeloid 
leukemia (CML), thereby establishing a clonal origin of hematological malignancies 
[Fialkow et al., 1967, Rowley, 1973]. However, only several years later a correlation 
between clonal hematopoiesis and the age of individuals was discovered by studying 
skewed X-chromosome inactivation patterns in women of different age [Fey et al., 1994, 
Busque et al., 1996]. Although these studies described clonal behavior within the 
hematopoietic system, only advances in whole-genome sequencing methods enabled to 
associate genomic backgrounds and specific genetic lesions with a clonal expansion.  
 The increasing number of somatic mutations per cell is a hallmark of aging [Lopez-
Otin et al., 2013]. Environmental exposure, error-prone repair of DNA single- or double-
stranded breaks, spontaneous deamination of methylcytosines, replicative stress and 
excessive proliferation / activation are the main factors giving rise to the accumulation of 
mutations over time [Jaiswal and Libby, 2019, Flach et al., 2014, Walter et al., 2015]. In 
humans, 50,000-200,000 HSCs actively contribute to blood production with one cell 
division occurring around every 25-50 weeks [Catlin et al., 2011, Lee-Six et al., 2018]. 
Although HSCs usually reside in a quiescent state, each cell acquires around 17 mutations 
in their whole genome and 0.13 ± 0.02 mutations in exons per year of life [Welch et al., 
2012]. While most of these mutations will not affect the functionality or the fitness of a 
cell, in rare instances a mutation will convey a selective advantage, resulting in an 
expansion of the clone at disproportionate rates compared to other HSC clones [Jaiswal 
and Libby, 2019].   
 Whole-exome sequencing studies investigating the mutational frequency in blood 
samples from individuals unselected for any hematological phenotypes detected the 
presence of clonal hematopoiesis in combination with somatic driver mutations in a large 
number of otherwise healthy people [Jaiswal et al., 2014, Genovese et al., 2014, Xie et al., 
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2014]. This phenomenon, termed clonal hematopoiesis of indeterminate potential (CHIP), 
furthermore strongly correlated with age, with detectable somatic mutations being found 
only rarely in individuals younger than 40 years, but frequencies steadily increasing with 
age (18.4 % in individuals ≥ 90 years) [Jaiswal et al., 2014]. Accordingly, the emergence of 
clonal hematopoiesis strongly depends on increasing aging-associated selective 
pressures, but also an immune-mediated clonal selection or chemotherapy-associated 
selective pressures were shown to promote a reduced clonality over time [Bowman et al., 
2018, Coombs et al., 2017].  
 
1.3.2 Mutational Acquisition, Cooperativity and 
Inflammatory Conditions Define the 
Evolutionary Path of Disease Development 
 
The most recurrent mutations identified in individuals with CHIP encompass genes which 
are also commonly mutated in myeloid cancers, such as DNMT3A, TET2, ASXL1, TP53, 
JAK2 or SF3B1, and thereby have linked the presence of CHIP to the development of 
subsequent hematological malignancies, and have led to the connotation of CHIP as a 
preleukemic state. [Sperling et al., 2017]. The presence of somatic mutations was 
associated with a ten-fold increased risk of developing hematological cancers, especially 
myeloid malignancies such as acute myeloid leukemia (AML) or myelodysplastic 
syndromes (MDS), but also with an increased overall mortality and an increased risk for 
cardiovascular disease [Jaiswal et al., 2014, Jaiswal et al., 2017]. Although clonal 
hematopoiesis has also been identified in the absence of any known driver mutations 
[Zink et al., 2017], CHIP carriers usually display only one driver mutation, whereas 
patients with overt malignancies display multiple [Jaiswal and Libby, 2019]. While a clonal 
expansion of mutated clones is a common characteristic of CHIP-defined preleukemic 
states, only after the successive acquisition of additional mutations, disease progression 
and malignant transformation is initiated (Figure 1-4A) [Sperling et al., 2017]. Here, 
different driver mutations associated with CHIP relay varying risks of eventually 
developing overt myeloid malignancies, thereby highlighting that specific mutations are 
associated with a higher or lower oncogenic potential (Figure 1-4B) [Abelson et al., 2018, 
Desai et al., 2018]. 
  In CHIP, driver mutations frequently affect direct or indirect epigenetic regulators 
which coordinate patterns of DNA methylation (DNMT3A, TET2, IDH1/2) or histone 
modifications (ASXL1), suggesting that disturbed epigenetic profiles are causative for 
disease initiation in many cases [Bowman et al., 2018]. Likewise, more than 70 % of 
patients diagnosed with AML carry at least one somatic mutation in a gene involved in 
regulating epigenetic patterns within a cell (Figure 1-5A and Figure 1-5B) [Cancer Genome 
Atlas Research et al., 2013, Papaemmanuil et al., 2016, Chen et al., 2013b]. On an 
evolutionary timeline, the acquisition of mutations in epigenetic regulators usually 
precedes the acquisition of later genetic lesions affecting transcription factors or 
activated signaling pathways, however, malignancy progression is frequently promoted 
through cooperative effects between early and late arising mutations [Corces-Zimmerman 
et al., 2014, Guryanova et al., 2016, Loberg et al., 2019, Kameda et al., 2015]. Importantly, 
these early mutations usually occur in HSCs, and HSC clones with preleukemic mutations 
were detected in remission samples, illustrating that these clones contribute to therapy 
resistance and function as a reservoir from which relapse evolves [Shlush et al., 2014, 
Corces-Zimmerman et al., 2014].  
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 Since the evolutionary path from preleukemia to overt hematological malignancies is 
shaped by the co-occurrence, cooperativity and mutual exclusivity of certain mutations 
(Figure 1-5C), varying combinations of genetic lesions will impact phenotype, prognosis 
and therapy response [Sperling et al., 2017, Papaemmanuil et al., 2016]. As preleukemic 
mutations alone rarely result in the progression towards an oncogenic transformation, 
combinatorial mouse models employed to investigate an interplay between individual 
mutations are critical to understand their role in disease development. Ideally, therapeutic 
strategies tailored to a specific mutational background then can be applied to target CHIP, 
diminish the selective advantage of mutated clones, and prevent a progression to 
hematological malignancies [Bowman et al., 2018].  
 
 
 
 
Figure 1-4: Mutation-Driven Clonal Expansion and Acute Myeloid Leukemia Risk. 
(A) The development of AML is defined by the sequential acquisition of mutations. Early mutations frequently affect 
direct or indirect epigenetic regulators, such as DNMT3A, TET2, IDH1/2 or ASXL1 and result in a clonal expansion of 
the respective clone. The accumulation of additional secondary or tertiary mutations further promotes leukemic 
progression and the emergence of overt malignancies. Late-occurring mutations predominantly affect genes involved 
in cellular signaling, such as FLT3 or NRAS, and in co-operation with earlier acquired preleukemic mutations shape the 
evolutionary path of disease development (Figure adapted from [Sperling et al., 2017]). (B) Mutations in AML-associated 
driver genes are commonly found in healthy individuals with clonal hematopoiesis before diagnosis of any 
hematological malignancies. Distinct mutations confer diverging risks of future AML development, as indicated by the 
relative frequency of mutations in pre-AML cases (red, individuals developed AML) or in control cases (blue, individuals 
did not develop AML) (Figure adapted from [Abelson et al., 2018]).  
 
 
 Recent studies additionally linked the presence of clonal hematopoiesis and 
preleukemic mutations to inflammatory conditions that result in an increased risk for 
cardiovascular disease [Jaiswal et al., 2017, Fuster et al., 2017]. Beside catalyzing the 
demethylation of 5-methylcytosines, Tet2 is also required to resolve inflammation in 
macrophages as a loss of Tet2 (e.g. due to loss-of-function mutations) was associated with 
an upregulation of several proinflammatory cytokines which function as proatherogenic 
mediators [Zhang et al., 2015, Fuster et al., 2017, Jaiswal et al., 2017]. The 
proinflammatory state could be directly linked to the development of a preleukemic 
clonal expansion [Meisel et al., 2018], thereby establishing the importance of 
inflammation as a critical factor that contributes to preleukemic clonal hematopoiesis 
and disease progression. 
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Figure 1-5: Landscape and Co-Occurrence of Driver Mutations in Acute Myeloid Leukemia Patients. 
(A) Most frequently detected driver lesions in a cohort of 1540 AML patients, including gene mutations and fusions, 
chromosomal aneuploidies and complex karyotypes. Direct or indirect Epigenetic regulators, such as DNMT3A, TET2 
or IDH1/2 are recurrently mutated (Figure adapted from [Papaemmanuil et al., 2016]). (B) Categories of genetic lesions 
detected in AML patients. More than 70 % of patents carry at least one mutation affecting an epigenetic regulator 
(involved in chromatin modifications or DNA methylation) (Figure adapted from [Chen et al., 2013b]). (C) Recurrent 
pairs of mutations co-occurring in a cohort of 1540 AML patients (Data from [Papaemmanuil et al., 2016]).  
 
  
1.4 IDH1-R132H Mutations Lead to Metabolic 
Imbalances 
 
1.4.1 IDH1/2 Mutations in CHIP and AML 
 
Mutations in isocitrate dehydrogenase 1 or 2 (IDH1 / IDH2) initially were only rarely found 
in individuals with CHIP, arguing against a preleukemic nature of these mutations [Jaiswal 
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et al., 2014, Genovese et al., 2014, Xie et al., 2014]. Yet, large cohort risk stratification 
studies revealed not only that IDH1/2 mutations occur in healthy individuals several years 
before AML diagnosis, but also classified them among mutations associated with the 
highest risk for future AML development, with nearly all subjects carrying IDH1/2 
mutations eventually progressing to AML [Abelson et al., 2018, Desai et al., 2018]. Despite 
the relatively low frequency compared to other CHIP-associated mutations such as 
DNMT3A or TET2 mutations, IDH1/2 mutations accordingly impose a strong risk for 
oncogenic transformation and are recurrently detected in around 15-20 % of patients 
diagnosed with AML [Cancer Genome Atlas Research et al., 2013, Papaemmanuil et al., 
2016]. In AML patients, IDH1/2 mutations frequently have been detected at high variant 
allele frequencies in HSCs, implying that these mutations are acquired at the first stages 
of disease evolution and function as initiating leukemogenic event [Corces-Zimmerman et 
al., 2014]. 
 
1.4.2 IDH1-R132H Mutations Produce the 
‘Oncometabolite’ D-2-Hydroxyglutarate 
 
As part of the tricarboxylic acid (TCA) cycle, homodimeric IDH1/2 enzymes catalyze the 
conversion of isocitrate to a-ketoglutarate (aKG) while concomitantly producing reduced 
NADPH and CO
2
 (Figure 1-6) 
 
[Cairns and Mak, 2013]. Although both enzymes catalyze the 
identical reaction, they differ in their cellular location, with IDH1 being localized the 
cytoplasm and in peroxisomes whereas IDH2 resides in the mitochondrial matrix [Cairns 
and Mak, 2013]. Recurrent cancer-associated IDH1 missense mutations almost exclusively 
affect the arginine residue at position 132 (R132) which is required for substrate binding 
and is most frequently substituted by histidine (R132H mutation) in a mutated context. 
[Mardis et al., 2009, Parsons et al., 2008, Yang et al., 2012]. Analogously, IDH2 mutations 
predominantly affect arginine residues R172 or R140, which likewise are involved in 
specifying substrate binding [Mardis et al., 2009, Parsons et al., 2008, Yang et al., 2012].  
 Due to its critical function during substrate binding, mutation of the R132 amino acid 
alters substrate specificity and abrogates aKG production [Dang et al., 2009, Ward et al., 
2010]. Instead, IDH1-R132H mutations instigate a gain-of-function and result in a 
neomorphic enzymatic activity, catalyzing the conversion of aKG and NADPH to the D-
enantiomer of 2-hydroxyglutarate (D2HG) and NADP+ [Dang et al., 2009, Ward et al., 
2010]. The IDH1-R132H mutation-mediated formation of D2HG leads to an excessive 
accumulation within the cell and secretion into surrounding tissues, so that elevated 
D2HG levels for instance can be detected in brain tumors of glioma patients and blood 
sera of AML patients harboring IDH1-R132H mutations [Andronesi et al., 2012, Choi et al., 
2012, Gross et al., 2010, DiNardo et al., 2013]. D2HG accumulation therefore serves as a 
predictive marker to infer an IDH1-R132H mutation status, as a diagnostic marker to 
detect IDH1-R132H mutated malignancies and as a prognostic marker to assess clinical 
outcomes [DiNardo et al., 2013]. Since oncogenic effects of IDH1-R132H mutations are 
dependent on the excessive production of D2HG, several pharmacological inhibitors, 
which allosterically target mutated IDH1 in order to reduce D2HG production, have been 
developed and are under clinical investigation [Golub et al., 2019].  
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Figure 1-6: Mutated IDH1/2 Converts a-Ketoglutarate to D-2-Hydroxyglutarate. 
IDH1/2 wildtype enzymes catalyze the production of a-ketoglutarate from isocitrate. However, recurrent IDH1-R132H, 
IDH2-R140Q and IDH2-R172K mutations lead to alterations in substrate specificity and a loss of regular catalytic 
activity, and ultimately result in mutated IDH1/2 enzymes gaining the function to convert a-ketoglutarate to D-2-
hydroxyglutrate (Figure adapted from [Molenaar et al., 2018a]). 
 
 
1.4.3 Excessive D2HG Levels Inhibit DNA and Histone 
Demethylases 
 
Based on the structural similarity of aKG and D2HG, oncogenic functions of D2HG are 
mediated by acting as an inhibitor for aKG-dependent dioxygenases, including enzymes 
of the TET family (TET1, TET2, TET3) or histone demethylases of the Jumonji class (Figure 
1-7) [Xu et al., 2011, Chowdhury et al., 2011, Lu et al., 2012]. TET enzymes are critical 
enzymes involved in the active demethylation of 5-methylcytosines (5-mC) by catalyzing 
the hydroxylation of 5-mC to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), 
and 5-carboxycytosine (5-caC) [Ito et al., 2010, Ito et al., 2011]. Owing to the inhibition of 
TETs, IDH1-R132H mutations consequently were associated with a hypermethylation or a 
CpG island methylator phenotype [Figueroa et al., 2010, Noushmehr et al., 2010, Turcan 
et al., 2012], which is reversed upon treatment with IDH1- or DNMT inhibitors 
[Borodovsky et al., 2013, Turcan et al., 2013, Kernytsky et al., 2015]. Interestingly, IDH1-
R132H and TET2 mutations usually are mutually exclusive in AML patients and aberrant 
DNA methylation patterns in IDH1-R132H mutated cells are phenocopied by TET2 
knockouts [Figueroa et al., 2010], illustrating that a D2HG-mediated inhibition of TETs is 
a critical mechanism contributing to oncogenic transformation.  
 Likewise, inhibition of Jumonji C-domain lysine demethylases (KDM2A, KDM4A, 
KDM4C, KDM4D, KDM5B) by D2HG results in the accumulation of methylated lysine 
residues, in particular of tri-methylated H3K9 and tri-methylated H3K27 [Lu et al., 2012, 
Chowdhury et al., 2011]. IDH1-R132H mutations furthermore affect chromatin structures 
and loops by compromising binding of the insulator protein CTCF [Flavahan et al., 2016], 
which is required to form boundaries between TADs [Rao et al., 2014]. Mutation-
dependent DNA hypermethylation interferes with binding patterns and consequently 
results in deregulated enhancer-promoter interactions or deregulated enhancer 
activations [Flavahan et al., 2016]. Collectively, disturbed patterns of epigenetic 
modifications induced by IDH1-R132H mutations are key mechanisms that cause 
alterations in epigenetic-based regulatory networks and thereby drive alterations in gene 
expression levels. 
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1.4.4 IDH1-R132H Mutations Alter DNA Damage and 
Repair Kinetics 
 
In addition to a deregulated epigenetic landscape, IDH1-R132H mutations further affect 
DNA damage response and DNA repair signaling pathways. Reactive oxygen species (ROS) 
are a primary source of oxidative damage to DNA and therefore need to be detoxified 
through several NADPH-dependent mechanisms [Gagne et al., 2017]. The consumption of 
NADPH by mutated IDH1 consequently will result in diminished levels of damage-
preventing antioxidants within the cell, and simultaneously will result in elevated levels 
of DNA damaging agents and a state of oxidative stress [Bleeker et al., 2010, Shi et al., 
2015, Shi et al., 2014].  
 In response to DNA damage, the kinase ataxia-telangiectasia mutated (ATM) functions 
as a critical regulator of downstream signaling pathways leading to the recruitment of 
repair factors to the site of damage [Shiloh and Ziv, 2013]. Repression of ATM levels by 
D2HG, mediated through the inhibition of KDM4 lysine demethylases, was shown to result 
in impaired DNA damage signaling and repair kinetics [Inoue et al., 2016]. Similarly, 
inhibition of lysine demethylases KDM4A/B, which are involved in orchestrating DNA 
damage response pathways, and aKG-dependent repair enzymes of the ALKB family was 
shown to promote the accumulation of DNA damage in IDH1-R132H mutated cells (Figure 
1-7) [Mallette et al., 2012, Young et al., 2013, Sulkowski et al., 2017, Wang et al., 2015].  
 Overall, the down-regulation of DNA damage sensing and repair pathways enables 
IDH1-R132H mutated cells to evade tumor suppression, while at the same time promoting 
genomic instability, random mutagenesis and the acquisition of additional driver 
mutations. On the other hand, these characteristics can be leveraged in treatment settings, 
where IDH1-R132H mutated cells displayed a higher sensitivity to poly (ADP-ribose) 
polymerase (PARP) inhibitors, genotoxic chemotherapeutics such as alkylating agents, or 
radiation [Sulkowski et al., 2017, Wang et al., 2015, Li et al., 2013].  
 Furthermore, increased D2HG levels have been highlighted to interfere with mTOR 
signaling, HIF1 activity, RNA methylation and collagen maturation through the inhibition 
of various aKG-dependent enzymes [Gagne et al., 2017], thereby emphasizing the 
complexity and diversity of oncogenic effects arising from an IDH1-R132H mutation-
induced metabolic dysbalance.  
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Figure 1-7: Effects of IDH1/2 Mutations on Cellular Processes. 
Overview of cellular processes that are dysregulated upon the expression of an IDH1 or IDH2 mutation and the excessive 
production and accumulation of D2HG. The dysregulation of cellular processes is either mediated through an 
modification of enzymatic activities (enzymes inhibited through D2HG), or imbalances in NADP+/NADPH ratios (Figure 
adapted from [Molenaar et al., 2018a] and [Gagne et al., 2017]). 
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1.4.5 IDH1-R132H Mutation-Mediated Effects on 
Hematopoietic Stem and Progenitor Cell 
Function 
 
Within the hematopoietic system, investigations have tried to segregate effects 
determined through the inhibition of TET enzymes and effects determined through the 
impairment of other pathways. In AML patients, IDH1-R132H mutations were associated 
with similar aberrant epigenetic patterns as TET2 loss-of-function mutations, featuring a 
global DNA hypermethylation signature [Figueroa et al., 2010]. Both mutations 
furthermore resulted in defects in hematopoietic differentiation, in particular of the 
myeloid lineage, and an increased expression of stem cell markers [Figueroa et al., 2010]. 
These findings were recapitulated in Tet2 knockout mouse models, where Tet2 loss 
induced enhanced stem cell self-renewal, an enlargement of the HSPC compartment and 
skewed myeloid differentiation patterns [Moran-Crusio et al., 2011]. Equally, Idh1-R132H 
mutant mice featured enhanced numbers of early progenitors arising from changes in 
DNA methylation signatures which affect signaling pathways involved in hematopoietic 
cell proliferation, differentiation and leukemogenesis [Sasaki et al., 2012]. Yet, a direct 
comparison of both mouse models revealed that effects of Idh1-R132H mutations are cell 
type dependent. In HSCs, the expression of the Idh1-R132H mutation predominantly leads 
to altered histone methylation patterns, that result in the down-regulation of ATM and 
impaired DNA repair independent of Tet2 [Inoue et al., 2016]. On the other hand, in MPPs 
or myeloid progenitor populations, defects are driven by the inhibition of Tet2 and 
resemble defects observed in Tet2 knockout mice [Inoue et al., 2016, Moran-Crusio et al., 
2011].  
 Despite the overlapping DNA hypermethylation signature and mutual exclusivity, the 
occurrence of IDH1/2 mutations and TET2 mutations in hematological disorders varies 
substantially. Compared to IDH1/2 mutations, TET2 mutations are more frequently 
observed in CHIP, chronic myelomonocytic leukemia (CMML), MDS or myeloproliferative 
neoplasms (MPNs), whereas combined IDH1/2 mutation frequencies are higher in AML 
and associated with a decreased survival when found in MDS [Shih et al., 2012, Thol et al., 
2010]. These findings have led to the hypothesis that IDH1 mutations are linked to more 
acute and aggressive diseases and confer a higher oncogenic potential than TET2 
mutations. However, this association could only partly be recapitulated in mutant mouse 
models. Underlining varying clinical features, Idh1-R132H mutated mice succumb 
prematurely due to anemia, splenomegaly and decreased bone marrow cellularity only 
after long latencies, while Tet2 loss results in a more rapid and more aggressive 
development of myeloid neoplasms reminiscent of CMML [Inoue et al., 2016, Moran-
Crusio et al., 2011, An et al., 2015].  
Due to the low transforming potential of Idh1-R132H mutations in mice, studies have 
begun to investigate the interplay of Idh1/2 mutations with further secondary activating 
mutations in Npm1, Flt3 or Nras [Ogawara et al., 2015, Chen et al., 2013a, Kats et al., 
2014]. A co-occurrence of these mutations clearly accelerated the onset and progression 
of myeloproliferative diseases, thereby underpinning the preleukemic characteristic of an 
Idh1-R132H mutation alone and highlighting that the course of disease highly depends 
on and is determined by secondary events and their cooperation [Ogawara et al., 2015, 
Chen et al., 2013a, Kats et al., 2014].   
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1.5 DNMT3A-R882H Mutations Deregulate 
DNA Methylation Landscapes 
 
1.5.1 DNMT3A Activity Balances HSC Activity 
 
Early work focusing on the role of Dnmt1 within the hematopoietic system illustrated that 
epigenetic DNA methylation patterns maintained by Dnmts are essential for the 
functionality, homeostasis, self-renewal and differentiation of HSCs [Broske et al., 2009, 
Trowbridge et al., 2009]. In line, loss of Dnmt3a led to impaired HSC differentiation and 
increased HSC frequencies within the bone marrow due to the upregulation of HSC 
multipotency genes. [Challen et al., 2011]. Although some compensatory effects between 
Dnmt3a and Dnmt3b were observed, evidence suggests that Dnmt3a is the main driver of 
DNA methylation in HSCs in order to regulate HSC maintenance [Challen et al., 2014]. 
While it was initially assumed, that a loss of Dnmt3a results in a global hypomethylation 
phenotype, Dnmt3a knockout HSCs displayed DMRs defined by both hyper- and 
hypomethylation [Challen et al., 2011]. Conserved stretches of lowly methylated regions, 
termed methylation canyons, are defined by highly methylated canyon boundaries 
maintained by Dnmt3a [Jeong et al., 2014]. Canyon-associated genes, encompassing 
developmental TFs or HSC regulatory genes, become deregulated upon the erosion of 
boundaries through Dnmt3a loss, thereby leading to a contraction or expansion of loci-
specific canyons [Jeong et al., 2014, Jeong et al., 2018]. Yet, more complex regulatory 
networks, including activating and repressing histone marks as well as loci-specific 
competition and cooperation between Dnmt3a and Tet2 balance HSC self-renewal and 
differentiation through the regulation of lineage-specific TFs and self-renewal genes 
[Jeong et al., 2014, Zhang et al., 2016]. Accordingly, double-knockout of Dnmt3a and Tet2 
promoted an accelerated development of malignancy and the induction of myeloid or 
lymphoid disease [Zhang et al., 2016]. Loss of Dnmt3a alone led to an immortalization of 
HSCs with indefinite self-renewal potential in serial rounds of transplantations, mediated 
through aberrant methylation at canyon-associated HSC regulatory elements [Jeong et al., 
2018]. However, despite favoring HSC self-renewal at the expanse of differentiation, mice 
transplanted with Dnmt3a deleted HSCs eventually developed myeloid or lymphoid 
malignancies such as MDS, AML or T-cell acute lymphocytic leukemia (T-ALL) [Celik et al., 
2015, Mayle et al., 2015], suggesting that a Dnmt3a knockout-mediated block in 
differentiation can be overcome under certain conditions or upon acquisition of 
cooperating mutations. 
 
1.5.2 DNMT3A-R882H Mutations Affect 
Methyltransferase Activity and Result in a 
Dominant-Negative Phenotype 
 
Research investigating the role of DNMT3A in the hematopoietic system was sparked 
through the detection of a wide range of nonsense, missense and frameshift mutations in 
AML patients [Ley et al., 2010]. Since then, DNMT3A mutations have been identified in a 
wide range of hematological malignancies, including MDS, MPN, or T-ALL  [Roller et al., 
2013, Celik et al., 2016], but also in individuals with CHIP, where DNMT3A is the most 
frequently mutated gene [Jaiswal et al., 2014, Genovese et al., 2014, Xie et al., 2014]. 
Mutations were detected with a high variant allele frequency in HSCs and result in a 
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preleukemic state characterized by a clonal expansion of mutated HSCs, thereby 
providing the basis for disease progression and remission [Shlush et al., 2014, Corces-
Zimmerman et al., 2014]. The majority of DNMT3A mutations were confined to the 
methyltransferase domain and in particular enriched for missense mutations affecting 
the arginine residue at position 882 (R882), which in most cases is substituted by a 
histidine residue (R882H mutation) [Ley et al., 2010, Roller et al., 2013, Celik et al., 2016]. 
DNMT3A-R882H mutations furthermore were associated with a strong loss in methylation 
activity and mechanistically could be traced back to a blocked ability to form active homo-
tetramers which catalyze the transfer of methyl groups to cytosines [Holz-Schietinger et 
al., 2012]. Importantly, R882H-mutated DNMT3A also inhibits wildtype DNMT3A activity 
by equally disrupting the homo-tetramer formation of wildtype enzymes in a dominant-
negative fashion [Russler-Germain et al., 2014]. As a consequence, DNMT3A-R882H 
mutated AML samples are characterized by a uniform focal hypomethylation across all 
genomic regions (promoter, gene bodies, intergenic regions, etc.) [Russler-Germain et al., 
2014]. Although CpG island hypermethylation was detected to a certain degree in mutant 
samples, the DNMT3A-R882H mutation-mediated hypomethylation is thought to function 
as initiating event, whereas observed hypermethylation patterns arise as a secondary 
effect during AML progression [Spencer et al., 2017].  
 In Dnmt3a-R878H (mouse homologue to the DNMT3A-R882H mutation) mutated 
mice, the heterozygous expression of the Dnmt3a-R878H mutation caused an expansion 
of stem and progenitor cells similar to phenotypes observed in Dnmt3a knockout mice, 
indicating that the mutation alone is sufficient to promote clonal expansion of HSCs 
[Guryanova et al., 2016, Loberg et al., 2019]. Yet, only the successive acquisition of Npm1 
or Flt3 mutations resulted in the transformation of Dnmt3a-R878H mutated cells and the 
progression to AML- and MPN-like phenotypes [Guryanova et al., 2016, Loberg et al., 2019], 
demonstrating that a co-occurrence and cooperativity between DNMT3A-R882H and 
additional secondary mutations is required to drive hematological malignancies in a 
DNMT3A mutated context. The co-occurrence of Idh2-R140Q and Dnmt3a-R878H 
mutations was not sufficient to engender manifestations of hematological diseases, yet 
cells were distinguished by an epigenetic antagonism and the reversion of hyper- and 
hypomethylation patterns observed in the respective single-mutants [Glass et al., 2017]. 
 
 
1.6 DNA Damage and Repair Pathways 
Maintain Genome Integrity 
 
1.6.1 Sources of DNA Damage 
 
While DNA damage in mammalian cells occurs at a rate of more than 70,000 alterations 
per day [Tubbs and Nussenzweig, 2017], DNA repair mechanisms are critical in order to 
maintain genome integrity and prevent the excessive acquisition and accumulation of 
mutations.  
 Endogenous DNA damage predominantly arises from chemical reactions the DNA 
molecule is engaged in, for instance hydrolytic or oxidative reactions with molecules 
naturally present in the cell [Chatterjee and Walker, 2017]. Due to its chemical structure, 
DNA is predisposed to spontaneous deamination and depurination, the non-enzymatic 
transfer of methylgroups via S-adenosylmethionine (SAM), or oxidative damage induced 
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by ROS, with all reactions eventually leading to lesions within the DNA molecule 
[Chatterjee and Walker, 2017]. Additionally, errors occurring during DNA replication, 
including base substitutions, insertions or deletions, as well as during the action of 
topoisomerase enzymes to remove superhelical tension further contribute to 
endogenously derived DNA damage [Loeb and Monnat, 2008, Wang, 2002]. On the other 
hand, exogenous DNA damage occurs due to the interaction of the DNA molecule with 
environmental, physical or chemical agents, such as ionizing and ultraviolet radiation, 
alkylating agents, aromatic amines, etc. [Chatterjee and Walker, 2017].  
 Depending on its source, endogenous or exogenous damage frequently results in the 
formation of single-stranded breaks (SSBs) or, less frequent, in the formation of double-
stranded breaks (DSBs) which are more perilous due to a higher risk of chromosomal 
rearrangements, amplifications or deletions [Delia and Mizutani, 2017].  
 
1.6.2 The DNA Damage Response Pathway 
 
Upon the formation of SSB or DSB lesions, the activation of the DNA damage response 
(DDR) machinery encompasses a complex network of signaling pathways to coordinate 
not only the detection and repair of lesions, but also to transiently arrest cell cycle activity, 
and, in cases of excessive damage, induce apoptotic or senescent cell programs [Ciccia 
and Elledge, 2010].  
Forming the cornerstone of the DDR pathway, the protein kinases ATM, ATR and 
DNA-PK, are activated by DNA breaks and phosphorylate multiple downstream targets to 
regulate repair and cellular activity [Blackford and Jackson, 2017]. Here, ATM primarily is 
recruited to DSBs and orchestrates the activity of several cell cycle checkpoints, whereas 
ATR is primarily responsive to SSBs generated during replication stress and activates S-
checkpoint signaling  [Blackford and Jackson, 2017]. DNA-PK, similarly to ATM, is 
recruited to DSBs, but promotes its repair via non-homologous end joining (NHEJ) whereas 
ATM activation frequently results in resolving DSBs via homologous recombination (HR). 
The decision between NHEJ and HR depends on multiple factors, such as cell cycle phase, 
local chromatin environment or the structure of DNA ends [Scully et al., 2019].  
 
1.6.3 Homologous Recombination and the Repair of 
Double-Strand Breaks 
 
Following the recruitment of ATM to DSBs, ATM phosphorylates and activates 
downstream mediators such as MDC1, 53BP1 and BRCA1, which in part are antagonizing 
and counteracting each other in order to promote either NHEJ (53BP1) or HR (BRCA1) 
[Blackford and Jackson, 2017]. A critical step facilitating repair via HR is the resection of 
DSB ends to yield single stranded DNA (ssDNA) 3’ ends mediated by the endonuclease 
activity of the MRN complex and the exonuclease activity of EXO1/BLM [Nimonkar et al., 
2011, Mimitou and Symington, 2008, Symington and Gautier, 2011]. The generated ssDNA 
stretches are rapidly bound by RPA complexes which then are displaced by RAD51 to 
form a RAD51-nucleoprotein filament (facilitated by mediator RAD52) [Baumann et al., 
1996, Sugiyama et al., 1997, San Filippo et al., 2008]. In contrast to NHEJ, HR relies on 
pervasive sequence homology between the broken DNA molecule and a donor strand 
template (usually the homologous chromosome), and involves templated strand synthesis 
during the repair process [Scully et al., 2019]. In mammalian cells, BRCA2 serves as the 
key recombination mediator which aids in RAD51-mediated strand invasion and 
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homologous pairing of the RAD51 ssDNA filaments and complementary sequences [Yang 
et al., 2005a, Jensen et al., 2010]. Heteroduplex formation, followed by the engagement of 
DNA polymerases results in the extension of the invading strand using the donor strand 
as a template [Chen et al., 2008, van der Heijden et al., 2008, McVey et al., 2016]. 
Eventually, several subpathways can be employed to resolve and disintegrate the 
homologous structures, depending on various fates of the RAD51-mediated 
recombination synapse [Scully et al., 2019].  
 
1.6.4 PARP1 Mediates Single-Strand Break Repair 
and is Targeted in Patients with Defects in 
Homologous Recombination   
 
Although being in part also involved in DSB repair, PARP1 is the key enzyme which detects 
and binds SSBs and mediates excision repair [Ray Chaudhuri and Nussenzweig, 2017]. 
Following SSB lesion detection, PARP1 recruits scaffold proteins (XRCC1), phosphatases 
(PNKP), ligases (LIG3) and DNA polymerases (Pol d, Pol e, and Pol b) to process and fill the 
strand gap [Ray Chaudhuri and Nussenzweig, 2017].  
 Upon bulky DNA lesions (e.g. UV damage), the global genome nucleotide excision 
repair (GG-NER) pathway is employed which involves lesion recognition by XPC, RAD23B 
as well as the DDB1-DDB2 complex and is promoted by PARP1 [Pines et al., 2012, Robu et 
al., 2017]. Subsequent steps, which in part are also facilitated by PARP1, involve chromatin 
relaxation and remodeling, lesion verification and excision, and eventually gap filling and 
ligation [Marteijn et al., 2014, Ray Chaudhuri and Nussenzweig, 2017].  
 Due to its important role in lesion recognition and repair, PARP inhibitors recently 
have emerged as promising targeted therapy options in the context of synthetic lethality 
[Lord and Ashworth, 2017]. Patients carrying germline mutations in BRCA1 or BRCA2 have 
elevated risks of developing breast, ovarian and other cancers, because of an only 
inefficient repair of DSBs by HR [Miki et al., 1994, Wooster et al., 1995, Paul and Paul, 
2014]. Inhibition of PARP causes persistent SSBs, which upon replication result in the 
collapse of replication forks and the generation of DSBs [Lord and Ashworth, 2017]. 
Exploiting the deficiencies in HR repair arising through dysfunctional BRCA1/2, the 
overwhelming accumulation of DSBs eventually results in chromosomal instability, cell 
cycle arrest and cell death [Farmer et al., 2005, Bryant et al., 2005]. Although reports 
meanwhile suggest that PARP inhibitors function by interfering with the catalytic cycle of 
PARP and thereby result in cytotoxic lesions consisting of trapped PARP [Murai et al., 
2012, Pommier et al., 2016], other tumor entities that likewise display defects in HR due 
to ATM deficiency or due to IDH1/2 mutations were shown to be similarly hypersensitive 
and more susceptible to PARP inhibitors [Weston et al., 2010, Sulkowski et al., 2017].  
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Aims of the Thesis 
 
 
The impact of an IDH1-R132H mutation on a cell is diverse, ranging from deregulation of 
the epigenetic landscape to defects in DNA damage and DNA repair as well as alterations 
in cellular signaling [Gagne et al., 2017]. Importantly, many oncogenic functions of IDH1-
R132H mutations are derived from the analysis of brain tumor cells, whereas the effects 
on hematopoietic cells still remain more elusive.  
 In the hematopoietic system, earlier work suggests the effects of an Idh1-R132H 
mutation to depend on the cell type affected. While in LT-HSCs functionality is impaired 
through a prevailing inhibition of histone demethylases and a down-regulation of the 
damage-response gene ATM, in downstream populations (e.g. ST-HSCs, MPPs) effects of 
an Tet2 inhibition predominate and result in altered DNA methylation and differentiation 
patterns [Inoue et al., 2016]. However, although Idh1-R132H mutated HSCs display an 
accumulation of DNA damage and an impaired repair efficiency, how these characteristics 
affect functionality, self-renewal, differentiation and reconstitution potential in a 
transplantation (or serial transplantation) setting needs to be determined.  
Moreover, the fraction of hematopoietic cell types analyzed in the context of Idh1-R132H 
mutations remains incomplete. For instance, as Tet2 also is involved in regulating the 
expression of inflammatory mediators in macrophages [Zhang et al., 2015, Fuster et al., 
2017, Jaiswal et al., 2017, Meisel et al., 2018] , it seems likely that Idh1-R132H mutations 
are not confined to only affect functionality of stem and progenitor cells, but also 
differentiated cell populations such as monocytes or macrophages. Furthermore, how 
gene networks, which are dysregulated by Idh1-R132H mutations in different cell types, 
potentially contribute to cancer initiation or progression is only poorly understood. Yet, 
breakthroughs in single-cell RNA sequencing methods not only allow to analyze the 
transcriptomic landscape of a large number of single cells, they also can be applied to 
dissect cellular heterogeneity in the hematopoietic compartment and reconstruct 
differentiation trajectories [Giladi et al., 2018, Nestorowa et al., 2016, Velten et al., 2017, 
Laurenti and Gottgens, 2018]. 
 Despite the fact that in humans, IDH1-R132H mutations represent a substantial risk 
factor for disease progression and AML development [Abelson et al., 2018, Desai et al., 
2018], the oncogenic potential in mice is limited [Sasaki et al., 2012, Inoue et al., 2016]. 
Whereas cooperative effects of Idh1/2 mutations with proliferative and activating 
mutations in Npm1, Flt3 or Nras have been described previously [Ogawara et al., 2015, 
Chen et al., 2013a, Kats et al., 2014], an interplay between Idh1-R132H mutations and 
other early preleukemic mutations such as Dnmt3a-R878H / DNMT3A-R882H mutations, 
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has not been investigated extensively. Importantly, since IDH1-R132H and DNMT3A-
R882H mutations frequently co-occur in AML patients (see Figure 1-5C) [Cancer Genome 
Atlas Research et al., 2013, Papaemmanuil et al., 2016], studying their interactions 
therefore is of particular clinical relevance.  
 Collectively, the main aim of this doctoral thesis was to characterize in detail the 
effect of Idh1-R132H and DNMT3A-R882H mutations alone or in combination on 
hematopoietic functionality and differentiation, and to identify gene regulatory networks 
which are deregulated upon the expression of these mutations in individual hematopoietic 
cell types.  
 To address this aim, the following primary objectives were devised throughout this 
thesis: 
 
1. Generation of in vitro and in vivo model systems to investigate the effects of Idh1-
R132H and DNMT3A-R882H mutations. 
 
2. Establishing a conditional and inducible mouse model which expresses the Idh1-
R132H and / or the DNMT3A-R882H mutation in the hematopoietic compartment. 
 
3. Characterization of the functionality and reconstitution potential of Idh1-R132H 
and DNMT3A-R882H single-mutated- as well as Idh1-R132H DNMT3A-R882H 
double-mutated HSCs in transplantations and serial transplantations. 
 
4. Characterization of the blood and bone marrow composition of mice transplanted 
with Idh1-R132H and DNMT3A-R882H single-mutated- as well as Idh1-R132H 
DNMT3A-R882H double-mutated cells. 
 
5. Generation of a genotype-specific transcriptomic landscape of the hematopoietic 
compartment, encompassing stem cells, progenitor cells and differentiated cells. 
 
6. Reconstruction of transcriptome-based differentiation trajectories and their 
plasticity in response to the expression of single or combined Idh1-R132H and 
DNMT3A-R882H mutations. 
 
7. Identification of hematopoietic cell types to be most affected by Idh1-R132H and 
/ or DNMT3A-R882H mutations. 
 
8. Identification of hematopoietic cell type-specific gene regulatory programs 
differentially expressed between the individual mutated genotypes. 
 
9. Correlation of aberrant transcriptome-defined cell populations with surface 
marker-defined cell populations for prospective analysis and characterization. 
 
 
 Overall, our phenotypic and molecular analysis of Idh1-R132H and / or DNMT3A-
R882H mutated hematopoietic compartments will enhance our understanding of how 
these mutations alone or in combination interact to drive initiation and progression of 
leukemia development. The identification of aberrantly expressed gene regulatory 
networks will further be of benefit in designing treatment strategies tailored for patients 
carrying single or combined IDH1-R132H and DNMT3A-R882H mutations.  
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Results 
 
 
In the course of this thesis, effects of an Idh1-R132H mutation were investigated in a 
hematopoietic cell line model as well as in a hematopoiesis-specific knock-in mouse 
model. Experiments performed in cell lines focused on addressing the impact of Idh1-
R132H mutations on cell growth, proliferation and DNA damage repair, whereas 
experiments in mice were specifically aimed to characterize self-renewal, repopulation- 
and multi-lineage potential of Idh1-R132H mutated HSCs. In addition, we investigated the 
cooperativity of Idh1-R132H mutations and DNMT3A-R882H mutations in a double-
mutated mouse model and assessed mutation-mediated differentiation defects 
phenotypically and at a molecular level by using single-cell and bulk RNA-sequencing.  
 
 
3.1 Characterization of an Idh1-R132H 
Mutated Cell Line Model  
 
In order to investigate the effects of Idh1-R132H mutations on myeloid cells, we expressed 
this mutation in the myeloid 32D bone marrow cell line. Therefore, we cloned a cDNA 
encoding the Idh1-R132H mutation into a lentiviral overexpression plasmid, where the 
expression of the Idh1-R132H mutation and an mCherry fluorescent reporter are driven 
from a spleen focus forming virus (SFFV) promoter (Figure 3-1A). After successful 
transduction and sorting of the cells based on mCherry expression, we used an enzymatic 
assay [Balss et al., 2012] to quantify D-2-Hydroxyglutarate (D2HG) levels in the respective 
32D cell lysates. As expected, we detected a more than 20-fold increase in D2HG levels 
(normalized to the overall protein content) in 32D cells that were transduced with Idh1-
R132H constructs, compared to cells that were transduced either with an empty vector 
construct or with an Idh1 wildtype (Idh1-WT) overexpressing construct (Figure 3-1B).   
 Having confirmed the increased production of D2HG due to the expression of the 
Idh1-R132H mutation in our model system, we next characterized the functional 
consequences of this metabolite on 32D cells. Based on previous findings that linked the 
Idh1-R132H mutation and the concomitant increase in D2HG to alterations in DNA 
damage response and DNA repair pathways  [Sulkowski et al., 2017, Inoue et al., 2016], 
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we specifically assessed proliferation and DNA damage rates in our 32D cell line model. 
By using combined 5-Ethynyl-2´-deoxyuridine (EdU) - 7-Aminoactionomycin (7AAD) 
labeling, we measured percentages of cells in G0-/G1- phase, S-phase or G2/M-phase of 
the cell cycle (Figure 3-1C). Idh1-R132H mutated cells displayed increased percentages of 
cells that are not actively cycling (G0-/G1-Phase), whereas percentages of DNA replicating 
cells (S-phase) were reduced (Figure 3-1D). In line with this, we could show decreased 
proliferation rates of Idh1-R132H mutated cells in a co-culture assay, where Idh1-R132H 
mutated cells and empty vector transduced cells were seeded at a 1:1 ratio. By using two 
different fluorescent proteins as reporter (mCherry for Idh1-R132H / Idh1-WT transduced 
cells, GFP for empty vector transduced cells), relative growth rates were tracked over time 
by quantifying mCherry:GFP ratios using flow cytometry (Figure 3-1E). Whereas co-
cultured Idh1-WT and empty vector transduced cells displayed equal growth rates, Idh1-
R132H transduced cells were defined by markedly reduced growth rates, that resulted in 
a continuous decrease of relative Idh1-R132H mutated cell frequencies.  
 
 
 
Figure 3-1: Idh1-R132H Mutated 32D Cells Display Aberrations in Cell Proliferation.  
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(A) Schematic overview of lentiviral Idh1-R132H, Idh1-WT and empty vector overexpression plasmids used for the 
transduction of the 32D myeloid bone marrow cell line. (B) Enzymatic quantification of D2HG in 32D cell lysates 
transduced either with an empty vector, Idh1-WT or Idh1-R132H overexpression plasmid (n = 2, mean ± SD). (C) 
Representative FACS gating scheme of an EdU-7AAD staining performed with transduced 32D cells. Pacific Blue signal 
correlates with incorporated EdU and allows cell cycle state assignment. (D) Quantification of cell cycle phases for empty 
vector, Idh1-WT and Idh1-R132H transduced cells. The depicted p-value was calculated by contrasting S-phase 
frequencies from Idh1-R132H cells with S-phase frequencies from empty vector cells (n = 3, mean ± SD). (E) Competitive 
proliferation assay of either Idh1-WT or Idh1-R132H transduced cells co-cultured with empty vector transduced cells 
seeded at a 1:1 ratio. Idh1-R132H or Idh1-WT cells were distinguished from empty vector cells based on the respective 
fluorescence signal (mCherry vs. GFP). Fluorescence signals were determined by flow cytometry (n = 2, depicted curves 
were smoothened based on a loess (locally estimated scatterplot smoothing) regression model, confidence interval (0.95) 
is plotted around curve).  
 
 
 To assess whether the reduced proliferation rates could be traced back to an 
increased amount of DNA damage in these cells, we performed a comet assay to measure 
DNA damage levels under steady state conditions, directly after irradiation, and after 
recovery phases following irradiation. Here, we observed that already under steady state 
conditions, Idh1-R132H mutated 32D cells feature significantly higher DNA damage levels 
as quantified by the olive tail moment of individual cells (Figure 3-2A). Directly after 
irradiation with 2- or 5 Gy, the observed effect became even more pronounced, while after 
a 30- or 60 min recovery phase, DNA damage levels again reached physiological levels, 
suggesting that repair kinetics in Idh1-R132H mutated cells are comparable to empty 
vector transduced cells.  
 As Idh1-R132H mutations were shown to result in defects in the homologous 
recombination (HR) pathway which is required for the efficient repair of double-stranded 
breaks (DSBs)  [Sulkowski et al., 2017], we next investigated whether the Idh1-R132H 
mutated 32D cell line model is more sensitive to PARP inhibitors. While PARP is 
predominantly involved in the repair of single-stranded breaks (SSBs), inhibition of PARP 
causes persistent SSBs, which frequently lead to the generation of DSBs during DNA 
replication cycles. In case deficiencies in HR-mediated repair exist, DSBs accumulate over 
time and eventually lead to synthetic lethality, decreased survival rates and an increased 
sensitivity to PARP inhibitors. Therefore, we analyzed cell viability of Idh1-R132H mutated 
32D cells in response to different concentrations of the PARP inhibitor Olaparib over 3 
days (Figure 3-2B). We found Idh1-R132H mutated cells to be significantly more sensitive 
to PARP inhibition, especially at a concentration of 1 µM Olaparib. Increasing 
concentrations (4 µM Olaparib) did not aggravate discrepancies between Idh1-R132H 
mutated and empty vector transduced samples, but still resulted in significant differences 
in cell viability after three days of treatment. 
Taken together, we established an Idh1-R132H mutated cell line model and could 
verify the expression of the mutation by measuring increased levels of the oncometabolite 
D2HG. On a functional level, the Idh1-R132H mutation resulted in reduced cell 
proliferation and higher DNA damage rates already at steady state. Cell viability assays 
after Olaparib treatment suggest that defects in HR could contribute to Idh1-R132H-
mediated defects in DNA damage repair, yet further molecular analyses are required to 
determine detailed mechanisms underlying repair deficiencies.    
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Figure 3-2: Idh1-R132H Mutated 32D Cells Display Increased DNA Damage Rates and Sensitivity to PARP Inhibitors. 
(A) Quantification of comet assays performed either untreated or after irradiation and recovery phases as indicated. 
Between 925 and 1693 cells were analyzed per sample (Student’s t-test, p-values are indicated for significant results (p 
< 0.05)) (Comet assays were performed by Reinhard Gliniorz in collaboration with Dr. Peter Schmezer and PD Dr. Odilia 
Popanda) (B) Analysis of cell viability by cell titer blue assays of transduced 32D cells after treatment with the PARP-
inhibitor Olaparib. Cells were treated over 3 days and cell viability was determined at each day. Fluorescence intensities 
correlate with cell viability (n=3, error bars indicate mean ± SD, Student’s t-test, p-values are indicated for significant 
results (p < 0.05)) (Cell titer blue assays were performed by Dr. Ali Bakr). 
 
 
3.2 Characterization of a Hematopoiesis-
Specific Idh1-R132H Knock-In Mouse 
Model  
 
To recapitulate previous findings from our cell line model in an in vivo setting, we 
employed an inducible Idh1-R132H mutated mouse model. Here, two opposing lox sites 
flank an R132H mutated exon 3, which is reversely inserted in the endogenous Idh1 locus 
between exon 3 and exon 4 (Figure 3-3A). The regular non-mutated exon 3, which is 
transcribed in the absence of Cre recombinase (Cre) activity, is flanked by lox sites of 
equal orientation. Upon Cre activity within the cell, the non-mutated exon 3 is excised due 
to the orientation of the lox sites, while the inverted R132H mutated exon 3 is inserted in 
the correct orientation and becomes actively transcribed.  
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 As Idh1-R132H mutations occur very early in AML development and often within then 
hematopoietic stem cell compartment [Corces-Zimmerman et al., 2014], we restricted 
tamoxifen-inducible CreERT2 expression to the HSPC compartment by driving its 
expression under the control of the stem cell-specific enhancer of the stem cell leukemia 
(Scl) locus [Gothert et al., 2005]. The Scl enhancer is responsible for driving Scl expression 
only within the most immature hematopoietic cell types [Gottgens et al., 2002, Sanchez et 
al., 1999, Sanchez et al., 2001], thereby confining the activity of Cre to primarily HSCs in 
our mouse model. To monitor Cre activity after tamoxifen induction, we made use of an 
enhanced yellow fluorescent protein (EYFP) reporter mouse model, where the EYFP gene 
is inserted after a lox-flanked STOP codon within the Rosa26 locus and transcribed after 
the Cre-mediated excision of the STOP codon [Srinivas et al., 2001]. For all experiments 
described hereafter, we used transgenic mice that were heterozygous for the mutated 
Idh1-R132H allele, the Rosa26-EYFP allele, as well as for the Scl-CreERT2 transgene 
(Idh1+/R132H, Scl-CreERT2+/d, Rosa26-EYFP+/d, denoted as Idh1 mice). Control mice were 
heterozygous for the Scl-CreERT2 transgene and the Rosa26-EYFP allele but lacked a 
mutated Idh1-R132H allele (Idh1+/+, Scl-CreERT2+/d, ROSA26-EYFP+/d, denoted as control 
(CTRL) mice). 
 To induce the expression of the Idh1-R132H mutation and the EYFP reporter gene, we 
induced Cre activity by treating our mice with tamoxifen for 5 consecutive days (2 mg / 
day). Two to four weeks after tamoxifen treatment, we analyzed the bone marrow of 
injected animals for EYFP expression (Figure 3-3B). Among total bone marrow (TBM) cells, 
we detected around 6-7 % EYFP+ cells. However, when gating for hematopoietic stem and 
progenitor cells (Lineage—, Sca1+, cKit+ (LSK) cells), HSCs, or LT-HSCs (for all gating schemes 
see Supplemental Figure A-1 and Supplemental Figure A-2), the percentage of EYFP+ cells 
increased the more immature the cell type was (Figure 3-3C). LT-HSCs reside at the top of 
the hematopoietic hierarchy and consequently, with 35-40 % of EYFP+ cells, they displayed 
the highest fraction of EYFP+ cells, indicating that due to the Scl enhancer-driven 
expression, Cre activity indeed was highest in HSCs and decreased in more differentiated 
cells. It is important to note that EYFP positivity observed in more differentiated cells 
could in fact be derived from labelled EYFP+ HSCs giving rise to EYFP+ downstream cells, 
and not necessarily reflects the activity of Cre within these cells. To address whether EYFP+ 
cells in the bone marrow give rise to differentiated cell types of all lineages in the 
periphery, we also quantified EYFP expression in the blood of injected animals. We found 
EYFP expression to be present in B-cells, T-cells and myeloid cells (Figure 3-3D), suggesting 
that EYFP positivity can be used as a marker to trace differentiation of EYFP-labelled stem 
cells in, for example, transplantation settings. In mice that did not carry the Scl-CreERT2 
or the Rosa26-EYFP allele, we could not detect any EYFP+ cells in the bone marrow at all 
(Figure 3-3E and Figure 3-3F). 
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Figure 3-3: Idh1-R132H Scl-CreERT2 Rosa26-EYFP Mice Express EYFP in the Bone Marrow and Blood after Tamoxifen 
Treatment. 
(A) Schematic overview of transgenic mice used throughout this study. Upon Cre activity the non-mutated Idh1 exon 3 
is excised and the R132H mutated exon 3 is inversed and transcribed. CreERT2 expression is driven from the Scl locus 
controlled by the stem cell-specific Scl 3’ enhancer and the 6E5 exon 4 promoter. The fluorescence marker EYFP, inserted 
into the Rosa26 locus, is used as a reporter for Cre activity. (B) Schematic overview of the experimental setup. (C + D) 
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Exemplary quantification of EYFP expression in the bone marrow (C) and blood (D) of tamoxifen-injected Idh1 and CTRL 
animals by flow cytometry.  (E + F) Exemplary quantification of EYFP expression in the bone marrow of injected animals, 
that lack either a Scl-CreERT2 transgene (E) or a Rosa26-EYFP allele (F) by flow cytometry.  
 
 
 While EYFP expression serves as a marker for Cre activity within the cell, the 
recombination events occurring at the Idh1 locus and the Rosa26 locus are not only 
independent of each other, they also may occur at different efficiencies or different rates. 
To assess how recombination at the Rosa26 locus as measured by EYFP expression 
correlates with recombination at the Idh1 locus, we sorted EYFP+ and EYFP— bone marrow 
cells from tamoxifen-injected animals and performed a recombination-specific PCR for 
the Idh1 locus. Here, Idh1 locus recombination events occurred both in EYFP+ as well as in 
EYFP— cells sorted from Idh1 mice, confirming an independency of the recombination 
events (Figure 3-4A). As expected, cells sorted from CTRL mice did not show any Idh1 
locus recombination events.  
 To determine the exact recombination frequency at the Idh1 locus in both EYFP+ and 
EYFP— cells, we sorted single EYFP+ and EYFP— HSCs from Idh1 mice, grew colonies from 
these cells in liquid culture and subsequently performed the Idh1 locus recombination-
specific PCR on each of the colonies (Figure 3-4B). In EYFP+ single-cell-derived colonies, we 
observed an Idh1 locus recombination efficiency of 91.4 %, resulting in the expression of 
the Idh1-R132H mutation in almost all EYFP+ cells (Figure 3-4C). In contrast, also 53.7 % of 
EYFP— single-cell derived colonies featured an Idh1 locus recombination, implying that 
roughly every second EYFP— cell also expresses the Idh1-R132H mutation and that 
recombination at the Idh1 locus is favored and occurs more likely than recombination at 
the Rosa26 locus. Yet, due to the high concordance of Idh1 locus recombination in EYFP+ 
cells, EYFP expression can be used as a marker to strongly enrich for cells that express 
the Idh1-R132H mutation.  
 In order to show that the recombination of the Idh1 locus results in transcription of 
the Idh1-R132H mutation, we designed Idh1-R132H mutation-specific primers that only 
show an amplification product when the Idh1-R132H mutation is expressed. This is 
enabled by the specific design of one of the primers, which overlaps with the mutated 
codon at the 3’ end. Using cDNA synthesized from total RNA as a template, we could 
detect a mutation-specific amplification product only in cells derived from Idh1 mice but 
not from CTRL mice (Figure 3-4D). An analogous Idh1 wildtype-specific primer, however, 
resulted in an amplification product in cells coming from both Idh1 and CTRL animals, 
since Idh1 mice were heterozygous for the Idh1-R132H mutation and still carried one Idh1 
wildtype allele. Quantification of D2HG levels in the blood serum of tamoxifen-treated 
animals revealed that D2HG concentrations in serum of Idh1 mice were increased around 
two-fold compared to concentrations in the serum of CTRL mice (Figure 3-4E). Although 
the exact number or fraction of Idh1-R132H mutated bone marrow cells cannot be 
determined due to the discrepancy between EYFP and Idh1 locus recombination, the 
observed elevated D2HG levels suggest, that already a low percentage of Idh1-R132H 
mutated bone marrow cells (around 7% EYFP+ TBM cells after tamoxifen treatment, see 
Figure 3-3C) is sufficient to result in a remarkable increase in D2HG levels.  
 In summary, we have characterized a tamoxifen-inducible hematopoiesis-specific 
Idh1-R132H mutation mouse model where EYFP expression serves as a surrogate marker 
for the expression of the Idh1-R132H mutation. Comparable to the Idh1-R132H 32D cell 
line model, the expression of the mutation resulted in increased levels of D2HG in the 
blood serum of tamoxifen-treated animals. 
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Figure 3-4: Tamoxifen-Treated Idh1-R132H Scl-CreERT2 Rosa26-EYFP Mice Express the Idh1-R132H Mutation and 
Accumulate Increased Levels of D2HG in the Blood Serum.   
(A) EYFP+ and EYFP— cells were sorted from Idh1 or CTRL mice as indicated and an Idh1 locus recombination-specific 
PCR was performed. The upper band at 501 bp indicates the presence of the recombined mutated allele, resulting in 
the expression of the Idh1-R132H mutation, whereas the band at 425 bp indicates the presence of an Idh1 wildtype 
allele. (B) Experimental setup for determining the correlation between EYFP expression and recombination efficiency at 
the Idh1 locus. (C) From single cells sorted as illustrated in (B), single-cell-derived colonies were grown and the 
recombination efficiency at the Idh1 locus was determined by recombination-specific PCR (EYFP— n = 41, EYFP+ n = 35) 
(PCRs performed by Umut Kilik). (D) Idh1-R132H mutation-specific primers were designed to validate the expression of 
the Idh1-R132H mutation on RNA level in blood cells from Idh1 or CTRL mice as indicated. After isolation of total RNA 
and synthesis of cDNA, the PCR was performed either with wildtype- or mutation-specific reverse primer but with the 
same forward primer. (E) Enzymatic quantification of D2HG levels in the blood serum of tamoxifen-treated Idh1 and 
CTRL mice (CTRL n = 2, Idh1 n = 4, Student’s t-test). 
 
 
3.3 Effects of Idh1-R132H Mutations on Bone 
Marrow Repopulation and Multi-Lineage 
Potential  
 
Having validated the expression of the Idh1-R132H mutation in EYFP+ cells from Idh1-
R132H Scl-CreERT2 Rosa26-EYFP mice, we next addressed functional effects of the Idh1-
R132H mutation on proliferation and self-renewal capacity of LT-HSCs. A standard in vitro 
assay to assess these aspects is a colony-forming unit (CFU) assay, where cells are seeded 
in a semi-solid medium to form colonies and serially replated after a certain time. EYFP+ 
LT-HSCs were sorted from tamoxifen-treated Idh1 and CTRL mice and the number of 
colonies formed was assessed in three serial platings. While in general, the number of 
colonies decreased with each plating, especially in the second and third plating, a trend 
towards a smaller number of colonies in Idh1-R132H mutated cells became evident 
(Supplemental Figure A-3).  
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 For many years, transplantation of HSCs into lethally irradiated recipients has been 
considered the gold standard to assess engraftment, repopulation and self-renewal 
potential as well as lineage output in an in vivo setting. As recombination efficiency in 
individual animals is likely to vary due to technical confounders (injection procedure, 
body weight of the mouse, etc.), a transplantation setting allows us to assess functionality 
of a defined cell type in a reproducible way in that always the same number of cells is 
transplanted into irradiated recipients. Therefore, 100 EYFP+ LT-HSCs from tamoxifen-
treated Idh1 or CTRL mice were isolated and transplanted into lethally irradiated recipient 
mice together with supportive TBM cells (Figure 3-5A). To discriminate between donor 
cells, supportive bone marrow and recipient cells, we used congenic strains for donor, 
recipient and supportive cells, that express different alleles of the pan-leukocyte marker 
CD45. Six weeks after transplantation of the cells into recipients, we began monitoring of 
recipient mice by drawing blood samples at regular intervals in order to analyze its 
cellular composition as a surrogate for the cellular output of transplanted LT-HSCs. The 
overall composition and the overall frequencies of specific cell types were determined by 
a HemaVet 950 FS hematology system. Here, white blood cell-, leukocyte-, neutrophil-, 
monocyte-, platelet- and red blood cell counts were mostly comparable for Idh1 and CTRL 
transplanted mice during the monitoring phase 6-22 weeks post-transplantation 
(Supplemental Figure A-4).  
 By using flow cytometry, the engraftment and lineage output of transplanted donor 
cells was specifically examined by measuring the overall fraction of CD45.1+ donor cells 
in the recipient mice. Normalized to the rate of CD45.1/2 double-positive supportive bone 
marrow cells, we could detect a higher ratio of CD45.1+ cells in mice that were 
transplanted with Idh1-R132H mutated cells compared to mice what were transplanted 
with CTRL cells (Figure 3-5B). Although the increased CD45.1+ cell ratio levelled out at 
later time points, this data suggests that Idh1-R132H mutated LT-HSCs possess a higher 
engraftment and proliferative potential in that they are capable of repopulating the 
recipient blood system more rapidly by generating more progeny. To determine whether 
the specific lineage output of Idh1-R132H mutated LT-HSCs is comparable to control 
HSCs, we also quantified the fraction of terminally differentiated CD45.1+ B-cells, T-cells 
and myeloid cells in the blood of transplanted mice (Figure 3-5C). Especially at the end of 
the monitoring phase, Idh1-R132H mutated mice seem to produce slightly less T-cells 
than CTRL mice but at the same time produce marginally higher rates of myeloid cells.  
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Figure 3-5: Idh1-R132H Mutated LT-HSCs Display an Increased Engraftment Potential after Transplantation. 
(A) Schematic illustration of the experimental transplantation setup. One hundred EYFP+ LT-HSCs from tamoxifen-
treated Idh1 or CTRL donor mice were transplanted together with 300,000 supportive TBM cells into lethally irradiated 
recipients. Following transplantation, blood composition was monitored at regular intervals. The expression of different 
CD45 alleles was used to discriminate between donor, recipient and supportive cells. (B + C) Quantification of overall 
CD45.1+ cell rates and frequencies of CD45.1+ B-cells, T-cells and myeloid cells in the blood of transplanted mice by 
using flow cytometry (CTRL n = 17, Idh1 n = 17, three independent transplantations, curves were smoothened based on 
a loess (locally estimated scatterplot smoothing) regression model, confidence interval (0.95) plotted around curve, 
Student’s t-test, p-values are indicated for significant results (p < 0.05)).  
 
 
  In order to understand the molecular features underlying the observed 
phenotypes, we isolated EYFP+ LT-HSCs from transplanted recipients after the 22-week 
long monitoring phase and performed RNA sequencing (RNA-seq) from three LT-HSC 
replicates of each genotype. Global correlation analysis of the individual samples revealed 
a high correlation even for samples from different genotypes (Figure 3-6A). Yet, Idh1 and 
CTRL samples clustered apart from each other based on calculated sample distances while 
the individual replicates clustered together within a given genotype (Figure 3-6B). To 
examine the heterogeneity of individual samples, a principle component (PC) analysis 
(PCA) was performed, illustrating a large heterogeneity within Idh1-R132H mutated 
samples, but not within CTRL samples, based on principle components 1 (PC1) and 2 (PC2) 
(Figure 3-6C). However, PC3, explaining around 20 % of the variance within the data set, 
clearly separated Idh1 from CTRL samples (Figure 3-6D). We next called differentially 
expressed (DE) genes between Idh1 and CTRL samples and found only a small number of 
genes to be deregulated in Idh1 samples (18 genes up-regulated, 3 genes down-regulated), 
when applying log2 fold change (fc) ≤ -1 or ≥ 1 and adjusted p-vaule (padj) < 0.05 as 
filtering criteria (Figure 3-6E). To further assess the biological relevance of deregulated 
genes, we used a ‘Gene Set Enrichment Analysis’ (GSEA) to identify significantly enriched 
or depleted groups of genes within the Idh1-specific transcriptomic profile. Beside several 
metabolism-associated gene sets, we also found DNA repair- and inflammation-associated 
gene sets to be slightly enriched in Idh1-R132H mutated samples (Figure 3-6F). Among 
DNA repair-associated genes, genes which are directly involved in DNA damage sensing 
and DNA binding to induce downstream repair pathways (e.g. Rad52, Rpa2, Xpc, or Ddb2) 
as well as several DNA and RNA polymerases (e.g. Pola2, Polb, Polr2a) and their respective 
subunits were higher expressed in Idh1-R132H mutated samples. Interestingly, affected 
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genes play a crucial role in distinct repair pathways, such as HR (Rad52, Rpa2) or GG-NER 
(Xpc, Ddb2). This suggests that Idh1-R132H mutations do not exclusively affect a single 
pathway. Regarding inflammation related genes, many genes that were found to be higher 
expressed in Idh1-R132H mutated samples were genes which are induced in response to 
interferon (IFN) signaling or which regulate the expression of IFNs (Ifi27, Ifitm1, Ifit1, Ifit3, 
Irf2, Irf5, Irf8), implying that elevated IFN levels within the bone marrow niche could 
impact HSC functionality in Idh1-R132H mutated mice. 
   
 
 
 
Figure 3-6: Idh1-R132H Mutated LT-HSCs Express Higher Levels of DNA Repair- and Inflammation-Associated Genes 
(A) Scatter plots showing normalized expression values for each gene in a pairwise comparison across individual 
samples. The Pearson correlation coefficient for each comparison is depicted in each plot.  (B) Heatmap depicting sample 
distances across samples based on their normalized gene expression profile (using all genes). Calculation of distances 
and clustering of samples was computed using Euclidean distances. (C+D) PCA of individual samples based on their 
normalized gene expression profile (using all genes). PC1 and PC2 (C) or PC3 and PC4 (D) are plotted against each other. 
Percentages indicate the magnitude of variance within the data set which is explained by the individual PCs plotted. (E) 
Volcano plot showing DE genes between Idh1 and CTRL samples. Genes with a log2 fc ≤ -1 or ≥ 1 and a padj < 0.05 are 
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highlighted. (F) Heatmap depicting normalized expression values of selected DNA repair and inflammation-associated 
genes. Displayed genes represent ‘core-enriched’ genes from the ‘Hallmark’ gene sets ‘DNA_REPAIR’, 
‘INTERFERON_ALPHA_RESPONSE’ and ‘INTERFERON_GAMMA_RESPONSE’ and were determined by ‘Gene Set Enrichment 
Analysis’ (GSEA) between Idh1 and CTRL samples. Clustering of rows and columns is based on Euclidean distances. The 
color scale represents row z-scores.  
 
 
 Taken together, we could show that, functionally, Idh1-R132H mutated LT-HSCs show 
a better engraftment and reconstitution potential in a transplantation setting whereas the 
lineage output of Idh1-R132H mutated LT-HSCs was mostly comparable to CTRL LT-HSCs. 
At the molecular level, Idh1-R132H mutated cells display trends towards an aberrant 
expression of DNA repair- and inflammation-related genes, although the heterogeneity of 
Idh1-R132H mutated replicates needs to be taken into consideration when interpreting 
the results.  
 
 
3.4 Serial Transplantation of Idh1-R132H 
Mutated Hematopoietic Stem Cells 
 
Similar to other regenerative tissues, the age-dependent functional degeneration of the 
hematopoietic system is closely linked to a decline in HSC function and self-renewal 
capacity over time. The ‘stemness’ and self-renewal potential of HSCs is commonly 
measured by serial transplantations, where bone marrow cells from primary recipient 
mice are successively transplanted into further lethally irradiated recipients. Previously, 
it has been shown that the self-renewal capacity and functionality of HSCs decreased with 
the number of serial transplantations [Harrison et al., 1978, Kamminga et al., 2005]. At 
the molecular level, several reports identified an accumulation of DNA damage and 
defects in DNA repair pathways to be critical factors for the functional decline in HSCs 
[Rossi et al., 2008, Flach et al., 2014, Rossi et al., 2007, Rube et al., 2011, Wang et al., 2012]. 
Since Idh1-R132H mutated HSCs exhibited an increase in DNA damage [Inoue et al., 2016] 
and an upregulation of DNA repair-associated genes, we hypothesized that Idh1-R132H 
mutated HSCs either exhaust prematurely or, because of the constituent accumulation of 
additional mutations, are prone to leukemic transformation in a serial transplantation 
setting.  
 We initially transplanted 300 EYFP+ LT-HSCs isolated from Idh1 or CTRL mice together 
with 300,000 supportive TBM cells into primary recipients and serially transplanted the 
total bone marrow of primary recipients into secondary and tertiary recipients 20-22 
weeks after transplantation (Figure 3-7A). Flow cytometry analysis of donor chimerism 
(i.e. proportion of CD45.1+ cells) in the bone marrow of primary recipients revealed that, 
in line with previous experiments, Idh1-R132H mutated LT-HSCs are characterized by a 
better engraftment and repopulation potential as measured by an increased ratio of 
CD45.1+ cells to CD45.1/2 double-positive cells (Figure 3-7B). In primary recipients, the 
rate of CD45.1+ cells further expanded in both Idh1 and CTRL transplanted mice over time, 
but with CTRL mice constitutively displaying decreased rates compared to Idh1 
transplanted mice. Relative to CD45.1+ cell rates from primary recipients, rates stayed 
level in both Idh1 and CTRL secondary and tertiary transplanted mice. It is worth noting, 
that whereas only little engraftment was observed in two CTRL tertiary recipients, good 
engraftment was observed in all Idh1 tertiary recipients, arguing against an Idh1-R132H 
mutation-mediated premature decline in self-renewal capacity. In order to estimate the 
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frequency of HSCs in each genotype, we analyzed the composition of the bone marrow by 
flow cytometry at the time of each bone marrow transplantation (22 and 42 weeks).  In 
primary recipients, the frequency of LSK cells and HSCs, especially ST-HSCs, was slightly 
reduced in Idh1-R132H mutated recipients, whereas the frequency of combined MPP3 and 
MPP4 cells was slightly increased (Figure 3-7C, frequencies normalized to the percentage 
of overall EYFP+ cells). In secondary recipients, a similar trend of decreased LSK and HSC 
frequencies in Idh1-R132H mutated mice was observed, with ST-HSC frequencies being 
significantly lower in Idh1 transplanted mice. Comparable tendencies were noted in 
primary and secondary recipients when cell frequencies of HSC and MPP populations were 
normalized to the fraction of EYFP+ LSK cells instead of overall EYFP+ cells (data not 
shown). Overall, one can conclude that the bone marrow composition in Idh1 and CTRL 
mice was rather comparable with only a minor depletion of HSCs upon serial 
transplantation. However, the functionality of transplanted Idh1-R132H mutated HSCs 
seems not to be compromised as engraftment and reconstitution was observed in all 
recipients. We furthermore quantified blood production and lineage output in secondary 
or tertiary recipients and found some variation in tertiary recipients, where Idh1 
transplanted mice displayed trends of decreased B-cell frequencies and increased T-cell 
and myeloid cell frequencies (Supplemental Figure A-5). 
 
 
 
 
Figure 3-7: The Functionality of Idh1-R132H Mutated HSCs is Unaltered in Serial Transplantations. 
(A) Schematic illustration of the serial transplantation experimental setup. Donor mice consisted of either Idh1 or CTRL 
mice. (B) Quantification of CD45.1+ cell rates in the blood of primary, secondary or tertiary transplanted mice by using 
flow cytometry (primary transplantation n=3, secondary transplantation n = 6, tertiary transplantation n = 6, curves 
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were smoothened based on a loess (locally estimated scatterplot smoothing) regression model, confidence interval (0.95) 
plotted around curve, Student’s t-test, p-values are indicated for significant results (p < 0.05)). (C) Quantification of 
frequencies of indicated cell types in the bone marrow of primary and secondary recipient mice using flow cytometry. 
Frequencies are calculated in relation to the percentage of overall EYFP+ cells in the bone marrow (primary recipients n 
= 3, secondary recipients n = 6, Student’s t-test, p-values are indicated for significant results (p < 0.05)). 
 
 
 Collectively, our data suggests that the self-renewal capacity of Idh1-R132H mutated 
HSCs is unaltered relative to CTRL HSCs upon serial transplantation. Furthermore, no 
clear indication of oncogenic transformation or disease development could be detected in 
all transplanted mice so far, implying that Idh1-R132H mutations alone do not lead to 
malignant transformation and that additional genetic or epigenetic hits are necessary for 
the induction of hematopoietic neoplasms. 
 
 
3.5 Cooperation of Idh1-R132H and DNMT3A-
R882H Mutations in Hematopoietic Stem 
Cells 
 
Due to the lack of evidence for malignant transformation in the context of an Idh1-R132H 
mutation as a single hit, we hypothesized that additional mutations co-occuring in Idh1-
R132H mutated cells might lead to the induction of a leukemic phenotype. DNMT3A 
mutations in general are not only among the most frequent mutations found in individuals 
with clonal hematopoiesis, they are also commonly detected in AML patients where they 
are moreover found to co-occur with mutations in IDH1 (see Figure 1-5C)  [Cancer Genome 
Atlas Research et al., 2013, Papaemmanuil et al., 2016, Desai et al., 2018, Abelson et al., 
2018, Shlush et al., 2014]. Although both, IDH1 and DNMT3A mutations are early events 
in leukemia pathogenesis, they are not known to strongly activate proliferation in affected 
preleukemic clones [Corces-Zimmerman et al., 2014]. Nevertheless, we speculated that the 
induction of both an Idh1-R132H and a DNMT3A-R882H mutation in the same HSC might 
synergistically alter the epigenetic landscape of affected cells in such a way that it is more 
permissive to leukemic transformation. To address this hypothesis, we made use of a 
mouse model, which conditionally expresses the DNMT3A-R882H mutation upon 
activation of Cre (Figure 3-8A). We crossed this conditional DNMT3A-R882H knock-in 
mouse model with our conditional Idh1-R132H knock-in mouse model to obtain inducible 
Idh1-R132H DNMT3A-R882H double-mutant mice. For all of the experiments described 
hereafter, mice heterozygous for the Idh1-R132H and the DNMT3A-R882H allele as well 
as for the Scl-CreERT2 transgene and the Rosa26-EYFP allele were injected with tamoxifen 
and used as donor mice for transplantations (genotype Idh1+/R132H, DNMT3A+/R882H, Scl-
CreERT2+/d, Rosa26-EYFP+/d, denoted as Idh1-DNMT3A mice). Mice heterozygous for the 
DNMT3A-R882H allele, the Scl-CreERT2 transgene and the Rosa26-EYFP allele but not for 
the Idh1-R132H allele were used as DNMT3A-R882H single-mutant control mice (genotype 
Idh1+/+, DNMT3A+/R882H, Scl-CreERT2+/d, Rosa26-EYFP+/d, denoted as DNMT3A mice) 
 Similar to the serial transplantation experiments described earlier, we chose an 
experimental setting where we transplanted 300 EYFP+ LT-HSCs from tamoxifen-treated 
donor mice together with 300,000 supportive TBM cells into lethally irradiated recipients. 
To eliminate the possibility that effects caused by the mutations arise only in aged mice 
after long latency times, we extended the monitoring period to over a year with drawing 
blood samples at regular intervals and performing a detailed analysis of the bone marrow 
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composition at around 62 weeks post-transplantation. Consistent with previous results, 
we observed a better engraftment with higher CD45.1+ cell rates not only in Idh1 and Idh1-
DNMT3A transplanted mice, but also in DNMT3A transplanted mice compared to CTRL 
mice (Figure 3-8B). Regarding the lineage output of transplanted LT-HSCs, tendencies 
towards a reduction in B- and T-cell frequencies and a concomitant increase in myeloid 
cell frequencies were detected in Idh1-R132H single-mutant mice especially at the end of 
the monitoring period one year after transplantation. In Idh1-DNMT3A mice, frequencies 
of myeloid cells were comparable to frequencies of CTRL transplanted mice, suggesting 
that an additional DNMT3A-R882H mutation does not elicit synergistic effects, but rather 
reverts the effects observed in Idh1-R132H single-mutated mice. Analysis of the overall 
blood counts of transplanted mice, however, revealed that neutrophil and monocyte levels 
were markedly elevated in Idh1-DNMT3A mice at early analysis time points (Supplemental 
Figure A-6). 
 
 
 
 
Figure 3-8: Blood Characteristics of Idh1-R132H DNMT3A-R882H Double-Mutant Mice are Similar to Control and 
Single-Mutant Mice. 
(A) Schematic illustration of the DNMT3A-R882H mouse model. Upon activity of Cre, a lox-flanked stop codon in front 
of the R882H mutated exon 23 is excised and the DNMT3A-R882H mutation is expressed. (B) Quantification of overall 
CD45.1+ cell rates as well as terminally differentiated CD45.1+ B-cells, T-cells and myeloid cells in the blood of 
transplanted mice by using flow cytometry (CTRL n = 19, Idh1 n =21, Idh1-DNMT3A n= 18, DNMT3A n =12, two to four 
independent transplantations per genotype, curves were smoothened based on a loess (locally estimated scatterplot 
smoothing) regression model, confidence interval (0.95) plotted around curve) (transplantation and analysis of DNMT3A 
mice was performed by Dr. Sina Stäble and Dr. Natasha Anstee).  
 
 
 Following the monitoring phase with periodic blood analysis, mice were sacrificed 
and the cellular composition of the bone marrow, including frequencies of hematopoietic 
stem and multipotent progenitor cells as well as that of committed progenitors (Lineage—
, Sca1—, cKit+ (LS-K cells)), and differentiated cells was comprehensively analyzed by flow 
cytometry. Within the HSC and MPP compartment, a trend towards an expansion of the 
LSK and MPP3 + MPP4 compartment was observed in Idh1-DNMT3A mice, whereas all 
other genotypes did not display any substantial abnormalities (Figure 3-9A). The 
committed progenitor / LS-K compartment, encompassing CMPs, GMPs and MEPs, of 
mutated mice did not reveal any significant changes in cell frequencies, yet tendencies of 
reduced numbers of B-cells and increased numbers of myeloid cells in the bone marrow 
of Idh1 and Idh1-DNMT3A transplanted mice were detected.  
 The fact that EYFP+ cells were detected in the bone marrow 60 weeks after 
transplantation suggests that no negative selection or selective depletion of Idh1-R132H 
or DNMT3A-R882H mutated cells is seen in any of the genotypes. Nevertheless, to rule 
out the possibility that the Idh1-R132H transgene is silenced in hematopoietic cells over 
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time without affecting EYFP expression, we quantified the levels of D2HG in bone marrow 
cell lysates of Idh1 and CTRL transplanted mice about one year post-transplantation. 
Normalized to the overall protein content in the cell lysate, the concentration of D2HG 
was elevated on average 7.5-fold in Idh1-R132H mutated mice, proving the continued 
transcriptional activity of the transgene (Figure 3-9B). As expected, the level of increase in 
D2HG levels measured in bone marrow lysates highly correlated with the percentage of 
EYFP+ cells in the bone marrow (Figure 3-9C). On the other hand, the frequency of EYFP+ 
HSCs in the bone marrow was inversely correlated with D2HG levels. While a larger 
number of mice is necessary to corroborate this correlation, it implies that the amount of 
D2HG present could modulate the expansion or depletion of the stem cell pool. Yet, the 
overall number of EYFP+ HSCs (normalized to the number of EYFP+ cells) in the bone 
marrow was unaltered in Idh1-R132H mutant mice (Figure 3-9A). We also investigated 
whether secreted D2HG likewise affects frequencies of EYFP— (i.e. supportive bone 
marrow) HSCs which do not express an Idh1-R132H mutation, but found D2HG levels not 
correlate with EYFP— HSC counts (Pearson correlation coefficient R = 0.21, data not shown). 
 In summary, we found some minor deviations in cell frequencies in Idh1-R132H 
DNMT3A-R882H double-mutated mice, but did not observe any indications of leukemic 
transformation in the context of a co-occurrence of both mutations. 
 
 
 
 
 
Figure 3-9: A Co-Occurrence of a Idh1-R132H and a DNMT3A-R882H Mutation Only Leads to Minor Changes in Bone 
Marrow Composition of LT-HSC Transplanted Mice. 
(A) Quantification of frequencies of indicated cell types in the bone marrow of transplanted recipient mice using flow 
cytometry. Frequencies are calculated in relation to overall EYFP+ cells in the bone marrow. Mice were sacrificed and 
analyzed 54 – 62 weeks post-transplantation (CTRL n = 8-14, DNMT3A n = 5, Idh1 n = 4-9, Idh1-DNMT3A n = 9) 
(transplantation and analysis of DNMT3A mice was performed by Dr. Sina Stäble and Dr. Natasha Anstee). (B) 
Quantification of D2HG levels in the bone marrow cell lysate of Idh1 and CTRL transplanted mice sacrificed 62 weeks 
after transplantation (CTRL n =3, Idh1 n = 5, Student’s t-test). (C) Correlation of measured D2HG levels in bone marrow 
cell lysates and percentages of EYFP+ cells or HSC frequencies in the bone marrow of CTRL or Idh1 transplanted mice 
(CTRL n = 3, Idh1 n = 5, lines were calculated using a generalized linear regression model, the Pearson correlation 
coefficient is depicted).  
LSK HSC LT−HSC ST−HSC MPP2 MPP3+4 MPP5
0.0
0.2
0.4
0.6
F
re
q
u
en
cy
in
%
(o
f
E
Y
F
P
+
C
el
ls
)
HSC and MPP Compartment
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●● ●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
B−Cells T−Cells Myeloid Cells
0
25
50
75
F
re
q
u
en
cy
in
%
(o
f
E
Y
F
P
+
C
el
ls
)
Differentiated CellsCommitted Progenitors
●
●
●
●
●
●
●
●
●
●
●
● ●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
LS−K CMP GMP MEP
1
2
3
F
re
q
u
en
cy
in
%
(o
f
E
Y
F
P
+
C
el
ls
)
Genotype
● ● ● ●CTRL DNMT3A Idh1 Idh1-DNMT3A
●
●
●
●
●
●
●
p = 0.0094
0.0
2.5
5.0
7.5
10
CTRL Idh1
D
2H
G
[p
m
o
l/
µ
g
P
ro
te
in
]
D
2H
G
[p
m
o
l/
µ
g
P
ro
te
in
]
D
2H
G
[p
m
o
l/
µ
g
P
ro
te
in
]
Genotype
●
●
CTRL
Idh1
●●●
●
●
●
●
●
CTRL Idh1
20 40 60 20 40 60
0.0
2.5
5.0
7.5
EYFP Percentage
Correlation D2HG − EYFP Percentage
● ●●
●
●
●
●
●
CTRL Idh1
0.05 0.10 0.05 0.10
0.0
2.5
5.0
7.5
HSC Frequency
Correlation D2HG − HSC Frequency
A
B C
R = 0.99 R = -0.65
3 Results 
 
 43 
3.6 Idh1-R132H Mutations Cause Increased 
Monocyte Levels in Lineage— Transplanted 
Mice  
 
Previous results have shown that in our hands, the Idh1-R132H mutation alone or in 
combination with a DNMT3A-R882H mutation does not lead to the development of 
hematological malignancies. Instead, Idh1-R132H mutations seem to evoke a 
differentiation bias towards the myeloid lineage at the expanse of the lymphoid lineage 
(see Figures 3-8B, 3-9A). In order to characterize mutation-mediated aberrant 
differentiation in more detail, we generated full chimeric mice, in which the entire 
hematopoietic system is replaced by mutated cells. This is in contrast to the 
transplantation experiments described previously, where the use of supportive bone 
marrow cells was necessary to ensure the immediate survival of the mice until 
transplanted LT-HSCs have engrafted and ensured the permanent production of 
differentiated blood cells. Even though the ratio of supportive bone marrow cells and its 
contribution to blood production steadily decreased over time, it is conceivable, that 
differentiation patterns of transplanted stem cells vary in a more drastic and stress-
imposing scenario where the whole hematopoietic system immediately has to be replaced 
by mutated cells and patterns are not obscured by the intermediate contribution of 
supportive bone marrow. 
 To overcome this requirement for supportive bone marrow, we employed a 
transplantation setting where we transplanted lineage negative (Lin—) cells that consist of 
all hematopoietic cell types except for terminally differentiated cells, so that downstream 
progenitors ensure the immediate blood production directly after transplantation, while 
long-term blood production is driven by HSCs after their engraftment (Figure 3-10A). 
Transplanted recipient mice were sacrificed and analyzed four months after 
transplantation, assuming that at this time point a stable engraftment and sustained 
blood production of all transplanted HSCs is reached. In addition to a surface marker- 
based analysis of cell types in the bone marrow by flow cytometry, we complementarily 
performed single-cell RNA-sequencing of selected bone marrow populations in order to 
comprehensively characterize hematopoietic differentiation trajectories at the molecular 
level (for a detailed description see chapter 3.7). To review the impact of an Idh1-R132H 
mutation on the myeloid compartment and myeloid differentiation patterns in more 
detail, we scrutinized this compartment by discriminating between terminally 
differentiated monocytes and granulocytes.  
 Within the HSC and MPP compartment differences in cell type frequencies were 
minute with Idh1-DNMT3A mice displaying a slight increase in LSK frequency and both 
Idh1 and Idh1-DNMT3A mice featuring a significant reduction in ST-HSC frequency (Figure 
3-10B). Furthermore, counts of LS-K and the therein enclosed CMP population were 
elevated in Idh1 and Idh1-DNMT3A transplanted mice (Figure 3-10C). Strongest 
disparities, however, were observed in differentiated cells, where the bone marrow of both 
Idh1 and Idh1-DNMT3A transplanted mice contained dramatically increased levels of 
terminally differentiated monocytes (Figure 3-10D).  
 Summarizing, in the Lin— transplantation experiments, we observed substantial 
differences between Idh1 or Idh1-DNMT3A mice and CTRL or DNMT3A mice that were not 
detected in other transplantation settings, suggesting that the lack of supportive bone 
marrow might increase selective pressures and thus leads to pronounced phenotypes as 
mutated cells are forced to completely reconstitute the entire hematopoietic system after 
transplantation. Consistent with previous findings, Idh1-R132H mutations alone or in 
Single-Cell RNA-Sequencing Identifies Hematopoietic Differentiation Trajectories  
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combination with DNMT3A-R882H mutations lead to a myeloid differentiation bias, which 
manifests in the expansion of bone marrow monocytes.  
 
 
 
 
 
Figure 3-10: Idh1 and Idh1-DNMT3A Lineage Negative Transplanted Mice Feature Increased Monocyte Counts in the 
Bone Marrow.  
(A) Schematic illustration of the Lin— transplantation setting. Donor mice consisted of tamoxifen-treated CTRL, 
DNMT3A, Idh1 or Idh1-DNMT3A mice. (B, C, D) Flow cytometry based quantification of indicated cell types in the bone 
marrow of transplanted mice four months after transplantation (CTRL n = 14-28, DNMT3A n = 12-26, Idh1 n = 13-30, 
Idh1-DNMT3A n = 10-18, at least three independent transplantations, Student’s t-test, p-values are indicated for 
significant results (p < 0.05)). 
 
 
3.7 Single-Cell RNA-Sequencing Identifies 
Hematopoietic Differentiation Trajectories  
 
In recent years, high-throughput single-cell RNA-sequencing (scRNA-seq) approaches have 
challenged the classical hierarchical model of hematopoietic differentiation. This 
technology provides a high-resolution transcriptome map of individual cells that can be 
used for the definition of cellular states and their transitions as well as the identification 
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of cellular priming and lineage commitment decisions [Watcham et al., 2019, Laurenti and 
Gottgens, 2018]. Single-cell gene expression profiles thereby provide a transcriptomic 
snapshot of hundreds to thousands of cells traversing along differentiation trajectories. 
Ordering cells based on their gene expression profiles results in the reconstruction of 
differentiation trajectories from immature stem and progenitor cells towards mature 
differentiated blood cells [Watcham et al., 2019, Laurenti and Gottgens, 2018]. Studies of 
the hematopoietic system using scRNA-seq have transformed our understanding of the 
different cellular compartments, unraveling unanticipated heterogeneity within flow 
cytometry defined ‘homogenous’ cell populations, with different subtypes reflecting 
diverging lineage priming and progressive commitment along trajectories [Velten et al., 
2017, Paul et al., 2015, Olsson et al., 2016, Villani et al., 2017, Rodriguez-Fraticelli et al., 
2018]. While flow cytometry-based approaches are restricted to a limited set of predefined 
markers, scRNA-seq quantifies the expression of thousands of genes per cell, thereby 
providing unprecedented detail, which not only can be harnessed to define cell states, but 
also to understand which cell states are predominantly affected by underlying mutations 
and how these mutations drive aberrant differentiation on a molecular level. 
 In order to reconstruct the transcriptomic landscapes of the hematopoietic system in 
the context of Idh1-R132H, DNMT3A-R882H and co-occurring Idh1-R132H and DNMT3A-
R882H mutations, we generated a multi-tiered single-cell gene expression map from Lin— 
transplanted mice at the time of stable engraftment (i.e. 20 weeks post transplantation). 
By combining three different parts of the hematopoietic system ranging from stem and 
progenitor cells (i.e. LSK cells) over committed progenitors (i.e. LS-K cells) to more 
differentiated cells (i.e. CD45+ TBM cells), we ensured to cover cells throughout the entire 
hematopoietic hierarchy (Figure 3-11A). This approach enables us to investigate the 
effects of the Idh1-R132H and DNMT3A-R882H mutations on gene expression profiles in 
virtually all hematopoietic cell types. Following cell sorting, single-cell gene expression 
profiles were generated using the droplet-based 10X Genomics platform using unique 
molecular identifiers (UMIs) to barcode individual RNA / cDNA molecules. For all samples, 
around 10,000 cells were loaded on the Chromium chip for library generation, the LSK-
CTRL sample being the only exception with only 3,366 cells being loaded (Figure 3-11B). 
Out of the loaded cells, between 3,000 and 5,000 cells (LSK-WT: 1,108 cells) were captured 
per sample, yielding transcriptome information for a total of 45,971 single cells (Figure 3-
11C). Initial filtering was performed based on the number of transcript counts and genes 
per cell as well as on the percentage of mitochondrial genes. Here, cells with low transcript 
and gene counts per cell or with high mitochondrial DNA contents likely represent 
damaged or dying cells, whereas cells with an unnatural high number of transcript and 
gene counts per cell are indicative of doublets. After filtering, 42,626 cells remained in 
the dataset. Across samples, we observed some variation in the number of transcript 
counts, genes and percentages of mitochondrial genes per cell with TBM samples being 
characterized by a lower number of detected genes and transcript counts per cell and a 
bimodal distribution of percentages of mitochondrial genes, probably reflecting different 
cell types with different mitochondria content (Figure 3-11D). For all genotypes, the 
highest numbers of genes per cell were detected in LS-K samples with between 3,000 and 
4,000 genes being identified. 
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Figure 3-11: Generating a Multi-Layered Single-Cell Transcriptomic Landscape of the Hematopoietic Compartment. 
(A) Experimental workflow for the generation of single-cell transcriptomic landscapes of the hematopoietic 
compartment. For each genotype, three cell layers (CD45+ TBM, LS-K, LSK) were isolated by flow cytometry and scRNA-
seq libraries generated using the 10X Genomics platform (adapted from 10X Genomics) (libraries were generated by Dr. 
Mark Hartmann, Maximilian Schönung and Katharina Bauer) (B + C) Overview of loaded and captured cell numbers per 
sample. Alignment, barcode and UMI counting was done using the ‘Cell Ranger’ software package from 10X Genomics 
(data processing was performed by Abdelrahman Mahmoud) (D) QC metrics of single-cells after data processing and 
filtering using the ‘Cell Ranger’ and ‘Seurat’ packages. Cells were filtered based on the number of detected genes 
(threshold: > 200 and < 5000 genes per cell) and the percentage of mitochondrial genes (threshold: < 10 %) (data 
processing was performed by Abdelrahman Mahmoud). 
 
 
 Subsequent to processing and quality control (QC) filtering, the R-package ‘Seurat’ 
was used for data normalization, scaling and clustering of cells. For visualization of single-
cell transcriptome profiles, the ‘Uniform Manifold Approximation and Projection’ (UMAP) 
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algorithm was applied to reduce the dimensionality of the dataset and to compute cell-to-
cell distances by which high-dimensional gene expression profiles of each single-cell can 
be distributed and ordered in a two-dimensional space. Here, annotation of the three bone 
marrow layers revealed a hierarchical ordering of LSK, LS-K and TBM populations with a 
high overlap between LSK and LS-K samples but a weak overlap of TBM and LSK or LS-K 
samples (Figure 3-12A). Our UMAP-based representation of the data is in line with 
previously published scRNA-seq data suggesting a continuous rather than a stepwise 
differentiation process in the hematopoietic system [Velten et al., 2017, Nestorowa et al., 
2016, Macaulay et al., 2016]. Annotation of the four individual genotypes illustrated a 
mostly even distribution of all genotypes, yet enrichment or depletion of specific 
genotypes in certain regions of the map were observed (Figure 3-12B). In light of the fact, 
that none of the mutated mice displayed indications of leukemia development or 
completely aberrant differentiation patterns, a similar representation of genotypes was 
expected at this point (see Supplemental Table A-1 for detailed peripheral blood and bone 
marrow composition of mice used in the scRNA-seq experiment).  
 
 
 
 
Figure 3-12: Visualization of Single-Cell Transcriptomes in a Two-Dimensional Space Reveals Hierarchical Structures 
and an Overlap of Sorted Cell Compartments. 
(A) UMAP-based dimensionality reduction and visualization of single-cell transcriptomes with an annotation of isolated 
cell layers. Hierarchical structures and a high overlap between LSK and LS-K populations are seen. For representative 
purposes, only 4,000 cells per compartment are depicted (initial data processing was performed by Abdelrahman 
Mahmoud). (B) UMAP-based dimensional reduction and visualization of single-cell transcriptomes with an annotation 
of individual genotypes. For representative purposes, only 4,000 cells per genotype are depicted (initial data processing 
was performed by Abdelrahman Mahmoud). 
 
 
 Clustering of cells was performed using a shared nearest neighbor (SNN) algorithm 
implemented in the ‘Seurat’ package, yielding 49 cell clusters in total.  In order to correlate 
these 49 clusters with specific hematopoietic cell populations, the expression of cell type-
defining genes was analyzed (Figure 3-13A) and cluster-specific markers were determined 
by calculating DE genes between the cluster of interest and all other remaining cells (see 
Material and Methods, Section 5.11.2 for detailed description). Individual clusters then 
were annotated manually by comparing cluster-defining genes with known hematopoietic 
marker genes (Figure 3-13B, list of marker genes see Supplemental Table A-2). As many 
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distinct clusters shared the expression of the same characteristic cell type-defining genes, 
annotated hematopoietic cell types frequently consisted of multiple individual clusters. 
For instance, the ST-HSC population was aggregated from three individual clusters which 
all displayed high expression levels of ST-HSC-defining marker genes. Eventually, this 
resulted in a total of 27 different annotated cell types derived from 49 previous clusters.  
 Starting from LT-HSCs at top of the hematopoietic hierarchy, four diverging 
directions of differentiation emerged in the LSK and LS-K compartments, leading towards 
megakaryocytic, erythroid, myeloid and lymphoid cell fates. Although terminally 
differentiated cell types derived from TBM samples clustered separate in the UMAP, they 
were distributed in proximity to their respective lineage progenitors.  
 In summary, by isolating LSK, LS-K and CD45+ TBM cells from transplanted mice, we 
have generated a multi-tier transcriptome map of the entire murine hematopoietic system. 
Detailed manual annotation of cell types allowed us to reconstruct trajectories into 
megakaryocytic, erythroid, myeloid and lymphoid lineages, which provided the basis for 
a detailed characterization of the molecular effects of Idh1-R132H and DNMT3A-R882H 
mutations throughout the entire hematopoietic system. 
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Figure 3-13: Single-Cell RNA-Sequencing Allows Reconstruction of Differentiation Trajectories. 
(A) Normalized expression of exemplary hematopoietic cell type-defining marker genes highlighted within the UMAP-
based representation of single-cell transcriptomic data. The color gradient from grey to dark blue indicates the level of 
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expression (grey = no expression, dark blue = high expression). Certain hematopoietic marker genes are only expressed 
in certain clusters, thereby allowing the annotation of clusters. (B) UMAP-based dimensional reduction and visualization 
of single-cell transcriptomes with an annotation of hematopoietic cell types. Clusters were annotated manually by 
investigating the expression of hematopoietic marker genes within cluster-defining genes. For representative purposes, 
only 15,000 cells are depicted (annotation of clusters was performed in collaboration with Dr. Simon Haas and Dr. Mark 
Hartmann). 
 
 
3.8 Idh1-R132H DNMT3A-R882H Mutated 
Mice Feature an Aberrant Myeloid 
Progenitor Compartment 
 
In order to investigate potentially diverging compositions of cell types in each genotype, 
we analyzed the contribution of individual genotypes to each of the annotated cell 
clusters. By comparing normalized cell numbers per sample and genotype within a given 
cluster, we found genotype-specific variation of cell type proportions to arise mainly in 
the LS-K and to a lesser extent also in the LSK compartment (Figure 3-14A). Differentiated 
cells represented in the TBM samples did not show skewed distribution across genotypes. 
The highest variability of genotype-specific cell type distribution was observed in clusters 
that were annotated as common myeloid progenitor (CMP) cells. In total, five cell clusters 
where annotated to the CMP compartment. Two out of the five CMP clusters were 
dominated by cells coming from Idh1-DNMT3A mice (common myeloid progenitor cluster 
#4 and #5), while other genotypes only marginally contributed to these clusters (Figure 3-
14A, for normalized cell frequencies per cluster and genotype see Supplemental Table A-
3). On the other hand, the monocyte / dendritic cell primed progenitor- (MoDCP) and the 
neutrophil primed progenitor (NeuP) clusters were depleted for cells from Idh1-DNMT3A 
mice. Within the LSK compartment, Idh1-R132H mutated mice displayed a slight tendency 
towards increased numbers of lymphoid primed progenitors when compared to other 
genotypes, but decreased numbers of LT-HSCs (Figure 3-14A, Supplemental Table A-3).  
 A focused UMAP representation of CMPs, MoDCPs and NeuPs clearly confirmed 
elevated levels of CMPs but diminished levels of MoDCPs and NeuPs in Idh1-DNMT3A mice 
(Figure 3-14B). Highlighting of the individual CMP subclusters indicates that CMP clusters 
#4 and #5 show the highest enrichment of Idh1-DNMT3A cells, whereas CMP cluster #1, 
#2 and #3 are not as strongly enriched for double-mutated cells (Supplemental Figure A-
7). 
 In relation to our previous FACS-based analysis of the bone marrow composition, a 
minor trend of an expansion of the CMP population was also detected in Idh1-DNMT3A 
mice based on flow cytometric quantification of cell populations (see Figure 3-10C), 
thereby validating genotype-specific dynamics within this population. For Idh1-R132H 
single-mutant mice, our FACS analysis indicated rather a depletion of ST-HSCs (see Figures 
3-7C and 3-10C) instead of LT-HSCs (as suggested by the scRNA-seq data), indicating that 
cell populations annotated by transcriptome profiles and cell populations defined by 
surface markers only overlap to a limited extent. Moreover, in our scRNA-seq dataset we 
failed to detect increased numbers of mature monocytes in TBM samples of Idh1 and Idh1-
DNMT3A mice as seen in flow cytometry-based quantifications. However, due to genotype-
specific differences in particular in the composition of the myeloid progenitor cell 
compartment, we further focused on characterizing these cell types in more detail. 
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Figure 3-14: Idh1-DNMT3A Mice Feature Increased Frequencies of Common Myeloid Progenitor Cells. 
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(A) Heatmap depicting the relative distribution of cell numbers from individual genotypes within annotated clusters. 
Color scale depicts column z-scores, thereby disregarding differential cell numbers that were initially captured per 
sample. Only clusters containing more than 1 % of the total sample cell number are shown. (B) Focused UMAP 
representation of CMP, MoDCP and NeuP populations per genotype. (C) K-nearest neighbor analysis of CMP, MoDCP and 
NeuP annotated clusters (analysis was performed by Abdelrahman Mahmoud). 
 
 
 K-nearest neighbor (kNN) analysis of the three myeloid progenitor populations (CMPs, 
MoDCPs and NeuPs) revealed that for each cell type Idh1-R132H DNMT3A-R882H mutated 
cells cluster away from CTRL, Idh1-R132H or DNMT3A-R882H single-mutated cells, 
further corroborating that combined mutations strongly affect the transcriptome of 
myeloid progenitor cells (Figure 3-14C). When calculating sample distances of each 
individual myeloid progenitor cell cluster per genotype, especially CMP cluster #4 and 
cluster #5 cells from Idh1-DNMT3A mice clustered away from CMP #4 and CMP #5 cells 
from other genotypes. Here, Idh1-DNMT3A CMP#4 cells clustered together with MoDCP 
cells whereas Idh1-DNMT3A CMP#5 cells clustered together with NeuP cells (Figure 3-15), 
suggesting these CMP clusters to display most aberrant transcriptomic profiles in relation 
to corresponding CMP cluster from CTRL or single-mutant mice. 
 Collectively, our data implies that Idh1-R132H DNMT3A-R882H double-mutants 
display a dysregulated expression of myeloid differentiation programs mediating the 
neutrophil versus monocyte trajectory. Aberrant expression profiles lead to an increase 
in CMP cell numbers and predominantly affect CMP sub-cluster #4 and #5, which, based 
on sample distances, deviate from corresponding clusters of other genotypes.  
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Figure 3-15: Genotype-Specific Sample Distances of Myeloid Progenitor Clusters Identify Aberrant Expression 
Profiles in Idh1-R132H DNMT3A-R882H Mutated Mice at the CMP Level.  
Heatmap depicting sample distances for each annotated myeloid progenitor cluster. Distances were calculated based 
on the average expression of all cells from one specific genotype within the indicated cluster. Calculation of distances 
and clustering of samples was computed using Euclidean distances. UMAP-based visualization of CMP, MoDCP and NeuP 
subclusters is shown in Suplemental Figure A-7. Idh1-DNMT3A CMP #4 cells cluster together with MoDCP cells (yellow 
box), whereas Idh1-DNMT3A CMP#5 cells cluster together with NeuP cells (red box). 
 
 
3.9 Diffusion Analysis of scRNA-seq Data 
Characterizes Aberrant Differentiation 
Trajectories  
 
Similar to UMAP-based representations, diffusion maps are non-linear dimensionality 
reduction methods which are based on diffusion-like dynamics and can be employed to 
order cells along their developmental paths as they traverse from multipotent to 
differentiated states. In order to reconstruct in particularly the myeloid differentiation 
axis for individual genotypes, we applied a diffusion algorithm implemented in the R-
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package ‘destiny’ [Angerer et al., 2016] on a subset of our scRNA-seq data set, containing 
annotated LT-HSC, ST-HSC, MPP, CMP, MoDCP and NeuP populations. 
 Distances of the fist diffusion component (DC1) mainly describe differentiation 
trajectories of cells passing from HSCs via MPPs and CMPs to MoDCPs or NeuP (Figure 3-
16A). While distances of the second diffusion component (DC2) segregate MPP-associated 
cell fates, distances of the third diffusion component (DC3) visualize a bifurcation point 
where fates are split into a neutrophil primed and monocyte / DC primed direction. 
Plotting of DC2 versus DC3 results in a differentiation map that illustrates three different 
trajectories that are associated with MPP, monocyte / DC or neutrophil cell fates (Figure 
3-16B, for DC1 vs. DC2 see Supplemental Figure A-8). As CMPs are located relatively in the 
center between ST-HSCs, MoDCPs and NeuPs, this map implies that myeloid primed cells 
follow a trajectory starting from LT-HSCs, and via ST-HSCs towards CMPs, but not MPPs, 
end in MoDCP or NeuP populations. Reconstruction of differentiation trajectories for each 
of the four genotypes was performed using the ‘slingshot’ algorithm [Street et al., 2018], 
which infers lineages based on the underlying diffusion components of each cell. For all 
of the four genotypes pseudotime-represented lineages could be reconstructed, that were 
associated with MPP-, monocyte / DC-  or neutrophil-defined cell fates (Figure 3-16C, 
lineages indicated as lines). Notably, even for Idh1-DNMT3A cells, the three reconstructed 
lineage trajectories only marginally deviated from those observed in other genotypes. Yet, 
Idh1-DNMT3A CMP cells formed a more diffuse and cloud-like structure as compared to 
CMPs from other genotypes. Moreover, especially monocyte- / DC-associated trajectories 
appeared more constrained in Idh1-DNMT3A cells, suggesting that in the Idh1-R132H 
DNMT3A-R882H mutated myeloid compartment a partial differentiation block occurs at 
the CMP stage and affects monocyte / DC differentiation patterns. 
 In summary, our data suggests that in Idh1-DNMT3A mice the myeloid differentiation 
trajectory shows aberrant behavior. Here, cells accumulate at the CMP stage and give rise 
to reduced numbers of downstream NeuP and MoDCP populations. These accumulated 
CMP cells in part recapitulate features of NeuP and MoDCP cells (as seen in Figure 3-15) 
and are likely still capable of producing sufficient amounts of mature monocytes, DCs 
and neutrophils as evidenced by our PB and TBM analyses of theses mice. Although 
diffusion maps and lineage inference methods could reconstruct similar lineage 
trajectories for all genotypes, the observed partial differentiation block seen in Idh1-
DNMT3A mice mirrors ineffective hematopoietic differentiation as seen for example in 
myelodysplastic syndromes. 
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Figure 3-16: Diffusion Analysis Allows the Inference of Lineage Trajectories Within the Myeloid Compartment. 
Diffusion components were calculated using the R-package ‘destiny’ based on the normalized expression values of cells 
within the LT-HSC, ST-HSC, MPP, CMP, MoDCP and NeuP cluster. (A) Dot plot illustrating the diffusion distances for the 
individual diffusion components. Average distances for all cells within the indicated population were calculated 
irrespective of genotypes. (B) Diffusion map of components two and three (DC2, DC3) for combined genotypes. For 
representative purposes only 5,000 cells are depicted. (C) Diffusion map of components two and three (DC2, DC3) for 
each individual genotype. Lineage trajectories were inferred for each genotype separately using the R-package ‘slingshot’ 
and are depicted as lines. For representative purposes only 2,500 cells per genotype are depicted.  
 
 
3.10 Molecular Signatures of Mutated 
Myeloid Progenitors 
 
Having revealed differentiation defects during myeloid differentiation in Idh1-DNMT3A 
mice, we further aimed to underpin these findings at the molecular level by calling DE 
genes between genotypes for each annotated population. We noticed the highest 
differential expression between genotypes to exist in annotated CMP or MoDCP 
populations, where especially Idh1-R132H DNMT3A-R882H mutated cells featured a large 
number of DE genes (log2 fc > 0.25, padj < 0.05) (Figure 3-17A), confirming that mutation-
dependent effects likely manifest in these populations or, alternatively, these cell types 
are most susceptible to effects mediated by combined Idh1-R132H and DNMT3A-R882H 
mutations. Within mature monocytes or neutrophils, the number of DE genes was rather 
limited.  
 Within the CMP population, we found several genes which are upregulated during 
myeloid differentiation to be significantly higher expressed in Idh1-DNMT3A CMPs 
compared to other genotypes (Figure 3-17B). These include general myeloid marker genes 
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such as Fcgr3 or Ms4a3, granulocyte differentiation associated genes such as Elane, Mpo 
or Ctsg, but also monocyte marker genes such as Ly6c2. Strikingly, a large variety of 
transcripts encoding for ribosomal proteins (Rps, Rpl) were strongly downregulated in 
Idh1-DNMT3A CMP cells, implying translation and protein synthesis rates to be 
diminished in comparison to other genotypes. Inferring metabolic defects, genes which 
are higher expressed in Idh1-DNMT3A CMP cells, were often related to metabolic and 
biosynthesis gene ontology (GO) terms (Supplemental Figure A-9). It needs to be 
mentioned though, that also DNMT3A-R882H single-mutated cells were enriched for GO 
terms linked to metabolic processes (Supplemental Figure A-9).  
 Regarding the MoDCP population, genes which are implicated in cell cycle regulation, 
such as Cdk1 or Cdc20, were among the highest upregulated genes in Idh1-DNMT3A 
MoDCP cells (Figure 3-17C). Consistently, GO terms associated with cell division, 
chromosome organization and regulation of cell cycle were enriched in Idh1-DNMT3A 
MoDCPs (Supplemental Figure A-9).  
 To probe whether MoDCPs indeed display higher cycling rates in Idh1-DNMT3A mice 
compared to other genotypes, we calculated S-phase and G2M-phase scores for each cell 
based on their gene expression profile and assigned score-based cell cycle phases in which 
cells are likely to reside in. As expected, HSCs were predominantly in a quiescent state 
assigned to a G1-phase (Figure 3-18A). Downstream progenitor cells, such as MPPs, CMPs 
or MoDCPs however, were predominantly assigned to the G2M- or S-phase of the cell cycle, 
suggesting that these populations are in a proliferative and amplifying state and 
responsible for driving the large-scale production of mature cell types. Comparing cell 
cycle assignments of myeloid progenitor populations per genotype revealed that Idh1-
DNMT3A MoDCPs indeed featured more cells in combined G2M- or S-phases but retained 
less cells in the G1-phase than other genotypes (Figure 3-18B). In CMPs or NeuPs the 
distribution of cell cycle phases was relatively equal for all genotypes, indicating that 
despite alterations in metabolic processes, proliferative rates seem to be unaffected in 
Idh1-R132H DNMT3A-R882H double-mutated CMPs. 
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Figure 3-17: Differential Expression Analysis of Myeloid Progenitor Populations Reveals Aberrant Expression of 
Myeloid Differentiation-Associated Genes in Idh1-R132H DNMT3A-R882H Mutated Cells. 
(A) Number of DE genes for each genotype and population. Differential expression was called between one specific 
genotype and all other genotypes within the same population. Genes with log2 fc > 0.25 and padj < 0.05 were considered 
as differentially expressed. (B + C) Heatmap depicting the top 20 DE genes for each genotype within CMP and MoDCP 
populations. Genotype-specific signatures were determined based on calling DE genes between one genotype and all 
other genotypes within the indicated population. Genes were ranked according to the calculated log2 fc (Differential 
expression analysis was performed by Abdelrahman Mahmoud). 
 
 
 For both Idh1-R132H single-mutated CMPs and MoDCPs, we noticed several 
inflammatory response-related genes to be among the most upregulated genes, such as 
Dusp1, Dusp2, Ccl3 or Ccl4 (Figure 3-17B and Figure 3-17C). Accordingly, gene signatures 
of LPS-treated monocytes or macrophages were enriched in Idh1-R132H mutated CMP and 
MoDCP cells (Supplemental Figure A-9). Collectively, this points towards an Idh1-R132H 
mutation-mediated induction of an inflammatory response in myeloid progenitors that 
resembles transcriptomic profiles from stimulated monocytes and macrophages.    
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Figure 3-18: Idh1-R132H DNMT3A-R882H Mutated Monocyte / Dendritic Cell Primed Progenitors Display Deviant 
Cell Cycle Phase Distribution. 
(A) UMAP-based representation of single-cell transcriptomes with colors illustrating the distribution of cell cycle phases 
across all cells. Cell cycle scores were calculated based on a predefined set of genes with characteristic expression levels 
during G2M- or S-phase. For each individual cell a G2M- and S-phase score was determined which was used to assign 
cell cycle phases. Cells with low G2M- and S-phase scores were assigned to the G1-phase. For representative purposes, 
only 15,000 cells are depicted. (B) Distribution of cell cycle phases per genotype and myeloid progenitor population.   
 
 
 In addition, we found the monocyte / macrophage proinflammatory stimuli-induced 
genes Klf2 and Klf6 to be consistently higher expressed in both Idh1 and Idh1-DNMT3A 
CMPs and MoDCPs (Figure 3-19.) Similarly, expression levels of the TFs, Fos, Jun, Junb, 
Jund and Myc, which specify monocyte development, differentiation and maturation, were 
in part substantially increased in Idh1-R132H single-mutated or Idh1-R132H DNMT3A-
R882H double-mutated CMPs and MoDCPs (Figure 3-19), suggesting that disturbed 
expression of these TFs could represent molecular determinants that drive or promote an 
aberrant monocytic differentiation as detected in Idh1 and Idh1-DNMT3A mice.   
 Taken together, we could correlate the accumulation of myeloid cells at the CMP stage 
in Idh1-DNMT3A mice with a dysregulated metabolic signature and disturbed expression 
levels of differentiation associated genes, such as Ly6c2 or Elane. Although in silico cycling 
behavior of cells at the CMP stage in Idh1-DNMT3A mice is comparable to other genotypes, 
the upregulation of myeloid marker genes suggests that cells display disturbed myeloid 
differentiation patterns. Yet, Idh1-DNMT3A MoDCP cells upregulate the expression of cell 
cycle-related genes to drive mature monocyte and DC production as illustrated by an 
increased S-/G2M-phase distribution of cells. Expression of the Idh1-R132H mutation 
alone or in combination with a DNM3TA-R882H mutation results in altered expression 
levels of several pivotal inflammatory and transcriptional regulators of the monocyte / 
macrophage lineage. 
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Figure 3-19: Regulators of Monocyte and Macrophage Development are Deregulated in Idh1-R132H Mutated Myeloid 
Progenitors.  
Violin plot showing the distribution of normalized expression values of monocyte / macrophage regulatory TFs per 
genotype in myeloid progenitor populations as well as in differentiated mature monocytes and neutrophils. Violins are 
scaled to an equal maximum width (Student’s t-test, p-values are indicated for significant results (p < 0.05) for the 
comparisons Idh1 vs. CTRL and Idh1-DNMT3A vs. CTRL). 
 
 
3.11 Identification of Surface Markers Specific 
for Idh1-R132H DNMT3A-R882H Mutated 
Myeloid Progenitor Cells  
 
Hypothesizing that the observed partial differentiation block at the CMP stage in Idh1-
DNMT3A mice mirrors a preleukemic state, we systematically assessed whether any 
candidate genes with aberrant overexpression in Idh1-R132H DNMT3A-R882H mutated 
CMPs hold potential to serve as surface markers for the early detection and diagnosis of 
Idh1-R132H DNMT3A-R882H mutated hematopoietic neoplasms. In order to rank genes 
according to the level of enrichment in Idh1-DNMT3A CMPs, we applied ‘SurfaceGenie’, a 
web-based application, which prioritizes genes with disparate measurements across 
genotypes based on the calculation of signal dispersion and signal strength coefficients 
[Waas et al., 2019]. By using a matrix consisting of normalized expression values of genes 
which are differentially expressed in Idh1-DNMT3A mutated CMPs, we specifically focused 
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on genes to be enriched in double-mutated cells. The ‘OmniGenie Score’ in the end served 
as a metric to rank genes based on the levels of disparity between Idh1-DNMT3A CMPs 
and CMPs from all other genotypes.  
 By far, we found the genes Ly6c2, encoding the Ly6C protein, and Elane to be 
expressed most divergently in Idh1-R132H DNMT3A-R882H mutated cells compared to 
other genotypes (Figure 3-20A) and validated the increased Ly6c2 expression in Idh1-
DNMT3A CMPs in our single-cell expression data set (Figure 3-20B). Ly6C is a classical 
surface marker which is expressed on mature monocytes, neutrophils and DC cells but 
also in myeloid progenitor cells as cells are specified to differentiate towards monocyte 
or neutrophil cell fates [Lee et al., 2013]. Within myeloid progenitor populations, Ly6C 
expression levels together with the expression of CD115 (Csf1r) have been employed to 
discriminate between cMoPs, GMPs and granulocyte progenitors (GPs) [Yanez et al., 2017, 
Hettinger et al., 2013, Yanez et al., 2015].  
 To correlate the observed increased transcriptomic Ly6c2 mRNA expression with 
Ly6C surface expression levels, we extended our flow cytometric analyses of the bone 
marrow of Lin— transplanted mice with Ly6C specific antibodies. Although aberrant gene 
expression profiles in our scRNA-seq data set were predominantly observed in 
transcriptome-defined CMP cells, we in particular focused on surface marker-defined GMP 
cells, hypothesizing that transcriptome-defined CMP cells most likely correlate with 
surface marker-defined GMP cells. Within the surface marker-defined GMP population 
(defined as Lin—, cKit+, Sca1—, CD34+, CD16/32+) we observed elevated Ly6C mean 
fluorescence intensities (MFI) in both Idh1 and Idh1-DNMT3A transplanted mice, 
indicating that increased transcriptomic levels also correlate with increased surface 
expression levels (Figure 3-20C). The fact that also Idh1-R132H single-mutants featured 
elevated Ly6C MFIs, however, is in contrast to our scRNA-seq data, where increased Ly6c2 
expression was exclusive to Idh1-DNMT3A CMPs. Quantification of cMoP frequencies 
(defined as Lin—, cKit+, Sca1—, CD34+, CD16/32+, CD115+, Ly6C+, gating scheme in 
Supplemental Figure A-1), as well as of ratios of Ly6C+ or CD115+ GMPs to Ly6C— or CD115— 
GMPs revealed that both Idh1 and Idh1-DNMT3A transplanted mice displayed increased 
cMoP counts, Ly6C+/Ly6C— GMP ratios and CD115+/CD115— GMP ratios (Figure 3-20D). 
Interestingly, increased cMoP counts and CD115+/CD115— GMP ratios were also detected 
in DNMT3A mice, but to a much milder degree as seen in Idh1 and Idh1-DNMT3A mice, 
while elevated Ly6C+/Ly6C— GMP ratios were restricted to only Idh1-R132H single- and 
Idh1-R132H DNMT3A-R882H double-mutant mice.  
 Altogether, based on our scRNA-seq data we have identified Ly6C as an Idh1-
DNMT3A-specific marker within transcrptome-defined CMPs. However, elevated cell 
surface levels of Ly6C were observed in both Idh1 and Idh1-DNMT3A surface marker-
defined GMPs, indicating discrepancies between our transcriptome and flow cytometric 
analysis. Furthermore, elevated levels of cMoPs within the myeloid progenitor cell 
compartment likely contribute to increased mature monocyte counts that were observed 
previously in Idh1 and Idh1-DNMT3A Lin— transplanted mice.  
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Figure 3-20: Ly6C Surface Expression is Increased in Idh1-R132H Mutated Myeloid Progenitor Cells. 
(A) Illustration of calculated ‘OmniGenie’ scores as a measure for ranking disparately expressed genes between Idh1-
DNMT3A CMPs and CMPs from all other genotypes. Scores were determined by using the ‘SurfaceGenie’ tool [Waas et 
al., 2019] with a normalized expression matrix filtered for genes differentially expressed (log2 fc > 0.25, padj < 0.05) in 
Idh1-DNMT3A mutated CMPs as input. (B) Quantification of normalized Ly6c2 RNA expression levels in annotated CMP 
cells per genotype (data from scRNA-seq data set). (C) Quantification of Ly6C cell surface expression (measured by mean 
fluorescence intensities determined by flow cytometry) in surface marker-defined GMP populations within the bone 
marrow of Lin— transplanted mice (CTRL n = 9, DNMT3A n = 8, Idh1 n = 9, Idh1-DNMT3A n = 7, two independent 
transplantations). (D) Quantification of cMoP frequencies, Ly6C+/Ly6C— GMP ratios and CD115+/CD115— GMP ratios in 
the bone marrow of Lin— transplanted mice. Frequencies of cMoPs, Ly6C+ GMPs, Ly6C— GMPs, CD115+ GMPs and CD115— 
GMPs are relative to overall EYFP+ cells in the bone marrow. Gating schemes shown in Supplemental Figure A-1 (CTRL n 
= 9, DNMT3A n = 8, Idh1 n = 9, Idh1-DNMT3A n = 7, two independent transplantations, Student’s t-test, p-values are 
indicated for significant results (p < 0.05)). 
 
 
 To validate whether Ly6C surface expression enriches for the aberrant CMP 
population identified in the scRNA-seq data set in Idh1-DNMT3A mice, we isolated Ly6C+ 
GMPs from Lin— transplanted mice and performed bulk RNA-seq. For each genotype, we 
sorted triplicates from individual transplanted mice. Clustering of samples and 
calculation of sample distances revealed that Idh1 and Idh1-DNMT3A samples as well as 
CTRL and DNMT3A samples clustered together, with the exception being one DNMT3A 
replicate which clustered together with all three Idh1-DMNT3A replicates (Supplemental 
Figure A-10A). Accordingly, the first PC separated Idh1 and Idh1-DNMT3A samples from 
CTRL and DNMT3A samples in a PCA, whereas the second PC separated Idh1 from Idh1-
DNMT3A samples (Supplemental Figure A-10B). It is worth noting, that with the exception 
of DNMT3A samples, replicates from all genotypes were relatively similar among each 
other. Calling of DE genes using log2 fc < -0.5 or > 0.5 and padj < 0.05 as cutoff resulted 
in 47 DE genes between Idh1 and CTRL samples (15 upregulated, 32 downregulated), 7 DE 
genes between DNMT3A and CTRL samples (3 up, 4 down), 56 DE genes between Idh1-
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DNMT3A and CTRL samples (23 up, 33 down), but also 66 DE genes between Idh1-
DNMT3A and Idh1 samples (61 up, 5 down) (Supplemental Figure A-10C). 
 Next, we investigated the expression of Idh1-DNMT3A-specific marker genes 
identified in scRNA-seq CMPs or MoDCPs in our bulk RNA-seq data from sorted Ly6C+ 
GMPs. Here, the expression levels of marker genes upregulated in Idh1-DNMT3A scRNA-
seq CMPs and MoDCPs were increased in Idh1-DNMT3A Ly6C+ GMPs but not in Idh1, 
DNMT3A or CTRL Ly6C+ GMPs (Figure 3-21A and Figure 3-21B). The only outlier consisted 
of the same DNMT3A replicate, which already clustered together with Idh1-DNMT3A 
samples in PCA and in sample distance analyses.  
 
 
 
 
 
Figure 3-21: Correlation of Transcriptome- and Surface Marker-Defined Myeloid Progenitor Populations. 
(A + B) Heatmap depicting normalized expression levels of Idh1-DNMT3A-specific marker genes, identified in scRNA-
seq CMPs (A) and MoDCPs (B), in bulk RNA-seq data of isolated Ly6C+ GMPs from Lin— transplanted mice. Idh1-DNMT3A-
specific marker genes in annotated scRNA-seq CMPs were called by comparing one genotype to all other genotypes 
within the CMP population and DE genes with a log fc > 0.25 and padj < 0.05 were considered as differentially expressed 
/ Idh1-DNMT3A specific. Each row represents a gene and clustering of rows and columns is based on Euclidean 
distances. Color scale represents row z-scores. 
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 In summary, we could demonstrate that Ly6C+ GMPs represent a surface marker-
defined bone marrow population that carries the aberrant gene expression signature 
observed in Idh1-R132H DNMT3A-R882H mutated scRNA-seq CMPs. By interrogating 
aberrantly expressed surface markers, we correlated cell populations defined by gene 
expression patterns with cell surface marker-defined populations. This allowed us to 
prospectively isolate an aberrant cell population from Idh1-DNMT3A mice, which will 
enable us to functionally characterize these cells in future experiments.  
 
 
3.12 Idh1-R132H Mutated Ly6C+ Progenitors 
Show Activation of an Inflammatory 
Signature 
 
In order to elucidate functional differences between mutated and CTRL Ly6C+ GMPs, we 
performed gene set enrichment analyses, comparing expression values from Idh1 and 
Idh1-DNMT3A replicates with CTRL replicates, but also comparing Idh1-DNMT3A 
replicates with Idh1 replicates. Due to the low number of DE genes between DNMT3A and 
CTRL Ly6C+ GMPs, we disregarded this comparison from further analysis. For both Idh1 
and Idh1-DNMT3A samples we found several inflammation-related gene sets, including 
‘Hallmark Interferon Alpha Response’, ‘Hallmark Interferon Gamma Response’ or 
‘Hallmark Inflammatory Response’ to be strongly enriched compared to CTRL samples 
(Supplemental Tables A-4 and A-5). We further aimed to identify upstream transcriptional 
regulators that were affected and which could explain the observed changes in gene 
expression. Consistently, multiple IFN signaling-related upstream regulators were 
activated in Idh1 and Idh1-DNMT3A Ly6C+ GMPs, among them IFNa, IFNb, the 
IFNa/b receptor IFNAR1, the interferon regulatory factors 3 and 7 (IRF3, IRF7), but also the 
downstream TF STAT1 which aggregates activation signals from IFN receptors and IRFs 
to mediate downstream transcriptional changes (Figure 3-22A, Figure 3-22B).  
 Regarding differences between Idh1-R132H single-mutated and Idh1-R132H 
DNMT3A-R882H double-mutated Ly6C+ progenitors, we observed a strong upregulation 
of Myc target genes in Idh1-DNMT3A samples (Figure 3-23A). Elevated Myc target gene 
levels were specific only for Idh1-DNMT3A samples with the DNMT3A_3 outlier-replicate 
again being the only exception. We next examined the expression of Myc target genes in 
myeloid progenitor populations of our scRNA-seq data set. Here, the highest overlap 
between Myc target genes and genotype-specific DE genes within the scRNA-seq CMP 
population was detected for Idh1-DNMT3A-specific DE genes, whereas the overlap 
between Myc target genes and DE genes from other genotypes was limited (Figure 3-23B). 
In line with this, Myc target genes were among gene sets enriched in Idh1-DNMT3A scRNA-
seq CMPs (Supplemental Figure A-9).  
 In light of the association between Myc and cell activation, proliferation and 
transcriptional amplification [Wasylishen and Penn, 2010, Nie et al., 2012], elevated Myc 
levels could indicate an early preleukemic or even proliferative activated state. Other 
reports however linked Myc signaling also to myeloid and especially monocytic 
differentiation [Rico et al., 2017, Lee et al., 2017], implying that augmented Myc expression 
could propel an expansion of monocyte progenitor and mature monocyte pools. 
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Figure 3-22: Idh1-R132H Mutated Ly6C+ Progenitors Display Elevated Expression of Interferon Signaling 
Components. 
(A) Analysis of potential upstream regulators that could explain differential expression patterns seen between Idh1-
DNMT3A and CTRL Ly6C+ GMPs as well as between Idh1 and CTRL Ly6C+ GMPs. The analysis was performed using 
‘Ingenuity Pathway Analysis’. X-axis displays the p-value of overlap between genes from the underlying data set and 
genes that are regulated by the indicated regulator. Color scale represents activation z-scores which are calculated to 
infer activation states of indicated regulators. (B) Schematic illustrations of the IFNa and IFNb signaling axis, including 
receptors and downstream TFs such as STAT1. Orange color indicates an activation of the regulator in the underlying 
dataset, blue color indicates an inhibition of the regulator in the underlying dataset. Illustrations were created with 
‘Ingenuity Pathway Analysis’. 
 
 
 To functionally test the differentiation potential of mutated myeloid progenitor cells, 
we sorted surface marker-defined CMPs (defined as Lin— cKit+ Sca1—, CD34+, CD16/32—, 
Ly6C—, CD115—, CD11b—, Ly6G—), which are upstream of the aberrant surface marker-
defined GMP population. Isolated CMPs were cultured in the presence of murine IL-3, IL-6 
and stem cell factor (SCF). After 72 h or 96 h we investigated the expression levels of 
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myeloid surface markers CD11b, CD115, Ly6C and Ly6G. As expected, cells downregulated 
the cKit expression during culture, indicating that cells started to differentiate (Figure 3-
24). We further observed slightly increased frequencies of Ly6C, CD115 and CD11b 
positive cells both after 72 h and 96 h of culture for Idh1 and Idh1-DNMT3A cells in 
comparison to CTRL or DNMT3A cells. Rates of Ly6G+ cells were also increased in Idh1-
DNMT3A and Idh1 cells, however the relatively low frequencies of overall Ly6G+ cells 
indicate that Ly6G expression probably is induced only later during the myeloid 
differentiation process.  
 Taken together, both Idh1-R132H and Idh1-R132H DNMT3A-R882H mutated Ly6C+ 
GMP cells are characterized by a drastically increased IFNa/b-related inflammatory 
signature that is driven by IRF3, IRF7 and STAT1 activity. Evidence for elevated Myc 
signaling was observed only in Idh1-DNMT3A myeloid progenitor cells and was validated 
both in scRNA-seq and bulk RNA-seq data from Ly6C+ GMPs. Although functional effects 
on differentiation processes recapitulated in vitro appear to be only marginal, our data 
highlights increased expression of myeloid marker genes, which likely is mediated by the 
Idh1-R132H mutation. This observation presumably mirrors the myeloid biased 
differentiation patterns within the hematopoietic compartment. 
 
 
 
 
Figure 3-23: Myc Target Genes are Higher Expressed in Idh1-R132H DNMT3A-R882H Mutated Ly6C+ GMPs. 
(A) Heatmap depicting normalized expression levels of Myc target genes in bulk RNA-seq data of sorted Ly6C+ GMPs 
from Lin— transplanted mice. Myc target genes were extracted from the ‘Molecular Signature Database’ (MSigDB). Each 
row represents one gene and clustering of rows and columns is based on Euclidean distances. Color scale represents 
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row z-scores. (B) Venn diagram illustrating the overlap between Myc target genes and genotype-specific DE genes in 
annotated scRNA-seq CMP populations. DE genes (log fc > 0.25 and padj < 0.05) were called by comparing one genotype 
to all other genotypes within the CMP population. Myc target genes were extracted from the ‘Molecular Signature 
Database’ (MSigDB).  
 
 
 
 
 
 
Figure 3-24: In vitro Differentiation Characteristics of Isolated CMPs Does Not Provide Evidence for a Differentiation 
Defect Towards Monocytes and Neutrophils in Mutated CMPs. 
Surface marker-defined CMPs (Lin— cKit+ Sca1—, CD34+, CD16/32—, Ly6C—, CD115—, CD11b—, Ly6G—) were isolated from 
Lin— transplanted mice, cultured for 72 h or 96 h and then analyzed by flow cytometry for surface expression of 
indicated markers. Y-axis frequencies indicate the frequencies of marker positive cells at the individual time points (for 
all genotypes n = 3, error bars indicate mean ± SD). 
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4  
 
 
Discussion 
 
 
The process of hematopoietic differentiation and the production of mature cell types is a 
highly dynamic process, which is regulated on multiple levels. In this context, several 
studies have generated maps of transcriptome and epigenome dynamics, including DNA 
methylation, chromatin accessibility and histone modifications, which accompany and 
govern cell fate and lineage commitment decisions [Farlik et al., 2016, Buenrostro et al., 
2018, Corces et al., 2016, Lara-Astiaso et al., 2014, Velten et al., 2017, Giladi et al., 2018, 
Lipka et al., 2014, Cabezas-Wallscheid et al., 2014]. Integration of these different 
molecular layers has dramatically increased our knowledge of regulatory mechanisms that 
are critical during hematopoiesis and serve as a reference when trying to elucidate the 
molecular and functional defects which are associated with hematopoietic pathologies.  
 Deregulation of the epigenetic machinery has been proposed for many years to be a 
cornerstone for the development of malignant cell growth, not only in the hematopoietic 
system but also in most, if not all, cancer types [Feinberg et al., 2016]. On an imaginary 
Waddington landscape, epigenetic regulators are thought to provide the structural basis 
which ensures that cells are guided to well-defined terminally differentiated cell states 
[Feinberg et al., 2016, Flavahan et al., 2017]. However, acquired epigenetic instability leads 
to the erosion of cell state-defining barriers, resulting in a more permissive state 
characterized by epigenetic plasticity that allows premalignant cells to adapt diverging 
transcriptional or developmental programs [Feinberg et al., 2016, Flavahan et al., 2017].  
 As a metabolic enzyme, mutations in IDH1 indirectly disturb epigenetic patterns 
through the excessive production of D2HG, which inhibits several DNA and histone 
demethylases. However, molecular details and mechanisms of how oncogenic Idh1-R132H 
mutations drive an oncogenic transformation in the hematopoietic system are largely 
unknown. Within this thesis, we have comprehensively characterized the impact of 
oncogenic Idh1-R132H mutations in the hematopoietic compartment by combining 
functional and molecular analyses. The transcriptomic landscape of not only Idh1-R132H 
single-mutated but also Idh1-R132H DNMT3A-R882H double-mutant hematopoiesis 
generated here at single-cell resolution serves as a roadmap that complements previous 
reference transcriptomic maps of murine hematopoiesis and allowed us to identify 
regulatory mechanisms that are altered in the context of single Idh1-R132H mutations 
and in combination with co-occurring DNMT3A-R882H mutations. Critically, our analysis 
provided the basis to define and pinpoint aberrant cell states which are most affected by 
the presence of an Idh1-R132H mutation and will enhance our general understanding of 
the functional and molecular consequences induced by Idh1-R132H mutations.  
Idh1-R132H Mutations in the Context of DNA Damage 
 68 
4.1 Idh1-R132H Mutations in the Context of 
DNA Damage 
 
Idh1-R132H mutations have been associated with an increase in DNA damage and DNA 
repair deficiencies, arising either through defects in the homologous recombination (HR) 
DNA repair pathway [Sulkowski et al., 2017], impaired sensing of DNA damage through 
downregulation of ATM [Molenaar et al., 2018b, Inoue et al., 2016], or through the 
inhibition of alkylated DNA repair enzymes of the ALKB family [Wang et al., 2015]. Here, 
the downregulation of ATM and the suppression of HR is mediated through the inhibition 
of aKG-dependent, DNA damage-induced histone demethylases KDM4A and KDM4B, 
supporting a model according to which epigenetic alterations represent the driving force 
of cellular transformation [Sulkowski et al., 2017, Inoue et al., 2016, Young et al., 2013, 
Mallette et al., 2012, Molenaar et al., 2018a]. 
We observed an increase in DNA damage rates in Idh1-R132H mutated as compared 
to wildtype 32D cells already in an untreated state, but even more pronounced after 
irradiation, indicating that an Idh1-R132H mutation per se is sufficient to entail an 
accumulation of damaged DNA. Following irradiation, we found DNA damage rates to 
rapidly reach steady state levels, arguing for an intact repair machinery in Idh1-R132H 
mutated 32D cells and for comparable repair kinetics to wildtype cells. It furthermore 
seems likely that the reduced cell cycle and proliferation rates, which we detected in Idh1-
R132H mutated 32D cells, can be traced back to the increased amount of DNA damage 
which would impair survival and proliferation of cells. Yet, this direct link still needs to 
be established in our model system. Alternatively, the imbalance of metabolites and 
associated metabolic processes induced by Idh1-R132H mutations could simply diminish 
regular proliferation rates, as cells would have to cope with these unfavorable conditions. 
In glioma, several reports have revealed that IDH1-R132H mutations rather inhibit the 
growth and proliferation of glioma cells, an observation which could contribute to the 
prolonged survival of glioma patients carrying IDH1-R132H mutations [Bralten et al., 
2011, Shi et al., 2014, Li et al., 2013, Sanson et al., 2009, Bhavya et al., 2019]. However, in 
these cases decreased proliferation rates were shown to be attributable to the depletion 
of the antioxidant glutathione (due to the decline of NADPH which is consumed during 
the production of D2HG), to elevated ROS levels, or to the suppressed expression of the 
branched-chain amino acid transaminase 1 (BCAT1), which promotes cell proliferation 
through initiation of the catabolism of branched-chain amino acids [Shi et al., 2014, Tonjes 
et al., 2013]. Yet, an increase in DNA damage rates was not shown to be causative to these 
phenotypes.  
In transplanted LT-HSCs, several DNA damage- and DNA repair-related genes were 
differentially expressed in Idh1-R132H mutated cells, thereby validating a close 
interconnection of Idh1-R132H mutations with altered DNA damage rates and DNA repair 
pathways. While we did not observe any variation in Atm transcript levels as published 
previously [Inoue et al., 2016], we for instance found Rad52, Rpa2, Xpc, Ddb2 expression 
levels to be increased in Idh1-R132H mutated LT-HSCs, with factors being pivotal for the 
repair of DNA by either HR (Rad52, Rpa2) or by GG-NER (Xpc, Ddb2). The fact that 
expression levels of these genes are elevated, could imply that increased DNA damage 
rates within the cell due to an expression of the Idh1-R132H mutation might lead to an 
enhanced transcription and recruitment of these repair factors to the sites of damage. 
However, whether Idh1-R132H mutated LT-HSC indeed display higher DNA damage rates 
in our mouse model needs to be quantified. As the Idh1-R132H mutation in our mice was 
expressed heterozygously, it seems conceivable that, because of lower expression levels, 
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mutation-mediated effects on DNA damage rates are not as pronounced as in cells that 
feature a homozygous expression or as in cells that were transduced with a mutation-
expressing lentiviral overexpression plasmid.  
In the hematopoietic system, the downregulation of ATM and the impairment of DNA 
repair were associated with reduced HSC numbers in the bone marrow and a decrease in 
self-renewal capacity [Inoue et al., 2016]. In our hands, we observed slight trends towards 
reduced HSC numbers in serially transplanted as well as in Lin— transplanted Idh1 mice. 
In line with this, in our scRNA-seq data set, the annotated LT-HSC cluster was depleted of 
cells from Idh1 mice. Furthermore, we detected an inverse correlation of D2HG levels in 
bone marrow cell lysates and HSC frequencies in the bone marrow, although this 
correlation was established with a limited number of mice and needs further validation. 
As this indicates that the excessive production of D2HG is likely to impact the size of the 
stem cell pool in the bone marrow, it remains unclear whether these observations in our 
model system are derived from alterations in DNA damage and DNA repair rates. 
Alternatively, D2HG-mediated changes in the epigenetic makeup of HSCs, their cellular 
metabolism, their cellular signaling, or an altered cytokine environment in the bone 
marrow could result in reduced activities and frequencies of HSCs. Nevertheless, our 
results clearly support that Idh1-R132H mutations lead to a reduction in HSC numbers, 
although molecular details and causative mechanisms to this finding need to be 
determined.   
 One may speculate that the excessive accumulation of DNA damage would hinder the 
long-term survival and self-renewal of Idh1-R132H mutated HSCs, leading to a gradual 
and successive decline in numbers and generation of downstream progeny. In contrast, in 
all competitive transplantation settings, we found Idh1-R132H mutated transplanted 
HSCs to yield a better engraftment in recipients, resulting in a higher donor chimerism 
and arguing against a decreased self-renewal capacity. In particular in serial 
transplantations, which impose a great amount of selective pressure and replicative stress 
on transplanted HSCs, we would have expected to observe a decline in HSC functionality 
particularly in secondary or tertiary recipients, if defects in DNA damage repair were to 
play a critical role. However, even in tertiary recipients, we found Idh1-R132H mutated 
cells to showcase a better reconstitution potential, whereas in tertiary transplanted CTRL 
mice two out of six animals hardly displayed any donor cell engraftment. As we failed to 
observe any reduced engraftment or reconstitution potential in Idh1-R132H mutated cells, 
the question remains whether higher rates of DNA damage within these cells indeed 
impair HSC functionality. In our hands, the lack of evidence for a premature attrition of 
HSCs potentially could be explained by either too low expression levels of the mutation 
(due to the heterozygosity of the mutated allele) to induce significant alterations in DNA 
damage rates and DNA repair pathways, or the experimental setup applied in our serial 
transplantations. While we initially transplanted isolated LT-HSCs into primary recipients, 
we transplanted unsorted TBM into further secondary or tertiary recipients. Independent 
of an Idh1-R132H mutated context, it was shown that when transplanting isolated HSCs 
together with a lower number of fresh supportive bone marrow cells (i.e. 200,000 cells) in 
all serial transplantations, the donor cell engraftment is markedly reduced already in 
tertiary recipients [Challen et al., 2011, Jeong et al., 2018], suggesting that constraints in 
HSC self-renewal and reconstitution potential might be more evident in such a setup. Yet, 
even in a setup of serially transplanting TBM into further recipients, only HSCs will display 
long-term engraftment and contribution to blood production, so that our applied setup 
similarly should be appropriate to test the limits of HSC self-renewal and longevity and 
how these might be altered due to the presence of an Idh1-R132H mutation and its effects 
on DNA damage and repair.  
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 On the other hand, a better engraftment of Idh1-R132H mutated HSCs in primary 
recipients could be a result from an intrinsic chronic inflammatory state. This would be 
in line with the inflammatory signatures we detected at the transcriptome level in these 
cells. In response to inflammatory signals, HSCs are known to transiently proliferate at 
much higher rates [Pietras, 2017, Essers et al., 2009, Baldridge et al., 2010], implying that 
these signatures could contribute to the rapid reconstitution of the blood system in 
primary recipients. In particular, it will be interesting to see how this proliferation-
inducing inflammatory signature will cooperate with higher expression levels of the 
mutation and potentially increased rates of DNA damage in a more stringent serial 
transplantation setup. 
 Overall, while our data points at alterations in DNA damage rates within Idh1-R132H 
mutated cells, so far, we could not determine molecular details of the interplay between 
Idh1-R132H mutations and defects in DNA damage repair in our experimental model 
systems. Since Idh1-R132H mutated HSCs displayed an enhanced engraftment and 
reconstitution potential, a detailed functional analysis of deregulated factors involved in 
DNA repair as well as a correlation with methylation and histone mark signatures will be 
required to elucidate the exact mechanisms of how Idh1-R132H mutations directly or 
indirectly are involved in changes in DNA damage repair and how these changes impact 
HSC functionality.  
 
 
4.2 Idh1-R132H Mutations Alone or in 
Combination with DNMT3A-R882H are not 
Sufficient to Induce Leukemic 
Transformation 
 
In AML patients, IDH1 mutations are considered to be early events during the 
pathogenesis of leukemia. They frequently occur already in HSCs and establish a pre-
malignant condition that serves as a basis for disease initiation and malignant 
transformation [Corces-Zimmerman et al., 2014]. Recent studies identified the presence 
of IDH1 mutations in healthy individuals several years before the diagnosis of AML 
[Abelson et al., 2018, Desai et al., 2018]. Although IDH1 mutations here are less prevalent 
than for example DNMT3A or TET2 mutations, they were among the mutations associated 
with the highest risk of disease development (measured by odds or hazard ratios) with 
almost all subjects carrying IDH1 mutations eventually developing AML [Desai et al., 2018, 
Abelson et al., 2018]. While this showcases a strong oncogenic potential of IDH1 mutations 
in humans, we failed to detect leukemic transformation in our Idh1-R132H mutated 
mouse model even after long latency times, but observed biased differentiation patterns 
that primarily affect the myeloid and monocytic lineage.  
 Critical aspects that are likely to influence disease latencies and phentoypes are 
expression levels of the Idh1-R132H mutation and of Cre recombinase within the cell and 
the overall mutational burden in the hematopoietic system. While a heterozygous 
expression of the mutated Idh1 allele is expected to result in lower expression levels and 
milder phenotypes, we drove Cre expression under the control of the Scl enhancer. 
Although this resulted in the expression of the Idh1-R132H mutation in HSCs, the overall 
recombination efficiency at the Idh1 locus was only in the range of 6-7 % (as measured by 
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EYFP+ TBM cells). This means that the overall mutational burden in the hematopoietic 
system was limited in primary mice, potentially leading to prolonged disease latencies 
and to changes in disease phenotypes. This is supported by the fact that strongest effects 
on hematopoietic differentiation were observed in Lin— transplanted mice, where virtually 
all cells in the hematopoietic system express the Idh1-R132H mutation due to the lack of 
any supportive bone marrow. As we detected significantly increased levels of D2HG in cell 
lysates and blood serum of both injected and transplanted mice, thereby demonstrating 
that in our mouse model the mutation induction leads to an accumulation of D2HG, we 
nevertheless are confident that identified phenotypes reliably reflect consequences of an 
expression of the Idh1-R132H mutation within the hematopoietic system.  
Previously reported mouse models for an Idh1-R132H mutation consisted of mice 
that were either crossed with LysMCre or VavCre mice. In both cases, the Idh1-R132H 
mutation is induced early on after the establishment of the adult hematopoietic system 
either in all hematopoietic cells (VavCre) or in developing myeloid cells (LysM) [Sasaki et 
al., 2012, Inoue et al., 2016]. Consistent with our findings, none of these mice developed 
a leukemia. However, VavCre Idh1-R132H mice displayed an infiltration of hematopoietic 
cells into the spleen, a phenotype commonly observed in mice in the context of myeloid 
neoplasms, and in the end succumbed prematurely with splenomegaly, anemia and 
thrombocytopenia [Inoue et al., 2016]. It may be that in our case the induction of the 
mutation in the already established adult hematopoietic system of eight- to ten-week-old 
mice constitutes a scenario that results in weaker phenotypes than for example a scenario 
where an Idh1-R132H mutation is expressed already in the embryo as soon as the 
hematopoietic system is established. Early hematopoietic cells could be more susceptible 
to effects mediated by the Idh1-R132H mutation, e.g. due to their epigenetic or 
transcriptomic profile, but only later in life or after certain stimuli these effects result in 
an abnormal hematopoietic phenotype. Alternatively, coupling of Cre to the Vav promoter 
could simply result in higher Cre expression levels within the cells. This might lead to 
higher recombination efficiencies at the Idh1 locus, resulting in higher D2HG levels and 
eventually in more pronounced phenotypes. Nevertheless, we believe that our applied 
experimental setup, where the induction of a heterozygous Idh1-R132H mutation is 
dependent on the tamoxifen-inducible CreERT2 recombinase under the control of the Scl 
enhancer, mirrors the situation observed in humans: here, heterozygous IDH1-R132H 
mutations are typically acquired late in life within the HSC compartment and this is 
believed to result in the establishment and expansion of a preleukemic clone that 
eventually progresses to overt leukemia. 
 In the end, the question remains whether single Idh1-R132H mutations at all and 
upon which conditions result in the initiation or progression of a leukemic phenotype. 
DNMT3A mutations are not only the most common mutations detected in patients with 
CHIP or AML, but also are found to co-occur with IDH1-R132H mutations [Shlush et al., 
2014, Abelson et al., 2018, Desai et al., 2018, Papaemmanuil et al., 2016, Cancer Genome 
Atlas Research et al., 2013]. Accordingly, we hypothesized that the expression of an 
additional DNMT3A-R882H mutation in Idh1-R132H mutated cells might result in the 
exacerbation of hematopoietic abnormalities. However, the observation that, similar to 
Idh1-R132H single-mutant mice, Idh1-DNMT3A mice displayed only minor variations in 
blood parameters and bone marrow composition, indicates that a co-occurrence of both 
mutations is not sufficient to induce malignant transformation. Yet, although our Idh1-
DNMT3A mice in part shared similar characteristics to our Idh1-R132H single-mutants 
(i.e. increase in monocytes and monocyte progenitors, inflammatory signature in Ly6C+ 
GMPs), our molecular data at least in part suggests a signature that is characteristic only 
for Idh1-DNMT3A mutated cells but not for single-mutants, implying that both mutations 
indeed cooperate to drive a unique gene expression profile. Especially in our scRNA-seq 
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data set we observed substantial differences between Idh1-DNMT3A mice and all other 
genotypes (discussed in detail in later sections 4.4 and 4.5).  
To our knowledge, only one study investigated the interplay between Idh1/2 and 
Dnmt3a-R878H mutations (mouse homologue to the DNMT3A-R882H mutation) in a 
mouse model before, however this work was focusing on the co-occurrence of an Idh2-
R140Q mutation with a Dnmt3a-R878H mutation [Glass et al., 2017]. Consistent with our 
findings, no aberrant hematological phenotype was observed in these mice six months 
after the induction of the mutation [Glass et al., 2017]. At the molecular level, the authors 
postulated antagonizing effects of co-occurring mutations, with Idh2-R140Q mutations 
conferring a DNA hypermethylation phenotype and Dnmt3a-R878H mutations leading to 
DNA hypomethylation, but differential methylation being predominantly lost in double-
mutated cells. In our model system, investigations of the epigenome will be a valuable 
resource to correlate transcriptomic with epigenomic signatures in order to understand 
how these mutations interact to drive observed aberrant gene expression profiles in 
specific cell types.  
Published studies regarding Dnmt3a-R878H mutated mice indicated that the 
expression of a Dnmt3a-R878H mutation alone does not entail the development of an 
overt leukemia with mutated mice displaying similar survival rates as their wildtype 
counterparts [Guryanova et al., 2016, Loberg et al., 2019]. However, Dnmt3a-R878H 
mutated mice here featured an expansion of the HSPC compartment indicative of a 
situation that resembles clonal hematopoiesis, as well as a myeloid differentiation bias 
[Guryanova et al., 2016, Loberg et al., 2019], phenotypes that we did not observe in our 
DNMT3A-R882H mutated mice. Yet, phenotypes described in these studies were very mild 
and more pronounced in aged mice after long latency times since the induction of the 
mutation [Guryanova et al., 2016, Loberg et al., 2019], indicating that, in line with our 
results, the oncogenic potential of a single DNMT3A-R882H mutation is rather limited.  
Dnmt3a knockout HSCs have been shown to exceed the lifespan and self-renewal 
potential of normal HSCs dramatically, being able to reconstitute the hematopoietic 
system in recipient mice over at least 12 rounds of serial transplantations [Jeong et al., 
2018]. It will be interesting to see how our DNMT3A-R882H single-mutants and Idh1-
R132H DNMT3A-R882H double-mutants will perform in serial transplantation settings 
and whether an immortalization is likewise induced by the expression of the DNMT3A-
R882H mutation. Here, one uncertainty of our mouse model consists of the fact that we 
expressed the human DNMT3A gene carrying the R882H mutation in our mice. Although 
the gene is highly conserved between humans and mice, it needs to be considered that the 
mode of action of the mutated human version in murine cells might not be identical to 
the mutated murine counterpart, therefore resulting in weaker phenotypes. Similar as for 
Idh1-R132H mutations, a homozygously expressed DNMT3A-R882H mutation or even a 
homozygous knockout of DNMT3A has more drastic implications and consequently will 
result in stronger hematopoietic aberrations and changes in self-renewal capacity. 
However, as both IDH1 and DNMT3A mutations usually are found heterozygously in 
patients, our approach closely mirrors situations and actual consequences of these 
mutations on cellular physiology as observed in patients. In contrast, a homozygous 
knockout or a homozygous expression of mutations might result in drastic and 
pronounced phenotypes, but is hardly comparable to disease scenarios found in AML 
patients.  
 In line with other reports, we conclude that, first, the oncogenic potential of Idh1-
R132H and DNMT3A-R882H mutations alone or combined is not sufficient to initiate 
leukemic transformation and, second, whether these mutations lead to the development 
of leukemia seems to be context-dependent and determined by other factors that drive 
oncogenesis in cooperation with these mutations. Here, we hypothesize that the onset of 
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hematopoietic diseases is dependent either on the timing of mutational acquisition, 
additional activating mutations or changes in the bone marrow environment (e.g. 
inflammatory stress).   
While we induced the expression of both Idh1-R132H and DNMT3A-R882H mutations 
at the same time point, one may speculate whether the temporal order of mutational 
acquisition might make a difference, as the initially acquired mutational hit could reshape 
the epigenome in a way that potentiates the effects of the second hit. However, these 
effects might be mitigated when mutations are acquired at the same time point as it is the 
case in our experimental setup.  
Other reports indicated that following a preexisting Dnmt3a-R878H / DNMT3A-
R882H or Idh1-R132H mutation, additional activating mutations in proproliferative genes 
such as Flt3 and Nras, or a cooperation with Npm1 mutations and Hoxa9 overexpression 
cause a progression to myeloproliferative disorders or AML-like phenotypes [Guryanova 
et al., 2016, Loberg et al., 2019, Yang et al., 2016, Meyer et al., 2016, Chen et al., 2013a, 
Ogawara et al., 2015, Kats et al., 2014, Chaturvedi et al., 2013]. Although Npm1, Flt3, or 
Nras mutations alone are capable of inducing myeloproliferative phenotypes in some 
cases, disease onset and progression was dramatically accelerated only together with 
Dnmt3a-R878H / DNMT3A-R882H or Idh1-R132H mutations, confirming that Idh1-R132H 
or Dnmt3a-R878H / DNMT3A-R882H mutations may shape an epigenetic landscape within 
the cell that promotes oncogenic transformation upon secondary events. We as well have 
begun to investigate the interplay of Idh1-R132H mutations and NRAS-G13D mutations in 
stem and progenitor cells using retroviral transduction. Here, preliminary data suggests 
that indeed both mutations cooperate to some extent and result in hematological 
phenotypes, although wildtype mice expressing a NRAS-G13D mutation alone already 
displayed severely reduced survival rates (data not shown). Nevertheless, further 
experiments will be required to corroborate these findings.  
 Another factor that could stimulate disease onset in the context of Idh1-R132H or 
DNMT3A-R882H mutations might be acute inflammatory stress. Treatments with 
inflammatory agents (for example LPS, polyinosinic:polycytidylic acid (pI:pC) or IFNs), 
provoke an activation of HSCs out of quiescence and induce cells to enter cell cycle [Walter 
et al., 2015, Essers et al., 2009, Baldridge et al., 2010]. Based on aberrant epigenetic 
patterns mediated by the presence of Idh1-R132H or DNMT3A-R882H mutations, 
excessive proliferation could lead to increased selective pressures followed by a clonal 
selection and expansion of mutated clones to initiate leukemogenesis. On the other hand, 
serial transplantations ideally should provoke a likewise scenario and since we have not 
observed strong hematological aberrations upon serial transplantations of Idh1-R132H 
mutated cells, it remains to be tested if these approaches indeed result in the development 
of hematopoietic neoplasms in our single-mutant or double-mutant mice.  
 In the end, despite the fact that the presence of an Idh1-R132H mutation alone or in 
combination with a DNMT3A-R882H mutation did not result in the development of an 
obvious hematopoietic disease phenotype, our mouse model allowed us to investigate the 
molecular details and signatures that are characteristic for these preleukemic cells and 
how these mutation-mediated alterations could incite cellular transformation upon 
secondary events.  
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4.3 Single-Cell Transcriptomic Landscapes of 
Mutated Hematopoietic Compartments 
 
A centerpiece of this study consisted of a comprehensive single-cell transcriptomic 
analysis of the hematopoietic compartment of wildtype and mutated mice. By sampling 
three different layers of the hematopoietic hierarchy, we were able to obtain a 
transcriptomic snapshot of virtually all cell types within the hematopoietic system for 
each genotype. A similar approach has been applied in order to investigate native and 
perturbed hematopoietic transcription landscapes [Giladi et al., 2018], however, 
irrespective of any mutational context. In our hands, this approach proved to be a 
powerful tool to expose informative heterogeneity between individual cell types derived 
from mutated mice, rendering possible to address which cell stages are most affected by 
certain mutations and how transcriptional signatures are altered. Here, we relied on the 
droplet-based 10X Genomics platform, which allowed us to sequence a relatively high 
number of cells per sample (ideally ~ 10,000 cells) at the cost of covering only a limited 
number of genes per cell (between ~ 3,000-5,000 genes) [Wilson and Göttgens, 2018]. The 
low number of detected genes per cell certainly represents a confounding factor as it is 
not possible to distinguish whether a gene with no counts detected is truly not expressed 
in this cell or whether this represents a technical dropout.  
 By isolating only loosely defined cell populations as LSK, LS-K or CD45+ TBM, we 
ensured to cover hematopoietic cells from all differentiation stages and lineages, 
including stem cells, progenitor cells and terminally differentiated cells. Contrarily, 
sequencing of stringently isolated individual populations such as HSCs, CMPs, GMPs, etc., 
inflicts potential disadvantages in that only a certain subset of cells might be defined by 
a particular set of surface markers used to isolate the population, whereas other subsets 
might be missed. For example, it was shown that classical surface marker-defined CMP 
and GMP populations consist of multiple transcriptionally heterogeneous subsets which 
show partial overlap between immunophenotypically defined CMPs and GMPs [Paul et al., 
2015]. Furthermore, it turned out that the surface markers CD34 and FcgR, which are 
commonly used to isolate these populations, are only poor predictors of cell identity and 
lineage biases [Paul et al., 2015, Watcham et al., 2019]. This illustrates, that a 
transcriptomic definition of cell states is much more suited to dissect population 
heterogeneity than surface marker-based definitions. However, these discrepancies could 
explain divergent findings between our flow cytometry analysis and our scRNA-seq 
analysis.  
 Our scRNA-seq data set encompassed more than 40,000 cells and we could 
recapitulate different lineage trajectories within the hematopoietic compartment that 
span the erythroid, megakaryocytic, lymphoid or myeloid lineages. In line with other 
reports, our transcriptional analysis suggested hematopoietic differentiation to be a 
continuous rather than a stepwise process and the acquisition of lineage-specific fates 
seems to be less sequential or hierarchical [Laurenti and Gottgens, 2018, Nestorowa et al., 
2016, Velten et al., 2017, Macaulay et al., 2016].  
Screening a large number of cells across different compartments, populations and 
genotypes, allowed us to identify cell stages that are most variable between genotypes. 
Most importantly, further interrogation of surface markers that are expressed on these 
cells, enabled the prospective isolation of these cells from the bone marrow in order to 
characterize them in more detail. By using Ly6C expression (in addition to cKit, CD34 and 
CD16/32 expression) as an additional marker within the myeloid progenitor cell 
compartment, we could show that Idh1-R132H DNMT3A-R882H mutated cells isolated 
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using this marker combination exhibit an expression signature similar to aberrant Idh1-
R132H DNMT3A-R882H mutated CMPs as defined in our scRNA-seq data set.  
 Based on our approach, it will be important to further complement and correlate 
transcriptional landscapes with further informative layers, such as chromatin 
accessibility, methylome profiles or clonal dynamics, to fully recapitulate disturbed 
regulatory networks of hematopoietic differentiation. For example, a method that 
simultaneously captures transcriptomes and somatic genotypes of cells was described 
recently, rendering it possible to disentangle clonal dynamics and cell ancestry 
information within a certain compartment and to resolve relationships between the 
genomic makeup and alterations in cell identities or lineage specifications [Nam et al., 
2019]. In our case, a combination of functional characterizations and perturbations will 
be of importance to further unravel how Idh1-R132H mutations alone or in combination 
with DNMT3A-R882H mutations will affect functionality of certain cell types. Integration 
of transcriptomic states with functional readouts (e.g. index-transcriptomics together with 
index-cultures or transplantations) or with CRISPR-based perturbation studies have been 
proven to be a powerful tool to dissect regulatory circuits and dependencies at the single-
cell level and will be essential to extend our understanding of the molecular mechanisms 
driving hematopoietic malignancies [Velten et al., 2017, Giladi et al., 2018, Jaitin et al., 
2016, Dixit et al., 2016]. 
  
 
4.4 Idh1-R132H Mutations Induce Altered 
Myeloid Differentiation Patterns 
 
During our analysis, we consistently observed the myeloid compartment to be most 
altered in either Idh1-R132H single-mutated or Idh1-R132H DNMT3A-R882H double-
mutated mice. Prominently, our flow cytometry analysis revealed especially monocytic 
differentiation trajectories to be highly affected, as we observed increased cMoP 
frequencies, Ly6C+ GMP ratios, CD115+ GMP ratios, as well as increased mature monocyte 
frequencies in the bone marrow of Idh1 and Idh1-DNMT3A mice. Our scRNA-seq analysis 
of the myeloid progenitor cell compartment clearly confirmed substantial discrepancies 
between mutant and wildtype cells. In particular, we found annotated CMP cells from 
double-mutated mice to be highly aberrant compared to corresponding single-mutated or 
CTRL CMPs. Both UMAP-based and diffusion map-based visualizations of single-cell 
transcriptomes suggest myeloid differentiation in Idh1-R132H DNMT3A-R882H mutated 
hematopoiesis to be severely compromised, resembling an accumulation of cells at the 
CMP stage and an ineffective hematopoietic differentiation that is characteristic for 
myelodysplastic syndromes. Based on these findings, it needs to be determined, why 
mature monocyte frequencies in the bone marrow in fact are elevated, since 
differentiation seems to be blocked at the CMP stage. One possible explanation could be 
that, although clusters were annotated as CMP cells, they still share similarities to 
committed monocyte progenitors, and accordingly drive the production of mature 
monocytes. This is supported by calculated sample distances of genotype-specific 
clusters, which indicates that certain Idh1-R132H DNMT3A-R882H mutated CMP cluster 
show similar expression profiles than MoDCP or NeuP cluster. In line with this, a 
differentiation trajectory associated with a monocytic cell fate could be reconstructed in 
double-mutated mice based on diffusion maps. Furthermore, cultured double-mutated 
surface marker-defined CMPs displayed comparable differentiation patterns to single-
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mutant or CTRL CMPs, inferring that monocytic differentiation still is intact and not 
completely blocked. Nevertheless, our scRNA-seq data clearly highlights an aberrant 
myeloid progenitor population specific for Idh1-R132H DNMT3A-R882H mice, yet, a 
further and more detailed functional characterization will be required to investigate, for 
instance, a preleukemic nature of this population (e.g. in a transplantation setting) or 
whether it shows a different response to additional stimuli or conditions (e.g. in response 
to treatment with specific cytokines or in response to a characteristic inflammatory 
cytokine environment in the bone marrow).  
 With regard to these aspects, it furthermore needs to be determined whether this 
aberrant population is specific to double-mutated mice or to a certain degree even is 
shared with Idh1-R132H single-mutant mice. Although gene expression signatures 
specific to exclusively double-mutated myeloid progenitors were identified (e.g. increased 
expression of Myc target genes), increased monocyte and monocyte progenitor counts 
(determined by FACS), elevated expression levels of critical genes governing monocytic 
cell fates (e.g. Jun, Fos, Klf2, Klf6), and IFN signatures in Ly6C+ GMPs were identified in 
both Idh1-R132H single-mutants and Idh1-R132H DNMT3A-R882H double-mutants. This 
at least in part suggests a high overlap of double-mutant phenotypes with Idh1-R132H 
single-mutant phenotypes. At this point, it needs to be noted that our scRNA-seq data was 
derived from a single mouse per genotype, whereas the FACS and bulk RNA-seq data is 
aggregated across multiple mice or even multiple transplantation cohorts, making this 
data more robust against experimental outliers.  
Analysis of the expression of Idh1 within the hematopoietic compartment revealed 
that Idh1 is almost exclusively expressed in myeloid progenitor cell populations as well 
as in mature monocytes (Supplemental Figure A-11). Accordingly, the effects of an Idh1-
R132H mutation here should be much more drastic as mutation-mediated metabolic 
imbalances are thought to strongly impact on cell physiology. On the other hand, cell 
types that express only low levels of Idh1 in the first place, will probably be only faintly 
affected by the expression of the mutation. Yet, it is imaginable that secreted D2HG in the 
bone marrow environment has an indirect impact on cell types that lack an expression of 
the mutated Idh1 allele. Nevertheless, our data clearly confirms that cell stages with a high 
Idh1 expression are most variable between genotypes, as we detected myeloid- and 
monocyte progenitor populations as well as mature monocytes to be altered in in Idh1-
R132H mutant mice. This is in line with previously reported VavCre-Idh1-R132H mice, 
which similarly displayed an expansion of CMP and GMP populations in the bone marrow 
[Inoue et al., 2016].  
 Interestingly, Tet2 loss in mice frequently leads to an oncogenic transformation of 
myeloid cells that resembles chronic myelomonocytic leukemia (CMML) and was 
associated with a profound increase in monocyte counts in the periphery [Moran-Crusio 
et al., 2011]. Since the monocytic compartment similarly seems to be highly disturbed 
through the expression of an Idh1-R132H mutation, our data suggests that Idh1-R132H 
mutations recapitulate phenotypes observed in Tet2 knockout mice and that a D2HG-
mediated inhibition of Tet2 could be a causative factor that contributes to aberrant 
monocytic differentiation patterns. Along these lines, further molecular (e.g. epigenomic) 
and functional validation experiments will be required to discriminate Idh1-R132H single-
mutant and Idh1-R132H DNMT3A-R882H double-mutant specific characteristics or 
whether a shared Tet2 inhibition is the main driver of observed phenotypes.  
 
 
 
4 Discussion 
 
 77 
4.5 Molecular Signatures of Mutated Myeloid 
Progenitors 
 
4.5.1 Deregulation of Monocytic Cell Fate-Associated 
Genes 
 
Differential expression analysis of Idh1-R132H DNMT3A-R882H double-mutant myeloid 
progenitor cells identified target genes of the oncogene Myc as well as a number of genes 
associated with various metabolic processes and mitochondrial biology to be upregulated. 
Besides being a critical regulator of proliferation and cell-cycle progression, Myc 
expression also correlates with an activation of multiple metabolic processes, such as 
glycolysis, nucleotide or lipid biosynthesis but also mitochondria biogenesis [Stine et al., 
2015]. Elevated Myc and Myc target gene levels accordingly could explain the observed 
transcriptomic profile detected in Idh1-R132H DNMT3A-R882H mutated CMPs. Consistent 
with Myc’s role in regulating cell-cycle activity, we found GO terms describing cell cycle 
associated processes to be enriched in Idh1-R132H DNMT3A-R882H mutated MoDCPs. 
Our trajectory analysis using diffusion-maps further corroborated a proliferative active, 
but rather diffuse and undifferentiated state of Idh1-R132H DNMT3A-R882H mutated 
myeloid progenitor cells that lead to an accumulation at the CMP stage.  
 Although it remains to be tested, we hypothesize that the accumulation of Idh1-
R132H DNMT3A-R882H mutated cells at the myeloid progenitor stage, characterized by 
an activation of Myc signaling, could reflect initial signs of a differentiation block, which 
would be consistent with a preleukemic state. Yet, despite the strong oncogenic role of 
Myc [Dang, 2012], we think that Myc expression levels in these cells are too low to elicit 
tumorigenicty. Other reports have showcased a role of Myc in regulating the 
differentiation of myeloid cells where it is highly expressed in MDPs and cMoPs, but 
expression levels declining drastically in mature monocyte populations in the blood and 
bone marrow [Mildner et al., 2017]. Here, the down-regulation of the Myc transcriptional 
program by mTORC1 signaling is required for terminal myelopoieis [Selvakumaran et al., 
1996, Lee et al., 2017], suggesting that a failure of cells to downregulate Myc could lead 
to an accumulation of cells at the progenitor stage as observed in our Idh1-DNMT3A 
mouse model. 
 Studies comparing the epigenomes of monocytes and granulocytes identified 
monocyte specific enhancers to be enriched for Myc binding sites and differentially 
methylated regions to overlap with Myc target gene sites [Rico et al., 2017]. Implying that 
the epigenomic profile in combination with Myc expression in myeloid progenitors could 
represent a critical step in specifying monocytic cell fate, it will be interesting to see how 
Idh1-R132H and DNMT3A-R882H mutations affect landscapes of DNA methylation or 
histone modifications to mechanistically interfere with this regulatory process, how Idh1-
R132H mutations interact with DNMT3A-R882H mutations to upregulate Myc signaling, 
and whether the observed phenotypes are driven by the D2HG-mediated inhibition of DNA 
or histone demethylases (e.g. TETs, KDM4 enzymes).  
 Dissecting the bone marrow composition of mutated mice by flow cytometry, we 
found both monocyte progenitor populations as well as mature monocyte populations to 
be expanded in Idh1 and Idh1-DNMT3A mice. On a molecular level, we could underpin 
this phenotype by a deregulation of several critical monocyte specific transcription 
factors, which display elevated expression levels in Idh1-R132H mutated cells, including 
Jun and Fos. The transcription factors c-Jun and c-Fos, together with additional subunits, 
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are critical parts of the TF complex AP-1, which is required for the specification of the 
monocytic lineage [Lord et al., 1993, Friedman, 2007b, Cai et al., 2008, Friedman, 2007a]. 
In combination with other myeloid determining TFs such as PU.1 and C/EBPa , AP-1 
activity drives differentiation into the monocytic lineage whereas absence of AP-1 but 
remaining PU.1 and C/EBPa activity results in granulocyte development [Cai et al., 2008, 
Friedman, 2007a]. Besides the activity of TFs, specific cytokine signaling is equally 
important to regulate developmental programs. Here, M-CSF and granulocyte colony 
stimulating factor (G-CSF) are pivotal cytokines that either induce monocytic or 
granulocytic differentiation, respectively. Importantly, M-CSF induced signaling 
culminates in the induction of Fos expression to direct monopoiesis [Jack et al., 2009], 
thereby further underlining the importance of a regulation of Jun and Fos levels for a 
balanced monocytic and granulocytic cell output. A recent report identified the histone 
demethylase Kdm6b as a regulator of Fos and Jun expression, where loss of Kdm6b was 
followed by an increased expression of AP-1 [Mallaney et al., 2019]. Although the authors 
here focused on the effect of Kdm6b loss on HSCs functionality, a D2HG-mediated 
inhibition of Kdm6b in myeloid progenitors could provide an intriguing mechanistic link 
that explains how Idh1-R132H mutations result in elevated Jun and Fos levels to promote 
monocytic differentiation. To substantiate this hypothesis, further mechanistic studies 
will be required that specifically investigate how Idh1-R132H mutations influence Jun or 
Fos levels in myeloid progenitors.  
 
4.5.2 Deregulation of Inflammation-Associated Genes 
 
Within the hematopoietic system, monocytes are critical effector cells of the innate 
immune system that are recruited to sites of inflammation in a proinflammatory 
mediator-dependent manner [Jakubzick et al., 2017, Guilliams et al., 2018]. Upon 
inflammation, monocytes synthesize and secret proinflammatory cytokines and 
differentiate into proinflammatory M1-macrophages to clear pathogens and to further 
promote inflammatory conditions [Jakubzick et al., 2017, Guilliams et al., 2018]. Bacterial 
LPS and IFNg here are critical regulators that stimulate the differentiation into this 
particular macrophage subtype [Orecchioni et al., 2019]. We found Idh1-R132H single-
mutant and especially Idh1-R132H DNMT3A-R882H double-mutant mice to display 
increased Ly6C expression within the myeloid progenitor compartment as well as 
enhanced frequencies of specifically Ly6CHigh inflammatory monocytes in the bone 
marrow. In line with this, scRNA-seq data of Idh1-R132H mutated CMPs, MoDCPs and 
monocytes revealed Idh1-R132H single-mutant-specific differentially expressed genes to 
be enriched in gene signatures of LPS-stimulated monocytes or macrophages. 
Furthermore, both Idh1-R132H single-mutated and Idh1-R132H DNMT3A-R882H double-
mutated Ly6C+ GMPs featured elevated IFN signaling levels. Overall, this data decisively 
points towards a link between the expression of the Idh1-R132H mutation and an 
inflammatory signature. 
 Severe and acute inflammatory states have been shown to induce an emergency 
production of increased levels of monocytes and a recruitment to inflammatory sites 
[Guilliams et al., 2018]. This emergency myelopoieisis often is accompanied by a rewiring 
of the epigenome and acquisition of epigenetic marks which entail a state of ‘trained 
immunity’ to ensure a long-lasting increased production of, for example, monocytes or 
macrophages [Netea et al., 2016]. With respect to Idh1-R132H mutations, it will be 
important to reveal whether increased monocyte and monocyte progenitor counts are 
derived from intrinsic effects of the Idh1-R132H mutation (for example through the 
dysregulation of lineage-specific transcription factors such as Jun or Fos, or a rewiring of 
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the epigenome) or rather are only an indirect consequence of inflammatory conditions in 
the bone marrow. Several genes, including Klf2, Klf6, Dusp1, Dusp2, Ccl3, Ccl4, and Junb, 
which we found to be dysregulated in Idh1-R132H mutated myeloid progenitors, are 
associated with an activation of monocytes or macrophages upon inflammatory stimuli. 
The TF Klf2 has been shown to act as a negative regulator of a proinflammatory activation 
of monocytes, whereas Klf6 especially regulates the inflammatory macrophage 
polarization upon proinflammatory stimuli such as LPS or IFN [Das et al., 2006, Jha and 
Das, 2017, Nayak et al., 2013, Thomas et al., 2016, Date et al., 2014]. Similarly, the 
expression of Dusp1, Dusp2, Ccl3 and Ccl4 is induced upon the activation of macrophages 
to regulate pathological inflammatory responses, whereas Junb was identified as a key 
transcriptional modulator to govern macrophage activation [Seternes et al., 2019, Maurer 
and von Stebut, 2004, Fontana et al., 2015]. Collectively, although we did not sample bone 
marrow macrophages in our scRNA-seq experiment, our data suggests that Idh1-R132H 
mutations, either directly or indirectly through inducing an inflammatory environment, 
establish a gene expression profile which is associated with an excessive activation of 
monocytes or macrophages and which contributes to or further promotes an 
inflammatory response.  
In macrophages, loss of Tet2 resulted in the upregulation of several inflammatory 
mediators such as IL-6, IL-1b, CXCL1, CXCL2 and CXCL3 as Tet2 was identified to directly 
be involved in the repression of these factors in order to resolve inflammation [Zhang et 
al., 2015, Jaiswal et al., 2017]. More specifically, the increased IL-6 production and a 
concomitant proinflammatory state were pivotal factors for the development of a 
preleukemic myeloproliferation in these mice [Meisel et al., 2018]. As Idh1-R132H mutated 
macrophages in theory are likely to phenocopy Tet2 knockout macrophages due to the 
D2HG-mediated inhibition of Tet2, the expression of the Idh1-R132H mutation in 
macrophages similarly could affect activation states of macrophages, lead to an increased 
secretion of proinflammatory cytokines and establish an inflammatory milieu in the bone 
marrow. An inflammatory environment in turn is likely to affect transcriptome profiles of 
e.g. HSCs, myeloid progenitors or monocytes. In line with this, we detected both an 
inflammatory signature in Idh1-R132H mutated HSCs as well as a strong IFN signature in 
Idh1-R132H mutated Ly6C+ GMPs. Importantly, macrophages have been shown to secrete 
high levels of IFNs (mainly IFNg, but also IFNb) upon activation [Kumaran Satyanarayanan 
et al., 2019] and thereby could explain observed elevated IFN signaling levels. Eventually, 
further functional characterizations of Idh1-R132H mutated macrophages will be needed 
to quantify their cytokine secretion and to disclose whether Idh1-R132H mutations 
mitigate the Tet2-mediated repression of proinflammatory mediators through inhibition 
of its enzymatic activity.      
 Besides changes in monocyte or macrophage activation states, inflammatory 
signatures as well could be derived from an activation of pathogen sensing mechanisms. 
Pathogen-associated molecular patterns are sensed by innate immune cells via pattern 
recognition receptors (PRRs) (e.g. TLRs) which, upon stimulation, induce the activation of 
several downstream inflammatory pathways to mediate an effective immune response 
[Kawai and Akira, 2010]. Whereas most of the TLRs are located on the outer cell membrane 
or in endosomes, a few cytosolic PRRs are activated through sensing of intracellular viral 
RNAs [Yoneyama and Fujita, 2009, Kawai and Akira, 2010]. IRF3 and IRF7 are key 
transcriptional regulators which are activated upon PRR-signaling and induce the 
transcription of IFNa and IFNb in order to orchestrate an antiviral innate immunity 
response [Mogensen, 2018]. We identified IRF3, IRF7 as well as IFNa and IFNb as critical 
upstream regulators with higher activation levels in Ly6C+ GMPs from Idh1-R132H single-
mutant and Idh1-R132H DNMT3A-R882H double-mutant mice, implying that 
corresponding mice either had to cope with an actual pathogen infection or experienced 
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an intrinsic activation of endogenous retroviruses (ERVs) which were sensed by cytosolic 
PRRs and resulted in the initiation of IFN signaling. Although we cannot completely rule 
out a bacterial or viral infection, risks were minimized by holding animals under 
pathogen-free conditions. Previous studies linked the upregulation of endogenous 
retroviruses to changes in DNA methylation, proposing a dysregulation of the epigenome 
to be a critical factor that could drive ERV transcription [Chiappinelli et al., 2015, Brocks 
et al., 2017, Daskalakis et al., 2018]. Despite the fact that in these cases ERV transcription 
was initiated through treatments with hypomethylating agents such as DNMT inhibitors, 
one could speculate that complex effects of Idh1-R132H mutations on DNA methylation 
and histone marks could cooperate to favor the expression of ERVs, eventually resulting 
in elevated IRF activity and IFN signaling levels. Yet, further experiments will be required 
to proof this hypothesis.  
 Chronic inflammation is a shared characteristic of many hematopoietic malignancies 
and plays an important role in disease progression with many patients exhibiting an 
excessive production of inflammatory cytokines [Craver et al., 2018]. Having detected 
alterations in IFN signaling at the transcriptional level, we proceeded to quantify secreted 
cytokine levels within the bone marrow compartment of Idh1-R132H mutated mice. 
Although we found several cytokines, among them IL-6, to be differentially expressed in 
a pilot experiment, these results need to be reproduced in future validation studies. In the 
context of Idh1-R132H mutations, it will be important to address which cell types are 
responsible for the aberrant expression of inflammatory mediators, which molecular 
mechanisms drive this overproduction and which role inflammatory signatures play with 
regard to defects in hematopoietic differentiation and malignant transformation. 
   
 
4.6 Conclusions and Perspectives 
 
In the course of this project, we have extensively studied molecular and phenotypic 
characteristics of an Idh1-R132H mutation in the hematopoietic system. Analysis of Idh1-
R132H single-mutant mice revealed that the overall functionality of HSCs is not 
compromised through the heterozygous expression of an Idh1-R132H mutation in single 
or serial transplantation settings, although our molecular data at least in part indicates 
disturbed expression levels of DNA damage- and DNA repair-associated genes. By 
integrating latest advances in high-throughput single-cell technologies and combinatorial 
Idh1-R132H and DNMT3A-R882H mouse models, we in detail delineated the cooperativity 
of both mutations and the repercussion that these mutations impose on different 
hematopoietic cell types. Single-cell transcriptomic data of virtually all hematopoietic cell 
types within the bone marrow compartment here will serve as a resource when 
investigating Idh1-R132H or DNMT3A-R882H mutations in the context of altered 
physiological conditions and additional extrinsic stimuli, such as induced chronic 
inflammatory states, aging or the cooperation with other mutations.  
 Neither single-mutant, nor double-mutant mice developed spontaneous 
hematological malignancies, illustrating that the oncogenic potential of these mutations 
is limited and possibly context-dependent in response to additional intrinsic or extrinsic 
factors. Rather, these mutations result in subtle abnormalities of hematopoietic 
differentiation. Idh1-R132H mutations alone or in combination with a DNMT3A-R882H 
mutation preferentially lead to a myeloid differentiation bias with slight predominance of 
the monocytic cell fate. By and large, this phenotype could be validated both at the 
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phenotypic as well as at the transcriptomic level. The expression of the Idh1-R132H 
mutation resulted in a deregulation of several critical regulators of myeloid and monocytic 
cell fate as well as inflammatory regulators that mediate the activation of monocytes or 
macrophages upon inflammatory stimuli. Pseudotime-inferred differentiation trajectories 
revealed an aberrant lineage specification in particular for Idh1-R132H DNMT3A-R882H 
double-mutated myeloid progenitor cells, which exclusively were characterized by 
elevated Myc signaling. Furthermore, this transcriptome-defined aberrant cell population 
could be correlated with a surface marker-defined cell population, enabling the use of 
certain surface marker combinations to prospectively isolate and characterize this 
population. Eventually, elevated IFN signaling was found as a common characteristic in 
Idh1-R132H and Idh1-R132H DNMT3A-R882H mutated monocyte progenitor populations 
and could contribute to altered differentiation patterns in response to a proinflammatory 
state.  
 Based on these results, several routes need to be considered for the future 
progression of this project. Most importantly, underpinning the rather descriptive 
characterization of altered cell states with functional studies will help to enhance our 
understanding of molecular mechanisms underlying these phenotypes. For instance, the 
characterization of DNA methylome and chromatin profiles of HSCs, myeloid progenitor 
cell populations, monocytes or macrophages from mutated mice will assist in unraveling 
whether the Idh1-R132H mutation mediates its effects via inhibition of Tet enzymes, via 
inhibition of histone demethylases, or via alternative mechanisms. Furthermore, the 
epigenomic characterization of these cell types will disclose the potential molecular 
interaction between Idh1-R132H and DNMT3A-R882H mutations. 
 Our group recently has invested significant efforts into the generation of a genome-
wide DNA methylation map of the entire murine hematopoietic system in order to 
investigate the DNA methylation programs which regulate hematopoietic differentiation 
and lineage commitment. This data will serve as a reference data set to identify how 
aberrant DNA methylation signatures contribute to the deregulation of hematopoietic 
differentiation observed in Idh1-R132H and / or DNMT3A-R882H mutated cells. The 
integration of epigenome and transcriptome data sets will furthermore be of use to 
identify disturbed regulatory networks, which we will focus on for further functional 
characterization. 
 On a functional note, a critical step will be to address if and how these findings 
translate to an altered cell function in affected cells. Regarding DNA damage and DNA 
repair, combining epigenomic and transcriptomic profiles with specific functional assays 
that quantify DNA damage rates, DNA repair kinetics and the mutational load of Idh1-
R132H mutated HSCs should decipher whether mutation-mediated defects in DNA repair 
pathways play a critical role in these cells, which repair pathways and enzymes specifically 
are affected, and how this impacts HSC attrition. Assays that quantify monocyte and 
macrophage differentiation, migration, stimulation or cytokine production should be 
employed to elucidate how and to which extent Idh1-R132H mutations affect monocyte 
and macrophage recruitment, activation and the establishment of an inflammatory 
environment within the bone marrow niche. Having identified altered regulatory 
networks, their impact on monocyte or macrophage function should be tested in 
perturbation studies using specific inhibitors, CRISPR/Cas9 or siRNAs which allow us to 
specifically modulate these networks. Based on this, it is our hope to identify druggable 
targets that can be exploited to establish novel therapeutic strategies specifically tailored 
for patients with hematopoietic neoplasms driven by IDH1-R132H or DNMT3A-R882H 
mutations.   
 Ultimately, it will be of utmost importance to understand which circumstances 
promote the initiation of preleukemic clonal expansion and leukemic transformation in 
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the context of Idh1-R132H and DNMT3A-R882H mutations. Since we started to investigate 
cooperating effects between Idh1-R132H and NRAS-G13D mutations, we plan to further 
elaborate molecular characteristics that define the interaction of preleukemic Idh1-R132H 
and DNMT3A-R882H mutations with secondary proliferative mutations in genes such as 
Flt3 or Npm1 mutations. Based on the proinflammatory conditions specific to the bone 
marrow compartment of Idh1-R132H mutant mice, it will be interesting to see how an 
application of chronic inflammatory stress (for example induced through serial injections 
with LPS, pI:pC or IFN) will affect functionality of mutated HSCs, myeloid progenitors, 
monocytes or macrophages and whether these conditions promote a leukemic 
progression. Understanding the molecular determinants that drive this progression will 
be essential to develop treatment options that can be applied to healthy individuals with 
existing preleukemic IDH1-R132H or DNMT3A-R882H mutations in order to prevent 
leukemic transformation.  
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Materials & Methods 
 
 
5.1 Culturing of Cell Lines and Primary Mouse 
Cells 
 
32D cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10 % fetal 
bovine serum (FBS, Biochrom), 1 % penicillin / streptomycin (Pen/Strep, Gibco) and 10 
ng/µl murine IL-3 (Peprotech).  
HEK293T cells and NIH/3T3 cells were cultured in DMEM medium supplemented with 
10 % FBS, 1 % Pen/Strep and 1 % L-glutamine (Gibco).  
 For in vitro differentiation experiments, isolated myeloid progenitor populations (i.e. 
surface marker-defined CMPs) were cultured in StemSpanTM SFEM medium (Stemcell 
Technologies) supplemented with murine IL-3 (10 ng/µl), murine IL-6 (10 ng/µl) and 
murine SCF (100 ng/µl) (Peprotech). 
 Cultured cells were incubated at 37°C and 5 % CO
2
 
 
 
5.2 Lentiviral Overexpression of Idh1 cDNA 
Constructs in 32D Cells 
 
5.2.1 Lentiviral Overexpression Plasmids 
 
The following plasmids were used to investigate the effect of Idh1-R132H mutations in 
32D cells: 
  
Table 5-1: List of Lentiviral Overexpression Plasmids. 
Name Backbone Insert Fluorescence 
LeGO-iC2 Empty Vector LeGO-iC2 - mCherry 
LeGO-iC2 Idh1-WT LeGO-iC2 Wildtype Idh1 cDNA mCherry 
LeGO-iC2 Idh1-R132H LeGO-iC2 Idh1-R132H mutated cDNA mCherry 
LeGO-iV2 Empty Vector LeGO-iV2 - GFP 
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5.2.2 Lentivirus Production  
 
Lentiviral particles were produced in HEK293T cells. For each virus production, a fresh 
vial of cells was thawed and cells were cultured for at least one week before the start of 
virus production. For each 150 cm2 (T150) flask of cells to be transfected, a transfection 
mix was prepared, consisting of 50 µg lentiviral plasmid of interest (either LeGO-iC2 
Empty Vector, LeGO-iV2 Empty Vector, LeGO-iC2 Idh1-WT or LeGO-iC2 Idh1-R132H), 37.5 
µg packaging plasmid psPAX2 (PlasmidFactory), 5 µg envelope plasmid pMD2.G 
(PlasmidFactory) and 90 µl 2 M CaCl
2
 (Calcium Phosphate Transfection Kit, Invitrogen), 
and was filled up with sterile ddH
2
O to a volume of 750 µl. The transfection mix was mixed 
with 750 µl 2x Hepes Buffered Saline buffer (HBS, Calcium Phosphate Transfection Kit, 
Invitrogen), vortexed thoroughly and incubated for 45 min at room temperature (RT). 
During the incubation, T150 flasks were coated with gelatin by incubating the flasks filled 
with 3 ml of EmbryoMax® 0,1% gelatin solution (Merck Millipore) at 37°C for 10 min. 
Afterwards, the gelatin solution was discarded and 2,5 x 107 HEK293T cells were seeded 
per gelatin-coated flask in 12 ml HEK293T medium supplemented additionally with 25 
µM chloroquine (Calcium Phosphate Transfection Kit, Invitrogen). After the incubation of 
the transfection mix, 1.5 ml chloroquine containing HEK293T medium was mixed with the 
transfection mix and added to the cell suspension in gelatin-coated flasks. Cells were 
incubated overnight at 37°C and on the next morning, the medium was replaced by fresh 
HEK293T medium, additionally supplemented with 1 % HEPES (Merck Sigma-Aldrich). 
After 24 h, the medium containing the virus particles was harvested and filtered using a 
0.45 µm PVDF filter unit (Merck Millipore). Fresh HEPES supplemented HEK293T medium 
was added to the cells and again after 24 h harvested and filtered. Afterwards, the filtered 
medium from the first and second harvest was pooled and centrifuged (Beckman Coulter 
Optima L-90K Ultracentrifuge) at 22,000 rpm for 2 h. Following centrifugation, the virus 
pellet was resuspended in an adequate volume of StemSpan SFEM medium (Stemcell 
Technologies) and stored in 10 µl aliquots at -80°C.  
 
5.2.3 Lentivirus Titration 
 
The titration of the produced lentiviruses was performed using the murine embryonic 
fibroblast cell line NIH/3T3. Cells were cultured at least one week before beginning the 
titration. One day before the start of the titration, 5 x 104 cells were seeded per well on a 
6-well plate and incubated overnight. On the following day, five dilutions of the virus 
(ranging from 1:400 to 1:400,000) were prepared in NIH/3T3 medium containing 8 µg/ml 
polybrene (Merck Sigma-Aldrich) and added to the cells. The number of cells per well at 
the time point of infection was determined by counting cells in a comparable well, equally 
seeded the day before. Subsequently to adding the virus, cells were incubated for 24 h at 
37°C. After this period, the medium was replaced by fresh NIH/3T3 cell medium and cells 
were incubated for additional 24 h. Transduced cells were harvested 48 h after infection 
with virus particles, and the percentage of mCherry or GFP positive cells was determined 
by FACS analysis. The virus titer (measured in infection units (IU) per ml) was calculated 
according to the following formula:  
 IU ml = Dilution	factor	x	frequency	of	positive	cells	x	number	of	cellsVolume	of	transduction  
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5.2.4 Lentiviral Transduction  
 
For the transduction of 32D cells, 1 x 105 cells were seeded per well on a 6-well plate in 2 
ml 32D cell medium additionally supplemented with 8 µg/ml polybrene (Merck Sigma-
Aldrich). The amount of virus to be added to the cells was calculated to yield a multiplicity 
of infection (MOI) of 2. The respective amount of virus then was added to each well and 
cells were incubated for 24 h at 37°C. Afterwards, the medium was replaced by fresh 32D 
cell medium and cells were incubated for another 24 h. Subsequently, cells were washed 
and mCherry or GFP positive cells were sorted on Aria I, Aria II, or Fusion cell sorter 
systems (BD Biosciences) using a 100 µm nozzle. Cells were sorted into 32D cell medium, 
taken back into culture under usual conditions and used in further experiments.  
 
 
5.3 Characterization of Transduced 32D Cells 
 
5.3.1 Cell Cycle Staining 
 
Before cell cycle analysis, 32D cells were seeded in starvation medium (32D cell medium 
depleted of IL-3) for 16 h in order to synchronize cell cycle phases. Afterwards, cells were 
transferred to regular 32D cell growth medium for 12 h. Cell cycle staining of 32D cells 
was performed using the Click-iTTM Plus EdU Flow Cytometry Assay Kit (Invitrogen), as 
described in the manufacturer’s protocol. In brief, 3 x 105 32D cells were seeded on a 6-
well plate in medium containing 10 µM EdU and incubated for 1-2 h. Cells were harvested, 
fixed and permeabilized using the 1X Click-iT Saponin-based permeabilization and wash 
reagent. Cells subsequently were incubated with the Click-iTTM Plus reaction cocktail 
(containing Pacific Blue coupled picolyl acide) as described in the manufacturers protocol. 
Eventually, cells were treated with 2.5 µl of ribonuclease-A (10 µg/ml) and incubated for 
20 min at 37°C. Subsequently, cells were pelleted, resuspended in 500 µl 7AAD solution 
(7AAD diluted 1:200 in PBS) and analyzed by FACS. Cell cycle phases were assigned based 
on 7AAD and Pacific Blue signals.  
 
5.3.2 Competitive Proliferation Assay 
 
Sorted 32D cells transduced either with LeGO-iC2 Idh1-WT or LeGO-iC2 Idh1-R132H 
constructs were seeded together with sorted LeGO-iV2 Empty Vector transduced cells at 
a 1:1 ratio (2.5 x 105 cells each in a 25 cm2 flask). The initial rate of mCherry and GFP 
positive cells was determined by FACS directly after seeding. Over a period of 2-3 weeks, 
the relative percentage of mCherry and GFP positive cells was measured regularly every 3 
days by FACS. During this period, cells were split equally for each co-seeding experiment.  
  
5.3.3 Alkaline Comet Assay 
 
Comet assays were conducted as described previously [Schmezer et al., 2001]. In brief, 
cells were counted, adjusted to an equal concentration, mixed with 0.7 % low-melting 
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agarose (SeaKem) and plated on comet assay slides (Trevigen). Subsequently, DNA damage 
was introduced by irradiation of embedded cells with 2 or 5 Gy, using a 134Cs radiation 
source with a dose rate of 0.575 Gy / min. Afterwards, cells were incubated for indicated 
recovery / reparation times in RPMI 1640 (Gibco) medium. Cells were lysed overnight 
using a 1 % TritonX100 lysis buffer. Following lysis, electrophoresis was conducted at 25V 
for 20 min. Eventually, DNA was stained by incubating cells in a SybrGreen® (Biozol) 
solution for 30 min. DNA damage analysis and evaluation was performed by fluorescence 
microscopy using a Metafer-4 (MetaSystems) fully automated cell scanning and analysis 
platform. Comet assays described in this thesis were performed by Reinhard Gliniorz in 
collaboration with Dr. Peter Schmezer and PD Dr. Odilia Popanda. 
 
5.3.4 Cell Viability Assay 
 
Transduced and sorted 32D cells were cultured in regular 32D cell medium supplemented 
with 1 µM or 4 µM olaparib (Selleck Chemicals). The cell viability for each condition was 
determined after one, two or three days by using the CellTiter-Blue® Cell Viability Assay 
Kit (Promega) according to the manufacturer’s protocol. In brief, cells were seeded in a 96 
well plate in regular 32D cell growth medium supplemented with Olaparib at indicated 
concentrations and incubated for the indicated time frame. Afterwards, CellTiter-Blue® 
Reagent was added to each well to be analyzed and cells were incubated for 2 h at 37°C. 
The fluorescence eventually was analyzed using a fluorometer, recording fluorescence at 
560
Ex
/590
Em
 nm wave lengths. Cell viability assays described in this thesis were performed 
by Dr. Ali Bakr.  
 
 
5.4 Validation of an Expression of the Idh1-
R132H Mutation  
 
5.4.1 D2HG Assay 
 
The quantification of D2HG in cell lysates and blood serum samples was carried out using 
an enzymatic assay described previously [Balss et al., 2012]. Cell lysates of 32D or bone 
marrow cells were obtained by repeated freeze / thaw cycles of cells resuspended in NP40 
cell lysis buffer. Lysates were spun down in a table-top centrifuge at 14,000 rpm for 5 
min, the supernatant transferred to a new tube and stored at -80°C. Blood serum was 
obtained by collecting blood in a Microvette® Serum-Gel tube (Sarstedt), followed by 
centrifugation at 10,000 g for 5 min. The supernatant was transferred to a new tube and 
stored at -80°C. For the D2HG assay, stored cell lysate or blood serum supernatants were 
thawed and 100 µl of the respective sample used in further proceedings.  
 Initially, samples were deproteinized using the Deproteinization Kit (Biovision) 
according to the manufacturer’s protocol. Briefly, 25 µl of perchloric acid solution was 
added to 100 µl of sample, followed by an incubation for 2 min on ice. Samples were 
centrifuged for 20 min at 4,000 rpm using a table-top centrifuge. From each supernatant, 
95 µl were transferred to a new tube and 5 µl of neutralization solution was added. 
Samples were again incubated for 2 min on ice and centrifuged for 20 min at 4,000 rpm. 
From each supernatant, 90µl were transferred to a new tube, from which 25 µl were used 
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per measurement. For each reaction (reaction volume 100 µl), an assay solution was 
freshly prepared, containing 100 mM HEPES (Merck Sigma-Aldrich) pH 8.0, 100 µM NAD+ 
(Applichem), 0.1 µg (D)-2-hydroxyglutarate dehydrogenase, 5 µM resazurin (Applichem) 
and 0.01 U/ml diaphorase (MP Biomedical). Twenty-five µl of sample was mixed with 75 
µl of assay solution and incubated at RT in the dark for 30 min. Fluorometric detection 
was carried out in triplicates per sample at 560
Ex
/610
Em
 nm wave lengths.  
 D2HG standards were prepared in NP40 lysis buffer or blood serum at concentrations 
of 0.5, 1, 2.5, 5, 7.5, 10, 25 and 50 µM D2HG. For each sample measurement, standards 
were prepared equally as the corresponding samples and measured on the same plate. 
The D2HG amount in each sample was determined by calculating a standard curve that 
was used to correlate fluorescence intensities and D2HG concentrations.  
 For cell lysate measurements, D2HG concentrations were normalized to the overall 
protein amount in each lysate, which was determined using the PierceTM BCA Protein Assay 
Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Initially, 1:25 
dilutions of each cell lysate were prepared by mixing 3 µl of cell lysate with 72 µl H
2
O. 
Afterwards, a BCA working reagent was prepared by mixing BCA Reagent A with BCA 
Reagent B at a rate of 50:1. For measurements, 25 µl of diluted lysate was mixed with 200 
µl of working reagent and incubated for 30 min at 37°C. The absorbance was measured at 
562 nm in duplicates for each sample.  
 Albumin standards were prepared at concentrations of 2, 1.5, 1, 0.75, 0.5, 0.25, 0.125 
and 0.025 µg/µl. For each measurement, 25 µl of each standard was mixed with 200 µl of 
BCA working reagent and measured together with cell lysate samples. The protein amount 
per sample was determined by calculating a standard curve that was used to correlate 
absorbance and protein amounts.  
 
5.4.2 Idh1 Locus Recombination-Specific PCR 
 
Genomic DNA was isolated using the QIAamp® DNA Micro Kit (Qiagen) according to the 
manufacturer’s protocol. The following primers were used to analyze the region of the 
distal lox site, allowing the discrimination between conditional alleles (mutated exon 3 
present but not expressed, locus not recombined), knock-in alleles (mutated exon 3 
expressed, locus recombined) and wildtype alleles: 
 
Table 5-2: List of Primers Used in Idh1 Locus Recombination-Specific PCRs. 
Primer Name Sequence 
Mf_5539 TGCAAAAATATCCCCCGGCTAGTGA 
Er_5538 CACCATTACCACCAACAGCAACATCTC 
  
 
 The PCR was performed using a HotStarTaq DNA Polymerase (Qiagen) according to 
the manufacturer’s protocol using the following cycling conditions: 95°C for 15 min, 35 
cycles of (i) 94°C for 30 s, (ii) 62°C for 30 s, (iii) 72°C for 1 min, 72°C for 10 min. PCR 
products eventually were analyzed on an 1 % agarose gel.  
 
5.4.3 Idh1-R132H Mutation-Specific PCR 
 
Total RNA was isolated using the RNeasy Micro Kit (Qiagen) according to the 
manufacturer’s protocol including an on-column DNase digestion. Purified RNA was 
quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific) and 100-500 
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ng of total RNA was used in cDNA synthesis reactions. cDNA was synthesized with 
random hexamer primers using the SuperScriptTM II Reverse Transcriptase Kit (Thermo 
Fisher Scientific) according to the manufacturer’s protocol. The expression of Idh1-R132H 
mutated transcripts and wildtype Idh1 transcripts were quantified using a SYBRGreen® 
Mastermix (Steinbrenner) in combination with wildtype- or mutation-specific primers on 
a LightCycler 480 II system (Roche). The following primers were used in combinations 
Idh1_Exon2_Fwd + Idh1_WT_Rev or Idh1_Exon2_Fwd + Idh1_R132H_Rev; Gapdh 
transcript expression was used for normalization: 
 
Table 5-3: List of Primers Used in Idh1-R132H Mutation-Specific PCRs. 
Primer Name Sequence 
Idh1_Exon2_Fwd AGGAGGTTCTGTGGTGGAGA 
Idh1_WT_Rev CTGTATTGGTCCCCATATGCATATC 
Idh1_R132H_Rev CTGTATTGGTCCCCATATGCATAGT 
Gapdh_Fwd TCCTGCACCACCAACTGCTTA  
Gapdh_Rev GGCATGGACTGTGGTCATGAG  
 
 
 The following cycling conditions were used for qRT-pCRs:  95°C for 15 min, 40 cycles 
of (i) 95°C for 15 s, (ii) 56°C for 20 s, (iii) 72°C for 15 s, 72°C for 10 min. Expression analysis 
was performed based on the 2—DDCt method and amplified PCR products eventually were 
visualized on an 1% agarose gel.  
 
 
5.5 Animals  
 
All animals were held and bred under specified pathogen-free conditions in individually 
ventilated cages at the animal facilities of the German Cancer Research Center (DKFZ). 
Experimental procedures were approved by the department for ‘Veterinär- und 
Lebensmittelwesen’ of the Regierungspräsidium Karlsruhe.  
 All mouse models (Idh1-R132H, DNMT3A-R882H, Scl-CreERT2, Rosa26-EYFP) 
described in this study initially were crossed with C57Bl/6-Ly5.1 mice to produce mice 
homozygously expressing the CD45.1 allele. Idh1R132H/R132H mice were bred with Scl-
CreERT2+/d Rosa26-EYFPd/d mice to produce Idh1+/R132H Scl-CreERT2+/d Rosa26-EYFP+/d mice 
which were used in described experiments. DNMT3A+/R882H mice were crossed with Scl-
CreERT2+/d Rosa26-EYFPd/d mice to yield DNMT3A+/R882H Scl-CreERT2+/d Rosa26-EYFP+/d mice 
which were used in described experiments. Idh1R132H/R132H DNMT3A+/R882H mice were bred with 
Scl-CreERT2+/d Rosa26-EYFPd/d mice to generate Idh1+/R132H DNMT3A+/R882H Scl-CreERT2+/d 
Rosa26-EYFP+/d mice which were used in described experiments. Idh1+/+ DNMT3A+/+ Scl-
CreERT2+/d Rosa26-EYFP+/d mice were used as CTRL mice in all experiments. For all 
experimental mice, genotypes were verified by established genotyping PCRs. Recipient 
C57BL/6J mice were obtained from Harlan Laboratories.  
 
5.5.1 Tamoxifen Injections  
 
To induce Cre recombinase activity, six- to ten-week old mice were intraperitoneally 
injected with 2 mg tamoxifen per day for five consecutive days. Tamoxifen solutions were 
prepared by mixing 50 mg of tamoxifen (Merck Sigma Aldrich) with 500 µl ethanol and 
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4.5 ml sunflower oil (Merck Sigma Aldrich). Fresh tamoxifen solutions were prepared every 
second day.  
 
 
5.6 Analysis of Murine Blood and Bone 
Marrow Composition 
 
FACS antibody panels used to analyze blood and bone marrow composition are indicated 
in the respective tables. All antibodies were titrated and applied in appropriate dilutions. 
Cells were stained in PBS (Merck Sigma Aldrich) supplemented with 2 % fetal calf serum 
(FCS, Gibco) (PBS/FCS) for at least 20 min at 4°C, washed once, resuspended in PBS/FCS 
and filtered. Flow cytometric analysis of blood and bone marrow cells was carried out on 
LSRII or Fortessa flow cytometer (BD Biosciences). FACS data was analyzed using the 
FlowJo 10 software package.  
 
5.6.1 Peripheral Blood Analysis 
 
Peripheral blood was drawn from facial veins and collected in K3 EDTA coated tubes 
(Sarstedt). Cell counts were determined using a HemaVet 950 FS veterinary hematology 
system (Drew Scientific). 
 For flow cytometric analysis, 30 µl of peripheral blood was mixed with 1 ml of 
Ammonium-Chloride-Potassium (ACK)-lysis buffer (Lonza) to lyse red blood cells and 
incubated for 10 min on RT. Afterwards, cells were centrifuged at 400 g for 5 min, and 
stained with the respective antibody panels depicted in Table 5-4 for 30 min at 4°C. Cells 
were washed once, resuspended in 200 µl PBS/FCS, filtered and analyzed by FACS. 
The antibody panel depicted in Table 5-4 allows the quantification of CD45.1, CD45.1/2 
and CD45.2 cell rates as well as B-cell, T-cell and myeloid cell frequencies.  
 
Table 5-4: Antibody Panel for Flow Cytometric Analysis of Peripheral Blood. 
Antigen  Clone  Fluorophore Company 
CD45.1 A20 APC-Cy7 Invitrogen 
CD45.2 104 Pacific Blue BioLegend 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
B220  RA3-6B2 PE-Cy7 eBioscience 
B220 RA3-6B2 APC eBioscience 
Gr1 RB6-8C5 APC eBioscience 
CD11b M1/70 APC Invitrogen 
 
5.6.2 Bone Marrow Analysis  
 
Mice were sacrificed by cervical dislocation and femora, tibiae, iliac crests and spine 
vertebrae were dissected and cleaned. Bones were crushed in Iscove’s modified Dulbecco’s 
medium (IMDM, Gibco) and the cell suspension filtered through a 40 µm cell strainer 
(Greiner Bio-One). 
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Cells were counted and stained with the respective antibody panels depicted in Table 5-5, 
Table 5-6, Table 5-7, Table 5-8 or Table 5-9 for 30 min at 4°C (maximal 2 x 107 cells stained 
in 500 µl PBS/FCS). Cells were washed once, resuspended in PBS/FCS, filtered and analyzed 
by FACS. 
 
The antibody panel depicted in Table 5-5 was used for the quantification of LT-HSCs, ST-
HSCs, MPP2, MPP3+4, MPP5, and LSK cell populations.  
 
Table 5-5: Antibody Panel for Flow Cytometric Analysis of Stem Cell- and Multipotent Progenitor Populations in the 
Bone Marrow.  
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
CD11b  M1/70 PE-Cy7 eBioscience 
Gr1 RB6-8C5 PE-Cy7 eBioscience 
B220 RA3-6B2 PE-Cy7 eBioscience 
Ter119 TER119 PE-Cy7 eBioscience 
cKit  2B8 APC Invitrogen 
Sca1 D7 APC-Cy7 BD Bioscience 
CD150 TC15-12F12.2 PE-Cy5 BioLegend 
CD48 HM48-1 PE eBioscience 
CD34 RAM34 eFluor 450 Invitrogen 
 
 
The antibody panel depicted in Table 5-6 was used for the quantification of MEP, CMP, 
GMP and LS-K populations.  
 
Table 5-6: Antibody Panel for Standard Flow Cytometric Analysis of Committed Progenitor Populations in the Bone 
Marrow. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
CD11b  M1/70 PE-Cy7 eBioscience 
Gr1 RB6-8C5 PE-Cy7 eBioscience 
B220 RA3-6B2 PE-Cy7 eBioscience 
Ter119 TER119 PE-Cy7 eBioscience 
cKit  2B8 APC Invitrogen 
Sca1 D7 APC-Cy7 BD Bioscience 
CD34 RAM34 Alexa Fluor 700 eBioscience 
CD16/32 93 eFluor 450 eBioscience 
 
 
The antibody panel depicted in Table 5-7 was used for the quantification of MEP, CMP, 
GMP, Ly6C+ GMP, CD115+ GMP, cMoP and LS-K populations.  
 
Table 5-7: Antibody Panel for Extended Flow Cytometric Analysis of Committed Progenitor Populations in the Bone 
Marrow. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
CD11b  M1/70 PE-Cy7 eBioscience 
Gr1 RB6-8C5 PE-Cy7 eBioscience 
B220 RA3-6B2 PE-Cy7 eBioscience 
Ter119 TER119 PE-Cy7 eBioscience 
cKit  2B8 APC Invitrogen 
Sca1 D7 APC-Cy7 BD Bioscience 
CD34 RAM34 Alexa Fluor 700 eBioscience 
CD16/32 93 eFluor 450 eBioscience 
Ly6C HK1.4 BV605 BioLegend 
CD115 AFS98 BV711 BioLegend 
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The antibody panel depicted in Table 5-8 was used for the quantification of B-cells, T-cells 
and myeloid cells.  
 
Table 5-8: Antibody Panel for Standard Flow Cytometric Analysis of Differentiated Cells in the Bone Marrow. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
B220  RA3-6B2 PE-Cy7 eBioscience 
B220 RA3-6B2 APC eBioscience 
Gr1 RB6-8C5 APC eBioscience 
CD11b M1/70 APC Invitrogen 
 
 
The antibody panel depicted in Table 5-9 was used for the quantification of B-cells, T-
cells, monocytes and granulocytes. 
 
Table 5-9: Antibody Panel for Extended Flow Cytometric Analysis of Differentiated Cells in the Bone Marrow. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
B220  RA3-6B2 APC eBioscience 
CD11b M1/70 BV785 BioLegend 
Ly6C HK1.4 BV605 BioLegend 
Ly6G 1A8 APC-Cy7 BioLegend 
 
 
5.7 Isolation and Purification of Surface 
Marker-Defined Bone Marrow Populations  
 
Mice were sacrificed by cervical dislocation and femora, tibiae, iliac crests and spine 
vertebrae were dissected and cleaned. Bones were crushed in Iscove’s modified Dulbecco’s 
medium (IMDM, Gibco) and the cell suspension filtered through a 40 µm cell strainer 
(Greiner Bio-One). Obtained TBM cells were either directly stained with respective antibody 
panels (e.g. to sort CD45+ TBM cells) or further processed to enrich Lin— bone marrow cells.  
 
5.7.1 Enrichment of Lineage Negative Bone Marrow 
Cells 
 
A density gradient centrifugation using Histopaque 1083 (Merck Sigma-Aldrich) was 
carried out to enrich low-density mononuclear cells (LDMNCs). Here, 6 ml of the filtered 
cell suspension (maximal concentration of 3 x 107 cells / ml) was loaded on top of 6 ml of 
Histopaque 1083 and centrifuged at 400 g for 20 min at 21°C without brakes. LDMNCs 
were harvested by collecting upper phase, interphase and lower phase. The remaining cell 
pellet was resuspended in 6 ml of fresh IMDM and subjected to an additional round of 
density gradient centrifugation. LDMNCs from both centrifugations were pooled, 
centrifuged and resuspended in 3 ml PBS/FCS. Cells were incubated for 30 min at 4°C with 
a cocktail of biotin-conjugated rat anti-mouse lineage antibodies (Table 5-10) at a 
concentration of 112.8 µl lineage cocktail per 1 x 108 cells. Afterwards, cells were washed 
once in PBS/FCS and incubated with anti-rat IgG-coated magnetic DynabeadsTM from the 
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DynabeadsTM UntouchedTM Mouse T Cells Kit (Invitrogen) for 45 min at 4°C. Magnetic 
depletion of Lin+ bone marrow cells using a DynaI MPC-6 magnet (Invitrogen) resulted in 
an enrichment of Lin— bone marrow cells. Lineage-depleted cells were washed in PBS/FCS 
and further stained with respective antibody panels.  
 
Table 5-10: Cocktail of Biotin-Conjugated Anti-Mouse Lineage Antibodies. 
Antigen Clone Concentration Company 
CD5 53-7.3 4.2 µg / ml BD Bioscience 
CD45R / B220 RA3-6B2 2.8 µg / ml BD Bioscience 
CD11b / Mac1 M1/70 2.6 µg / ml BD Bioscience 
CD8a 53-6.7 4.2 µg / ml BD Bioscience 
Ly6G and Ly6C (Gr1) RB6-8C5 2.4 µg / ml BD Bioscience 
Ter119 TER-119 2.6 µg / ml BD Bioscience 
    
5.7.2 Fluorescence Activated Cell Sorting of 
Hematopoietic Cell Populations 
 
FACS antibody panels used to label hematopoietic cells are indicated in the respective 
tables. All antibodies were titrated and applied in appropriate dilutions. Cells at a maximal 
concentration of 1 x 107 cells / ml were stained in PBS/FCS for at least 20 min at 4°C, 
washed, resuspended in PBS/FCS and filtered. Sorting of hematopoietic cell populations 
was carried out at Aria I, Aria II, or Fusion cell sorter systems (BD Biosciences) using a 100 
µm nozzle. Cells were sorted into 1.5 ml tubes containing 300 µl StemSpan SFEM medium 
(Stemcell Technologies) in case cells were taken into culture or used in transplantations. 
For further RNA-seq experiments, cells were sorted directly into 200 µl Arcturus® 
PicoPure® Extraction Buffer (Applied Biosystems), snap-frozen in liquid nitrogen and 
stored at -80°C until further processing. For further scRNA-seq experiments, cells were 
sorted into PBS/FCS.  
 
Sorting of CD45+ Total Bone Marrow Cells  
Following crushing of bones and filtering of cell suspensions, cells were counted and 
centrifuged at 400 g for 5 min.  Afterwards, cells were stained with the antibody panel 
depicted in Table 5-11 for 20 min at 4°C.  Cells were washed, resuspended in PBS/FCS + 
DAPI (diluted 1:1000), filtered and subjected to cell sorting.  
 
Table 5-11: Antibody Panel for the Isolation of CD45+ Total Bone Marrow Cells. 
Antigen  Clone  Fluorophore Company 
CD45.1 A20 PE eBioscience 
DAPI - - PeproTech 
 
 
Sorting of Cell Populations from Lineage-Depleted Bone Marrow Cells 
Following the enrichment of Lin— bone marrow cells, cells were washed, centrifuged at 400 
g for 5 min and stained with antibody panels depicted in Table 5-12, 5-13 or 5-14 for 20 
min at 4°C. Cells were washed, resuspended in PBS/FCS, filtered and subjected cell sorting. 
 
 
 
 
 
5 Materials & Methods 
 
 93 
The antibody panel depicted in Table 5-12 was used to isolate HSC and MPP populations 
from lineage-depleted bone marrow cells.  
 
 
Table 5-12: Antibody Panel for the Isolation of Stem Cell- and Multipotent Progenitor Populations. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
CD11b  M1/70 PE-Cy7 eBioscience 
Gr1 RB6-8C5 PE-Cy7 eBioscience 
B220 RA3-6B2 PE-Cy7 eBioscience 
Ter119 TER119 PE-Cy7 eBioscience 
Streptavidin - PE-Cy7 BioLegend 
cKit  2B8 APC Invitrogen 
Sca1 D7 APC-Cy7 BD Bioscience 
CD150 TC15-12F12.2 PE-Cy5 BioLegend 
CD48 HM48-1 PE eBioscience 
CD34 RAM34 eFluor 450 Invitrogen 
 
 
The antibody panel depicted in Table 5-13 was used to isolate committed progenitor 
populations from lineage-depleted bone marrow cells.  
 
Table 5-13: Antibody Panel for the Isolation of Committed Progenitor Populations. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
CD11b  M1/70 PE-Cy7 eBioscience 
Gr1 RB6-8C5 PE-Cy7 eBioscience 
B220 RA3-6B2 PE-Cy7 eBioscience 
Ter119 TER119 PE-Cy7 eBioscience 
Streptavidin - PE-Cy7 BioLegend 
cKit  2B8 APC Invitrogen 
Sca1 D7 APC-Cy7 BD Bioscience 
CD34 RAM34 Alexa Fluor 700 eBioscience 
CD16/32 93 eFluor 450 eBioscience 
Ly6C HK1.4 BV605 BioLegend 
CD115 AFS98 BV711 BioLegend 
 
 
The antibody panel depicted in Table 5-14 was used to isolate LSK, LS-K and Lin— 
populations from lineage-depleted bone marrow cells.  
 
Table 5-14: Antibody Panel for the Isolation of LSK, LS-K and Lin— Populations. 
Antigen  Clone  Fluorophore Company 
CD4 GK1.5 PE-Cy7 Invitrogen 
CD8a 53-6.7 PE-Cy7 eBioscience 
CD11b  M1/70 PE-Cy7 eBioscience 
Gr1 RB6-8C5 PE-Cy7 eBioscience 
B220 RA3-6B2 PE-Cy7 eBioscience 
Ter119 TER119 PE-Cy7 eBioscience 
Streptavidin - PE-Cy7 BioLegend 
cKit  2B8 APC Invitrogen 
Sca1 D7 APC-Cy7 BD Bioscience 
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5.8 Transplantations 
 
5.8.1 Primary Transplantations 
 
Sorted cells to be transplanted were centrifuged at 400 g for 5 min and resuspended in 
an appropriate volume of PBS. If necessary, cells were mixed with the indicated number 
of supportive bone marrow cells derived from heterozygous C57Bl/6-Ly5.1 mice. For Lin—
transplantations, no supportive bone marrow was used. Recipient mice were irradiated 
with 2 x 500 Rad one day prior to the transplantation. Per recipient mouse, 200 µl of cell 
suspension was injected into the tail vain using a 1 ml insulin syringe (BD Medical).   
 
5.8.2 Secondary and Tertiary Transplantations 
 
For secondary and tertiary transplantations, TBM cells from primary or secondary 
recipients were transplanted. Femora, tibiae, iliac crests and spine vertebrae were crushed 
and the cell suspension filtered. Cells were counted and the appropriate number of cells 
resuspended in an adequate volume of PBS. Per secondary or tertiary recipient mouse, 3 
x 106 TBM cells were transplanted in a volume of 200 µl injected into the tail vain.  
 
 
5.9 Colony-Forming Unit Assay  
 
LT-HSCs were sorted in 300 µl StemSpan SFEM (StemCell Technologies) medium, 
centrifuged at 400 g for 5 min and resuspended in PBS at a concentration of 600 cells per 
300 µl. Next, 300 µl of the cell suspension were mixed with 2.7 ml of MethoCultTM M3434 
methylcellulose medium (StemCell Technologies) and 1 ml was seeded on a 5 cm2 cell 
culture dish (Corning) in technical duplicates. Dishes were incubated for 7 days in a 
humidified 10 cm2 dish (Corning) at 37°C and 5 % CO
2
. Following incubation, colonies were 
counted manually and cells were harvested by diluting and resuspending the 
methylcellulose cell suspension in 2 ml PBS per plate. Harvested cells were centrifuged at 
400 g for 5 min and resuspended in an appropriate volume of PBS and counted. Five 
thousand cells were resupended in 300 µl of PBS, mixed with fresh 2.7 ml of MethoCultTM 
M3434 (StemCell Technologies) methylcellulose medium and seeded on 5 cm2 dishes. 
Secondary and all subsequent platings were incubated for 7-10 days at 37°C and 5 % CO
2
. 
Replating procedures were repeated until no growth of colonies was observed. CFU assays 
described in this thesis were performed in collaboration with Umut Kilik.  
 
 
 
 
 
5 Materials & Methods 
 
 95 
5.10 Bulk RNA-Sequencing  
 
5.10.1 RNA Extraction 
 
Cells were sorted into Arcturus® PicoPure® Extraction Buffer (Applied Biosystems), snap-
frozen in liquid nitrogen and stored at -80°C until further processing. Total RNA extraction 
was performed using the Arcturus® PicoPure® RNA Isolation Kit (Applied Biosystems) 
according to the manufacturer’s protocol. DNA was digested on-column using the RNase-
Free DNase Set (Qiagen). RNA was eluted in 10 µl H
2
O and concentrations were determined 
with a Qubit Fluorometer (Thermo Fisher Scientific) using a Qubit RNA High Sensitivity 
Kit (Invitrogen). RNA profiles were validated on an Agilent 2100 Bioanalyzer platform 
(Agilent Technologies) with an Agilent RNA 6000 Pico Kit (Agilent Technologies). RNA 
concentrations of samples were adjusted to an equal concentration for further processing.  
 
5.10.2 Generation of RNA-seq Libraries 
 
RNA-seq libraries were generated from extracted total RNA using the previously described 
Smart-seq2 protocol [Picelli et al., 2014]. In brief, cDNA was synthesized in a reverse 
transcription and template-switching reaction and amplified by pre-amplification PCR. 
cDNA was purified using Agencourt Ampure XP Beads (Beckaman Coulter) and quality-
checked on an Agilent 2100 Bioanalyzer platform (Agilent Technologies) using an Agilent 
High Sensitivity DNA Kit (Agilent Technologies). Libraries were generated using the 
Nextera XT DNA Library Prep Kit (Illumina) according to the manufacturer’s protocol. 
cDNA was tagmented and adapter-ligated fragments amplified by PCR. Amplified and 
indexed libraries were purified using Agencourt Ampure XP Beads (Beckaman Coulter) and 
quality-checked on an Agilent 2100 Bioanalyzer platform (Agilent Technologies) using an 
Agilent High Sensitivity DNA Kit (Agilent Technologies). Library concentrations were 
determined with a Qubit Fluorometer (Thermo Fisher Scientific) using a Qubit DNA High 
Sensitivity Kit (Invitrogen). For sequencing, libraries were pooled at equimolar ratios.  
 
5.10.3 Sequencing of RNA-seq Libraries 
 
Libraries were sequenced by 100 bp paired-end sequencing on a HiSeq 4000 platform 
(Illumina). Sequencing was performed by the Genomics and Proteomics Core Facility at 
the DKFZ. 
 
5.10.4 Analysis of Bulk RNA-Sequencing Data  
 
Alignment and Filtering 
Sequencing reads initially were aligned and filtered by the Omics IT and Data Management 
Core Facility of the DKFZ in collaboration with Stephen Krämer. The workflow was created 
by Dr. Naveed Ishaque. In brief, reads were aligned the GRCm38 (mm10) genome assembly 
using the ‘STAR’ aligner [Dobin et al., 2013]. Duplicate marking of the resultant main 
alignment file was performed using ‘sambamba’ [Tarasov et al., 2015], chimeric files were 
sorted using ‘samtools’ (i.e. ‘samtools sort’) [Li et al., 2009] and BAM indexes were 
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generated using ‘sambamba’ [Tarasov et al., 2015]. Quality control analysis was performed 
using ‘samtools’ (i.e. ‘samtools flagstat’) [Li et al., 2009] and ‘RNA-SeQC’ [DeLuca et al., 
2012]. Eventually, gene-specific read counting was performed using ‘featureCounts’ [Liao 
et al., 2014].  
 
Data Transformation and Sample Clustering 
Generated count matrices were filtered to exclude genes with low read counts (< 5) and 
counts were normalized using a regularized log (rlog) transformation implemented in the 
‘DESeq2’ R-package [Love et al., 2014]. Pearson correlation coefficients, sample distances 
and principal components were computed using the ’cor.test’, ‘dist’ and ‘prcomp’ 
functions implemented in the ‘R stats’ R-package.  
 
Differential Expression Analysis 
Differential expression between genotypes was determined using the ‘DESeq2’ R-package 
[Love et al., 2014]. The status of both Idh1-R132H and DNMT3A-R882H mutations was 
incorporated into the design formula (~ Mutation 1 * Mutation 2) and contrasts were 
specified accordingly to extract differential gene expression between genotypes in a 
pairwise comparison. Log2 fc shrinkage was performed using the ‘ashr’ shrinkage 
estimator [Stephens, 2017].  
 GSEA was performed using the ‘GSEA’ software from the Broad Institute [Mootha et 
al., 2003, Subramanian et al., 2005]. Filtered and rlog transformed count matrices were 
used as input and enriched gene sets were determined using ‘Hallmark’ gene sets as 
reference.  
 Upstream regulator analysis was performed using the Ingenuity Pathway Analysis 
platform (Qiagen). Differential expression results tables, containing log2 fc values, p-
values, and false discovery rate (fdr) values for a given pairwise comparison were used as 
an input. Log2 fc < -0.2 or > 0.2 and fdr < 0.1 were used as cutoffs for the upstream 
regulator analysis.  
 
 
5.11 Single Cell RNA-Sequencing  
 
5.11.1 Generation and Sequencing of Single-Cell 
RNA-Sequencing Libraries 
 
Hematopoietic cell layers (CD45+ TBM, LS-K, LSK) were sorted into PBS/FCS as described 
previously. ScRNA-seq libraries were generated at the Single-Cell OpenLab of the DKFZ by 
Katharina Bauer, Dr. Mark Hartmann and Maximilian Schönung using a Chromium Single-
Cell 3’ Reagent Kit v2 (10X Genomics) according to the manufacturer’s instructions. In 
brief, sorted cells were loaded onto a Chip A Single Cell, and mixed with a reverse 
transcription master mix and Single Cell 3’ Gel Beads. The mixture was processed in a 
Chromium Controller to generate Gel Bead-In-EMulsions (GEMs) and further incubated at 
(i) 53°C for 45 min, (ii) 85°C for 5 min, to synthesize barcoded full-length cDNA. Silane 
magnetic beads were used to remove leftover reagents and primers, the cDNA was 
released from GEMs, purified and eventually amplified by PCR. Amplified cDNA was again 
purified and sequencing libraries were constructed by enzymatic fragmentation, followed 
by end repair, A-tailing, adaptor ligation, and a final PCR reaction. Final libraries were 
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purified, quality-checked and eventually sequenced by 100 bp paired-end sequencing on 
a HiSeq 4000 platform (Illumina) at the Genomics and Proteomics Core Facility of the 
DKFZ. 
 
5.11.2 Analysis of Single-Cell RNA-Sequencing Data 
 
Initial processing of reads and preliminary analysis of scRNA-seq data was carried out by 
Abdelrahman Mahmoud. Reads were demultiplexed, aligned and filtered using the 10X 
Genomics ‘CellRanger’ pipeline in order to generate feature-barcode gene expression 
matrices. Downstream data processing was performed using the ‘Seurat’ R-package v3 
[Butler et al., 2018, Stuart et al., 2019].  
 
Filtering, Normalization, Scaling and Dimensionality Reduction of Data 
Low-quality cells were filtered based on the following cutoffs:  < 200 genes per cell, > 5000 
genes per cell, > 10 % mitochondrial genes. Data was normalized and scaled using the 
‘sctransform’ wrapper implemented in the ‘Seurat’ package, regressing out the number of 
UMIs and the mitochondrial percentage. Principal component analysis was performed 
using the ‘RunPCA’ function and the first 50 PCAs were used in downstream analysis. Cell 
cluster were determined based on a shared nearest neighbor (SNN) algorithm using the 
‘FindNeighbors’ and ‘FindCluster’ functions (‘FindCluster’ resolution = 3). Dimensionality 
reduction was conducted using the UMAP algorithm (‘RunUMAP’ function, parameters: 
dims = 1:25, n.neighbors = 200, min.dist = 0.99). 
 
Annotation of Cluster 
Cluster-specific signature genes were identified by running a differential expression 
analysis between cluster using a Wilcoxon rank-sum test (‘FindAllMarker’ function) with 
log fc and minimum fraction cutoffs of 0.25 (parameters min.pct = 0.25, logfc.threshold 
= 0.25). Cell cluster were annotated manually based on the list of cluster-specific signature 
genes. Annotation of cluster was carried out in collaboration with Dr. Simon Haas and Dr. 
Mark Hartmann. Cluster with equal annotation were aggregated to cell type specific 
clusters (e.g. ST-HSC cluster #1 and ST-HSC cluster #2). Sample distances between 
genotype specific cells for each cluster were determined using the ‘dist’ function 
implemented in the ‘R stats’ R-package. 
 
Differential Expression Between Genotypes 
Differential expression between genotypes was determined for each cell type-specific 
cluster using the ‘FindMarker’ function with a log fc cutoff of 0.25. DE genes for each 
genotype were called in a one vs. all comparison between all cells from the respective 
cluster or cell type. 
To identify genotype- specific enriched gene sets, the overlap between DE genes and gene 
sets deposited at the Molecular Signature Database (MSigDB) [Liberzon et al., 2015, 
Liberzon et al., 2011] were computed. ‘Hallmark’ gene sets, ‘Gene Ontology’ gene sets and 
‘Immunologic Signatures’ gene sets were used as reference for computing overlaps. 
 
Diffusion Maps and Lineage Interference 
Diffusion maps were created using the ‘destiny’ R-package and are based on a spectral 
non-linear dimensionality reduction method [Angerer et al., 2016]. Normalized single-cell 
gene expression data was used as an input. Based on the computed diffusion distances, 
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lineages were reconstructed based on pseudotime inference using the ‘slingshot’ R-
package [Street et al., 2018]. 
 
Cell Cycle Assignments 
Cell cycle phases for each cell were determined using the ‘CellCycleScoring’ function 
implemented in the ‘Seurat’ R-package. Cell cycle scores were assigned based on the 
expression of pre-defined G2/M- and S-phase markers. 
 
 
5.12 Data Processing, Visualization and 
Statistical Analysis 
 
Data was processed and visualized using the R environment. Processing and 
transformation of data was predominantly performed using the ‘dplyr’ R-package. 
Visualization of data was predominantly performed using the ‘ggplot2’, ‘pheatmap’, or 
‘Seurat’ R-packages. Statistical tests were computed using the ‘stats’ or ‘ggsignif’ R-
packages and are stated in the respective figure legends alongside sample sizes (n) and p-
values. Error bars indicate standard deviation (SD). Figures were designed using Affinity 
Designer 1.5.5.
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Appendix 
 
 
A.1 Supplemental Figures  
 
 
 
 
 
Supplemental Figure A-1: Representative FACS Analysis and Sorting Schemes to Quantify or Isolate Hematopoietic 
Stem- and Progenitor Cells. 
 (A) Representative gating scheme to isolate and quantify EYFP+ stem cell- and multipotent progenitor cell populations 
within the bone marrow of mice. (B) Representative gating scheme to isolate and quantify EYFP+ committed progenitor 
cell populations within the bone marrow of mice.  
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Supplemental Figure A-2: Representative FACS Analysis and Sorting Schemes to Quantify or Isolate Differentiated 
Hematopoietic Cells.  
(A) Representative gating scheme to quantify EYFP+ B-cells, T-cells, granulocytes and monocytes in the bone marrow of 
mice. (B) Representative gating scheme to quantify CD45.1+ cell-derived B-cells, T-cells, granulocytes and monocytes in 
the peripheral blood of mice. (C) Representative gating scheme to quantify EYFP+ B-cells, T-cells and overall myeloid 
cells in the bone marrow of mice. (D) Representative gating scheme to quantify CD45.1+ cell-derived B-cells, T-cells and 
overall myeloid cells in the peripheral blood of mice.  
 
 
 
 
 
 
 
Supplemental Figure A-3: Colony-Formation Assay of Idh1-R132H Mutated LT-HSCs. 
LT-HSCs were isolated from the bone marrow of primary tamoxifen-injected mice, seeded in methylcellulose medium 
and replated after 7-10 days. Before each replating the number of colonies was counted (n = 3, error bars indicate mean 
± SD). 
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Supplemental Figure A-4: Blood Parameters of LT-HSC Transplanted Idh1 and CTRL Mice. 
Quantification of overall blood cell counts of indicated cell types using a HemaVet 950 FS hematology system. Y-axis 
counts are shown either as 1,000(K) / µl or 1,000,000(M) / µl (CTRL n = 17, Idh1 n = 17, three independent 
transplantations, curves were smoothened based on a loess (locally estimated scatterplot smoothing) regression model, 
confidence interval (0.95) plotted around curve). 
 
 
 
 
 
 
Supplemental Figure A-5: Lineage Output of Serially Transplanted Idh1-R132H and CTRL LT-HSCs. 
Quantification of frequencies of indicated cell types in the peripheral blood of primary and secondary recipient mice 
using flow cytometry. Frequencies are calculated in relation to CD45.1+ cells (secondary transplantation n = 6, tertiary 
transplantation n = 6, curves were smoothened based on a loess (locally estimated scatterplot smoothing) regression 
model, confidence interval (0.95) plotted around curve). 
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Supplemental Figure A-6: Blood Parameters of Single-Mutant and Idh1-R132H DNMT3A-R882H Double-Mutant LT-
HSC Transplanted Mice. 
Quantification of overall blood cell counts of indicated cell types using a HemaVet 950 FS hematology system. Y-axis 
counts are shown either as 1,000(K) / µl or 1,000,000(M) / µl (CTRL n = 19, Idh1 n =21, Idh1-DNMT3A n= 18, DNMT3A 
n =12, two to four independent transplantations per genotype, curves were smoothened based on a loess (locally 
estimated scatterplot smoothing) regression model, confidence interval (0.95) plotted around curve) (transplantation 
and analysis of DNMT3A mice was performed by Dr. Sina Stäble and Dr. Natasha Anstee). 
 
 
 
 
 
 
 
Supplemental Figure A-7: UMAP-Based Representation of Myeloid Progenitor Subclusters per Genotype. 
Distribution of annotated myeloid cells per individual cluster. All cells per genotype are shown. Increased numbers of 
Idh1-DNMT3A cells are seen especially in common myeloid progenitor cluster #4 and #5. 
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Supplemental Figure A-8: Diffusion Component 1- and 2-Based Visualization of Inferred Trajectories and Diffusion 
Maps.  
Diffusion map of components 1 and 2 (DC1, DC2) for combined genotypes as well as separate genotypes. Lineages were 
inferred for each genotype separately using the R-package ‘slingshot’ and are depicted as lines. For representative 
purposes only 2,500 cells per genotype are depicted.  
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Supplemental Figure A-9: Enriched Gene Sets in Differentially Expressed Genes from scRNA-seq CMP and MoDCP 
Populations. 
Differential expression was called between one specific genotype and all other genotypes within the same population. 
Genes with log2 fc > 0.25 and padj < 0.05 were considered as differentially expressed. For each genotype, overlaps with 
gene sets were calculated using the ‘Molecular Signature Database’ (MSigDB) with ‘Hallmark’, ‘Gene Ontology’ and 
‘Immunologic Signatures’ gene sets as reference. 
 
 
 
GO_AXONAL_GROWTH_CONE
GO_CELLULAR_RESPONSE_TO_HEAT
GO_RESPONSE_TO_HEAT
GO_RESPONSE_TO_TOPOLOGICALLY_INCORRECT_PROTEIN
GSE22025_PROGESTERONE_VS_TGFB1_AND_PROGESTERONE_TREATED_CD4_TCELL_DN
GSE24026_PD1_LIGATION_VS_CTRL_IN_ACT_TCELL_LINE_UP
GSE43863_NAIVE_VS_LY6C_LOW_CXCR5NEG_CD4_EFF_TCELL_D6_LCMV_DN
GSE9509_LPS_VS_LPS_AND_IL10_STIM_IL10_KO_MACROPHAGE_20MIN_DN
GO_PROTEIN_FOLDING
GSE17721_0.5H_VS_12H_CPG_BMDC_UP
GSE17721_POLYIC_VS_GARDIQUIMOD_12H_BMDC_DN
GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_12H_CD4_TCELL_DN
GSE22432_MULTIPOTENT_VS_COMMON_DC_PROGENITOR_UNTREATED_UP
GSE22886_UNSTIM_VS_IL15_STIM_NKCELL_DN
GSE22886_UNSTIM_VS_IL2_STIM_NKCELL_DN
GSE32986_CURDLAN_LOWDOSE_VS_GMCSF_AND_CURDLAN_LOWDOSE_STIM_DC_DN
GSE43863_TH1_VS_TFH_MEMORY_CD4_TCELL_UP
GSE7831_UNSTIM_VS_INFLUENZA_STIM_PDC_4H_DN
GSE22025_UNTREATED_VS_PROGESTERONE_TREATED_CD4_TCELL_DN
GO_RNA_BINDING
GO_ELECTRON_TRANSPORT_CHAIN
GO_MITOCHONDRIAL_MEMBRANE_PART
GO_OXIDATIVE_PHOSPHORYLATION
GSE45837_WT_VS_GFI1_KO_PDC_DN
GO_CELLULAR_RESPIRATION
GO_RESPIRATORY_CHAIN
GO_ENERGY_DERIVATION_BY_OXIDATION_OF_ORGANIC_COMPOUNDS
GO_NUCLEOSIDE_MONOPHOSPHATE_METABOLIC_PROCESS
HALLMARK_OXIDATIVE_PHOSPHORYLATION
GO_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY
GO_GLYCOSYL_COMPOUND_METABOLIC_PROCESS
GO_NUCLEOSIDE_TRIPHOSPHATE_METABOLIC_PROCESS
GO_PURINE_CONTAINING_COMPOUND_METABOLIC_PROCESS
GO_ORGAONITROGEN_COMPOUND_METABOLIC_PROCESS
GO_ORGANELLE_INNER_MEMBRANE
GO_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC PROCESS
GO_ENVELOPE
GO_MITOCHONDRIAL_ENVELOPE
GO_MITOCHONDRIAL_PART
GO_MITOCHONDRION
0 5 10 15 20
−log10 p−value
0 1 2 3
−log10 p−value
Number of Overlapping Genes
15 20 25
Number of Overlapping Genes
2 3 4 5 6 7 8
DNMT3A CMPs DNMT3A MoDCPs
HALLMARK_MYC_TARGETS_V1
HALLMARK_OXIDATIVE_PHOSPHORYLATION
GO_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS
GO_MITOCHONDRIAL_ENVELOPE
GO_MEMBRANE_PROTEIN_COMPLEX
GO_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS
GO_POLY_A_RNA_BINDING
GO_MITOCHONDRIAL_PART
GO_SINGLE_ORGANISM_BIOSYNTHETIC_PROCESS
GO_INTRACELLULAR_VESICLE
GO_ENVELOPE
GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL
GO_CATABOLIC_PROCESS
GO_ENDOPLASMIC_RETICULUM
GO_RNA_BINDING
GO_IMMUNE_SYSTEM_PROCESS
GO_PHOSPHATE_CONTAINING_COMPOUND_METABOLIC_PROCESS
GO_SMALL_MOLECULE_METABOLIC_PROCESS
GO_MITOCHONDRION
GO_ORGANONITROGEN_COMPOUND_METABOLIC_PROCESS
0 10 20 30 40
−log10 p−value
0 10 20 30 40
−log10 p−value
30 40 50 60
Number of Overlapping Genes Number of Overlapping Genes
70 80 25 35 45 55 65
GO_MITOTIC_NUCLEAR_DIVISION
GO_ORGANELLE_FISSION
HALLMARK_E2F_TARGETS
GO_INTERSPECIES_INTERACTION_BETWEEN_ORGANISMS
GO_REGULATION_OF_PROTEOLYSIS
HALLMARK_G2M_CHECKPOINT
GO_CELL_DIVISION
GO_RIBONUCLEOPROTEIN_COMPLEX
GO_CHROMOSOME
GO_REGULATION_OF_CELL_CYCLE
GATTGGY_NFY_Q6_01
GO_MACROMOLECULAR_COMPLEX_ASSEMBLY
GO_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS
GO_MITOTIC_CELL_CYCLE
GO_CELL_CYCLE_PROCESS
GO_ESTABLISHMENT_OF_LOCALIZATION_IN_CELL
GO_CELL_CYCLE
GO_POLY_A_RNA_BINDING
GO_RNA_BINDING
GGGCGGR_SP1_Q6
Idh1-DNMT3A CMPs Idh1-DNMT3A MoDCPs
0 5 10 15 20
−log10 p−value
0 5 10 15 20
−log10 p−value
Number of Overlapping Genes
11 12 13 14 15 16
Number of Overlapping Genes
6 7 8
GSE16385_ROSIGLITAZONE_IFNG_TNF_VS_IL4_STIM_MACROPHAGE_UP
GSE19923_WT_VS_HEB_AND_E2A_KO_DP_THYMOCYTE_DN
GSE36891_POLYIC_TLR3_VS_PAM_TLR2_STIM_PERITONEAL_MACROPHAGE_UP
GSE7219_WT_VS_NIK_NFKB2_KO_DC_UP
GSE9988_LOW_LPS_VS_CTRL_TREATED_MONOCYTE_UP
GSE46606_UNSTIM_VS_CD40L_IL2_IL5_1DAY_STIMULATED_IRF4HIGH_SORTED_BCELL_DN
GSE14769_UNSTIM_VS_20MIN_LPS_BMDM_DN
GSE7219_UNSTIM_VS_LPS_AND_ANTI_CD40_STIM_NIK_NFKB2_KO_DC_DN
HALLMARK_TNFA_SIGNALING_VIA_NFKB
GSE14769_UNSTIM_VS_40MIN_LPS_BMDM_DN
GSE14769_UNSTIM_VS_20MIN_LPS_BMDM_DN
GSE14769_UNSTIM_VS_40MIN_LPS_BMDM_DN
GSE19401_NAIVE_VS_IMMUNIZED_MOUSE_PLN_FOLLICULAR_DC_UP
GSE19401_UNSTIM_VS_RETINOIC_ACID_STIM_FOLLICULAR_DC_UP
GSE19923_WT_VS_HEB_AND_E2A_KO_DP_THYMOCYTE_DN
GSE23925_LIGHT_ZONE_VS_NAIVE_BCELL_UP
GSE37605_C57BL6_VS_NOD_FOXP3_FUSION_GFP_TREG_DN
GSE42021_TREG_PLN_VS_CD24HI_TREG_THYMUS_UP
GSE36891_POLYIC_TLR3_VS_PAM_TLR2_STIM_PERITONEAL_MACROPHAGE_UP
GSE27434_WT_VS_DNMT1_KO_TREG_DN
Idh1 CMPs Idh1 MoDCPs
A Appendix 
 
 105 
 
 
 
Supplemental Figure A-10: Transcriptomic Analysis of Isolated Ly6C+ GMPs. 
(A) Heatmap depicting sample distances for each sample based on their normalized gene expression profile. Calculation 
of distances and clustering of samples was computed using Euclidean distances. (B) PCA of individual samples based 
on their normalized expression profile. (C) Volcano plot showing DE genes between indicated genotypes. Genes with a 
log2 fc ≤ -0.5 or ≥ 0.5 and a padj < 0.05 are highlighted and were considered as differentially expressed.  
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Supplemental Figure A-11: Idh1 Expression in the Hematopoietic Compartment Based on scRNA-seq Data. 
Normalized expression of Idh1 highlighted within the UMAP-based representation of single-cell transcriptomic data. 
The color gradient from grey to dark blue indicates the level of expression (grey = no expression, dark blue = high 
expression). 
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A.2 Supplemental Tables 
 
 
Supplemental Table A-1: Peripheral Blood and Bone Marrow Composition of Mice Used in scRNA-seq Experiments. 
 CTRL  Idh1 DNMT3A  Idh1-DNMT3A  
Peripheral Blood Counts  
(HemaVet 950 FS) 
    
White Blood Cells [K/µl] 13.12 11.82 9.36 12.08 
Neutrophils [K/µl] 2.21 2.56 2.00 2.48 
Lymphocytes [K/µl] 10.23 8.33 6.93 8.89 
Monocytes [K/µl] 0.660 0.910 0.420 0.670 
Red Blood Cells [M/µl] 9.790 9.660 9.670 10.03 
Platelets [K/µl] 831 781 792 922 
     
Peripheral Blood Cell Frequencies  
(FACS, Frequencies in % of CD45.1+ cells) 
    
B-Cells 66.6 61.9 65.1 64.3 
T-Cells 15.7 17.0 18.7 18.1 
Myeloid Cells 15.2 18.3 14.2 15.5 
     
Bone Marrow Cell Frequencies  
(FACS, Frequencies in % of EYFP+ cells) 
    
LSK 0.11 0.086 0.18 0.15 
HSC 0.028 0.00451 0.024 0.048 
LT-HSC 0.00732 0.000449 0.00883 0.021 
ST-HSC 0.014 0.00302 0.00839 0.013 
MPP2 0.011 0.00631 0.011 0.012 
MPP3+4 0.035 0.042 0.083 0.04 
MPP5 0.00883 0.014 0.019 0.014 
LS-K 1.89 1.82 2.11 2.15 
CMP 0.6 0.61 0.65 0.77 
GMP 0.49 0.38 0.51 0.45 
MEP 0.39 0.41 0.52 0.52 
 
 
 
 
 
Supplemental Table A-2: Hematopoietic Marker Genes Used for the Annotation of scRNA-seq Clusters. 
Population Marker Genes 
LT-HSCs Mllt3, Ly6a, Procr, Mpl, Lmo2, Meis1, Hlf, Ifitm1, Ifitm3, Angpt1 
ST-HSCs Cd34, Mllt3, Ly6a, Procr, Mpl, Lmo2, Meis1, Hlf, Ifitm1, Ifitm3, Angpt1,  
Lymphoid primed multipotent progenitor Cd34, Flt3, Dntt, Il7r, Ikzf1, Ly6d 
Megakaryocyte progenitor Pf4, F2r, Vwf, Gp1bb, Gp5, Gp9 
Erythroid progenitor Car1, Car2, Gata1, Gata2, Klf1, Epor, Gfi1b 
Common myeloid progenitor Flt3, Spi1, Cebpa, Cebpe, Ms4a3, Ctsg, Mpo, Prtn3 
Monocyte / DC primed progenitor Irf8, Irf4, Csf1r, Ly6c2, Klf4, F13a1, Elane, Ctsg, Mpo, Prtn3, Ms4a3 
Neutrophil primed progenitor Elane, Ctsg, Mpo, Prtn3, Ms4a3, Cebpe, Gfi1 
Erythroid cells Hba-a1, Hbb-bh1, Hba-a2, Hbb-bt, Hbb-bs, Gypa, Car2, Epor, Tfrc 
Monocytes Ly6c2, S100a4, Csf1r, F13a1, Ms4a4c, Ms4a6c, Fn1, Ccr2, Clec4a3, 
Clec4a1 
Dendritic cells Cd209a, Siglech, Cd7, Cd74 
Neutrophils Lrg1, Ltf, Ngp, Lcn2, Mmp8, Mmp9, S100a8, S100a9, Fcnb, Cd63, Retnlg, 
Ly6g 
Basophils Prss34, Fcer1a, Ms4a2, Il6, Csf1 
T-cells Cd3d, Cd3g, Cd3e, Cd8a, Cd8b1 
Natural killer cells  Gzma, Gzmb, Klra4, Klrk1, Klra7, Klre1, Klra8, Eomes, Ccl5, Tbx21 
Pro B-cells Dntt, Vpreb1, Igll1, Rag1, Rag2 
Pre B-cells Vpreb1, Igll1, Rag1, Rag2, Pcna, Tyms, Mki67, Top2a 
Immature B-cells Vpreb1, Igll1 
Mature B-cells Ms4a1, Cd74, H2-Aa, H2-Eb1, H2-Ab1, H2-DMb2, Iglc1, Iglc2, Iglc3 
Plasma cells Iglv1, Iglv3, Iglc1, Iglc2, Iglc3, Cd74 
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Supplemental Table A-3: Varying Cell Type Frequencies per Genotype in Annotated scRNA-seq Cluster. 
Frequencies are depicted as proportion of cells in indicated clusters in relation to the overall number of cells within 
genotype-specific LSK or LS-K samples. 
 
 
 CTRL Idh1 DNMT3A Idh1-DNMT3A 
LS-K Samples     
Common myeloid progenitor #1 0.046 0.060 0.074 0.088 
Common myeloid progenitor #2 0.096 0.104 0.079 0.095 
Common myeloid progenitor #3 0.063 0.051 0.057 0.019 
Common myeloid progenitor #4 0.014 0.015 0.017 0.149 
Common myeloid progenitor #5 0.032 0.034 0.041 0.145 
Monocyte / DC primed progenitor #1 0.155 0.113 0.110 0.022 
Monocyte / DC primed progenitor #1 0.067 0.073 0.035 0.009 
Neutrophil primed progenitor 0.098 0.096 0.078 0.010 
     
LSK samples     
LT-HSCs 0.204 0.068 0.214 0.194 
Lymphoid primed multipotent progenitor 
#1 
0.061 0.136 0.061 0.068 
Lymphoid primed multipotent progenitor 
#2 
0.040 0.020 0.030 0.032 
Lymphoid primed multipotent progenitor 
#3 
0.117 0.145 0.092 0.109 
 
 
 
 
Supplemental Table A-4: Enriched Gene Sets in Idh1-R132H Mutated Ly6C+ GMPs. 
Hallmark Normalized Enrichment Score Nominal P-Value False Discovery Rate 
INTERFERON_ALPHA_RESPONSE 2.331 0.000 0.001 
INTERFERON_GAMMA_RESPONSE 2.026 0.000 0.007 
INFLAMMATORY_RESPONSE 1.378 0.054 0.180 
IL6_JAK_STAT3_SIGNALING 1.173 0.225 0.348 
ESTROGEN_RESPONSE_LATE 1.040 0.339 0.497 
FATTY_ACID_METABOLISM 0.831 0.779 0.881 
OXIDATIVE_PHOSPHORYLATION 0.657 0.989 0.970 
 
 
 
 
Supplemental Table A-5: Enriched Gene Sets in Idh1-R132H DNMT3A-R882H Mutated Ly6C+ GMPs. 
 
Hallmark Normalized Enrichment Score Nominal P-Value False Discovery Rate 
INTERFERON_ALPHA_RESPONSE 1.995 0 0.009 
INTERFERON_GAMMA_RESPONSE 1.861 0 0.021 
MYC_TARGETS_V2 1.696 0.0154 0.043 
MYC_TARGETS_V1 1.393 0.0235 0.211 
ADIPOGENESIS 1.175 0.1561 0.543 
OXIDATIVE_PHOSPHORYLATION 1.016 0.3805 0.942 
UNFOLDED_PROTEIN_RESPONSE 0.991 0.4474 0.895 
ANGIOGENESIS 0.982 0.4282 0.810 
WNT_BETA_CATENIN_SIGNALING 0.872 0.6170 1 
PEROXISOME 0.859 0.7123 1 
FATTY_ACID_METABOLISM 0.835 0.7323 0.973 
REACTIVE_OXIGEN_SPECIES_PATHWAY 0.637 0.9282 1 
E2F_TARGETS 0.632 0.9969 1 
DNA_REPAIR 0.580 1 0.992 
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log  Logarithm 
LPS  Lipopolysaccharide 
LS-K  Lineage— Sca1— cKit+ cells 
LSK Lineage— Sca1+ cKit+ cells  
LT-HSC  Long-term hematopoietic stem cell 
M 
M   1,000,000 
M   Molar 
M-CSF  Macrophage colony-stimulating factor 
MDP  Monocyte-dendritic cell progenitor 
MDS  Myelodysplastic syndrome 
MEP  Megakaryocyte-erythroid progenitor 
MFI  Mean fluorescence intensity 
mg  Miligram 
min  Minute 
ml  Mililiter 
mM  Milimolar 
moDC  Monocyte-derived dendritic cell 
MoDCP  Monocyte / dendritic cell primed progenitor 
MOI  Multiplicity of infection 
MPN  Myeloproliferative neoplasm 
MPP  Multipotent progenitor 
MPS  Mononuclear phagocyte system 
MSigDB  Molecular Signatures Database 
N 
NADP+  Nicotinamide adenine dinucleotide phosphate 
(oxidized form) 
NADPH  Nicotinamide adenine dinucleotide phosphate 
(reduced form) 
NeuP  Neutrophil primed progenitor 
ng  Nanogram 
NK-cell Natural killer cell 
NHEJ  Non-homologous end joining 
nm  Nanometer 
P 
p   p-value 
padj  Adjusted p-value 
PARP  Poly (ADP-Ribose) polymerase 1 
PBS Phosphate buffered saline 
PBS/FCS  PBS + 2 % FCS 
PC  Principle component 
PCA  Principle component analysis 
PCR  Poymerase chain reaction 
pDC  Plasmacytoid dedritic cell 
PE  Phycoerythrin 
PE-Cy5  Phycoerythrin-cyanine 5 
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T-ALL  T-cell acute lymphoblastic leukemia 
TBM  Total bone marrow 
TCA  Tricarboxylic acid 
TET  Ten-eleven translocation methylcytosine 
dioxygenase 
TF  Transcription factor 
TLR  Toll-like receptor 
TNFa  Tumor necrosis factor alpha 
U 
U   Unit 
UMAP  Uniform manifold approximation and 
projection 
UMI  Unique molecular identifier 
W 
WT  Wildtype 
 
%  Percent 
°C  Degree Celsius 
5-caC 5-Carboxylcytosine 
5-fC 5-Formylcytosine 
5-hmC 5-Hydroxymethylcytosine 
5-mC 5-Methylcytosine 
7AAD 7-Aminoactinomycin 
aKG Alpha(a)-ketoglutarate 
µg  Microgram  
µl  Microliter 
µm Micrometer 
µM Micromolar  
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FACS sorting was supported by the Flow Cytometry Core Facility of the DKFZ. 
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